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VIRUS DIVERSITY AND THE ORDER NIDOVIRALES
Per definition viruses are inanimate organic entities that are capable to replicate them-
selves. However, in contrast to living beings their DNA or RNA genomes do not encode 
information for the expression of proteins involved in the synthesis of the four funda-
mental biological building blocks: amino acids, carbohydrates, lipids, and nucleoside 
triphosphates (NTPs). Because of this limitation, they are obligate intracellular parasites 
that strictly depend on the metabolism of a host cell. Additionally, host proteins may 
play essential or supporting roles during specific steps in the viral replication cycle – the 
most obvious being cellular receptors used for viral entry. In effect, host factors thus 
determine the spectrum of genetically related cellular species and cell types a virus can 
infect – in short the virus’ host range.
At the moment the International Committee on Taxonomy of Viruses (ICTV) recognizes 
about 3000 different virus species (1). On the other hand, it has been estimated that 
about 15  million different cellular species (~9  million eukaryotes, ~6  million prokary-
otes) live on this planet (2;3). If we assume that each of those is host to at least one virus 
species – likely a vast underestimation given that humans are host to 189 known viruses 
(4) – a lot remains to be discovered. To bring order into the known and anticipated virus 
diversity in terms of, for example, genome type and organization, or replication strategy, 
related viruses have been grouped into genera, (sub-)families, and orders (proceeding 
from lower to higher rank). However, due to the extreme divergence of viruses and 
fast evolution, the relationship between different ranks remains often obscure. In this 
respect, virus taxonomy stands in stark contrast to the Tree of Life that has been con-
structed for organisms to reflect the course of cellular evolution.
The viruses that are discussed in this thesis belong to the order Nidovirales. This name 
derives from the typical genome expression strategy of its members featuring a nested 
set of subgenomic (sg) mRNAs (in Latin, nidus means nest). At the moment four fami-
lies with different host ranges are united in the order: Arteriviridae (vertebrate hosts), 
Coronaviridae (vertebrate hosts), Mesoniviridae (invertebrate hosts), and Roniviridae 
(invertebrate hosts) (5-8). With the exception of the Mesoniviridae, all families contain 
economically important pathogens infecting livestock, for example swine (arterivirus 
porcine reproductive and respiratory syndrome virus, coronaviruses porcine epidemic 
diarrhea virus and transmissible gastroenteritis virus), cattle (bovine coronavirus), 
poultry (coronavirus infectious bronchitis virus, IBV), and prawn (ronivirus yellow head 
virus), and hence cause severe losses to the respective industries (9-14). Additionally, es-
tablished human coronaviruses may cause mild respiratory symptoms. Combined these 









































Recent years also saw the emergence of two previously unknown and highly pathogenic 
zoonotic coronaviruses in the human population: severe acute respiratory syndrome 
coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus 
(MERS-CoV) in 2012 (16;17). In contrast to the established human coronaviruses, 
which are constantly circulating in the human population, these viruses were initially 
directly transmitted from an animal reservoir to humans. In the case of SARS-CoV it is 
now believed that this reservoir may be one of the numerous bat species (18;19). From 
these animals the virus spread to humans and caused the first pandemic of the 21st 
century with major outbreaks in China and Southeast Asia but also Canada (20). Despite 
concerns that SARS-CoV might mutate to permanently establish itself within the human 
population, the virus disappeared – thanks to the imposed control measures like strict 
quarantine protocols  –  from circulation in humans in 2003 after causing about 8500 
cases, including 812 deaths (21). The second newly-emerged coronavirus, MERS-CoV, 
which might be transmitted by camels (22), appears to be even more lethal with a case 
fatality rate of above 30%. However, thus far the case numbers have remained low, with 
about 1000 cases between April 2012 and November 2014 (23). Still, the threat to global 
public health and economy, exemplified by the SARS and MERS outbreaks, but also 
the combined economic damage caused by the veterinary nidoviruses call for a more 
thorough understanding of nidovirus biology. Ultimately these efforts might contribute 
to the development of countermeasures to keep future outbreaks in check.
THE NIDOVIRUS REPLICATION CYCLE
Nidoviruses enter a host cell by receptor-mediated endocytosis utilizing a variety of 
entry receptors (24). Afterwards the viral genome, which is a single RNA molecule of 
positive (mRNA) polarity carrying a type-1 cap structure (cap-1) (mGpppNm) and a poly-
adenylate (polyA) tail at its 5’ and 3’  end, respectively, is released into the cytoplasm. 
The genome is organized into multiple open reading frames (ORFs) (Figure 1), of which 
ORF1a and ORF1b encode all nonstructural proteins (nsps) separated by a ribosomal 
frameshift site, comprising a secondary structure element called RNA pseudoknot and 
a uridine-rich so-called “slippery sequence”. It is estimated that in equine arteritis virus 
(EAV) about 15-20% and in the coronaviruses mouse hepatitis virus (MHV) and IBV up to 
40% of the translating ribosomes perform the -1 frameshift and hence synthesize a large 
polyprotein called pp1ab (25-28). In the remainder of the cases the ribosome reaches 
a stop codon that is located just downstream of the frameshift signal. The resulting 
polyprotein is known as pp1a. Interestingly, all key enzymes for RNA synthesis and pro-
cessing, for example the RNA-dependent RNA polymerase (RdRp), helicase, and – in the 













































are encoded downstream of the frameshift while known co-factors of these enzymes, 
RNA-binding and membrane-anchoring proteins, as well as proteolytic enzymes are so 
far exclusively mapped to pp1a (29-32). The frameshift is thus an elegant way to regulate 
the relative abundance of these key enzymes compared to other proteins controlling 
genome replication and expression. Surprisingly, a second frameshift site was recently 
discovered in all arteriviruses except EAV. This site, located further upstream roughly 
in the middle of ORF1a, is able to direct a -2 as well as a -1 frameshift and thus gives 
rise to two additional variants of the membrane-bound nonstructural protein nsp2, one 
of which being predicted to be soluble. This arterivirus frameshift site with dual shift 
capacity, which is controlled by trans-activation by the upstream nsp1β subunit, is the 
only one of its kind known to date (33;34).
In addition to the nsps that are directly translated from the genome, group-specific 





































Figure 1: Typical nidovirus genome organization illustrated using equine arteritis virus (EAV). Open read-
ing frames (ORFs) are indicated as boxes. Cleavage sites of replicase proteins in polyproteins 1a and 1ab 
are marked by triangles corresponding in color to the protease responsible for cleavage. Known trans-
membrane and enzymatic domains are indicated. Pro, protease; TM, transmembrane domain; RdRp, RNA-
dependent RNA polymerase; HEL, helicase; NendoU, endoribonuclease; E, envelope protein; GP, glycopro-
tein; M, membrane protein; N, nucleocapsid protein. The ribosomal frameshift site leading to expression 
of polyprotein 1ab is labeled with a star. Transcription-regulating sequences are indicated as gray boxes. 









































lated from an in part extensive set of sg  mRNAs (35). These mRNAs, which carry the 
same 5’- and 3’-terminal sequences as the genome in most nidoviruses, are transcribed 
with the help a unique mechanism involving subgenome-size negative-stranded (-) 
templates that in part arise from discontinuous RNA synthesis (see below). As for all 
positive-stranded (+)  RNA viruses, RNA replication (amplification of the genome) and 
transcription (synthesis of sg mRNAs) are thought to take place in association with an 
extensive network of modified membranes (36;37). For nidoviruses this membranous 
web takes mainly the form of interconnected double-membrane vesicles (DMVs) and 
convoluted membranes (CMs). It was speculated that these membrane structures may 
provide a scaffold for replication-transcription complex (RTC) assembly inside DMVs. 
Hence, it is thought that these structures support viral replication in two ways; on the 
one hand, by increasing local concentrations of NTPs, RNAs, and proteins required 
for RNA synthesis and, on the other, by shielding viral replication products, especially 
double-stranded replication intermediates, from detection by the host’s innate immune 
system. After encapsidation of the viral genome, particles bud into the lumen of the 
smooth endoplasmic reticulum (ER) or Golgi complex. From there they are transported 
via the cellular secretory pathway to be released from the plasma membrane (24).
MOLECULAR DETAILS OF NIDOVIRUS REPLICATION AND TRANSCRIPTION
Prison break: how nidoviruses with large genomes overcame size constraints
The genome sizes of nidoviruses range from 12-16 kilobases (kb) for arteriviruses (from 
here on referred to as “small nidoviruses”) to 20-34 kb for mesoni-, roni-, and coronavi-
ruses (“intermediate and large nidoviruses”). With these sizes especially the latter group 
deviates substantially from the average size of most (+) RNA virus genomes that typically 
are smaller than 10 kb (Figure 2) (38). Still, even the largest RNA virus currently known, 
the recently discovered ball python nidovirus – a proposed member of the Torovirinae, a 
subfamily of the Coronaviridae – with a genome size of 33.5 kb (39), is dwarfed by some 
DNA viruses, whose genomes can reach sizes in the range of megabase pairs (Mbp), 
for example mimiviruses (~1 Mbp) and pandoraviruses (~2.5 Mbp) (40;41). Considering 
these tremendous size differences, two questions arise: in what way are RNA viruses so 
fundamentally different from DNA viruses that a genome expansion of the scale of the 
latter did not occur, and how did large nidoviruses, at least to some extent, overcome 
the size restrictions imposed on other (+) RNA viruses?
To answer these questions, it should be informative to explore the underlying reason for 













































an RdRp that synthesizes copies of the viral genome during the infection of a host cell. 
The basic mechanism by which these enzymes fulfill this central function in the viral 
replication cycle can be simplified to two steps: the matching of an incoming NTP to 
the template and the formation of a chemical bond to extend the nascent RNA chain 
(43;44). The first step of this mechanism basically occurs by a trial-and-error method as 
polymerases lack the means to determine the identity of the nucleotide that is about to 
be copied or of the NTP that has entered the active site. Instead the selection and, ulti-
mately, the incorporation of an NTP is solely based on the relative difference between 
its dissociation rate from the active site and the rate of phosphodiester bond formation. 
Because a correct Watson-Crick base pair is energetically more stable than a mismatched 
one or any of the alternative base pairs, the correct NTP will, on average, remain at the 
active site for a longer period of time than an incorrect one. If this period is long enough 
for bond formation to occur, the RNA chain will be extended by this one nucleotide. If 
not, the NTP will diffuse away, and the next NTP can be tried at random. In summary, in 
order to minimize the number of errors but maintain RNA synthesis, the chemical reac-
tion rate should be much lower than the dissociation rate of incorrect NTPs but higher 
than the dissociation rate of correct NTPs.
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Figure 2: Genome sizes of positive-stranded RNA viruses. Size ranges of major families or genera and un-
classified viruses are indicated by black (nidoviruses) or gray boxes. The median size is marked by a white 









































In general, error rates of RdRps were estimated to range between 10-3 and 10-5 errors 
per nucleotide incorporated (45). That means most individual genomes of an average 
(+) RNA virus would differ by at least one nucleotide from each other. To emphasize this 
variation, the concept of a quasispecies was introduced, essentially representing a cloud 
of different variants of a consensus sequence that are heterogeneous in respect to their 
fitness (46;47). Depending on the environmental conditions, the composition of these 
quasispecies may differ. Interestingly, decreasing the variation within a quasispecies by 
increasing the replication fidelity of an RdRp was shown to strongly diminish the overall 
fitness of a virus population (48-52). It is therefore believed that on an evolutionary scale 
it is the quasispecies, rather than individual variants, that is targeted by selection. On 
the other hand, decreasing replication fidelity will lead to the accumulation of too many 
detrimental mutations, which will eventually prevent virus replication, a consequence 
that was termed “error catastrophe”. Because of these two opposing principles, RNA 
viruses are thought to be optimized to exist close to the threshold of this error catastro-
phe. In summary, this implies that the size of the genome is limited by the error rate of 
the RdRp it encodes. Interestingly, there seems to be a correlation between the size of 
RNA genomes and their RdRp genes (45). Whether these larger RdRps indeed operate 
with a lower error rate, however, remains to be seen.
To express the interdependence between replication fidelity, genome size, and genome 
complexity, the term “Eigen trap” has been coined (53). This term essentially conveys 
the fact that none of these three parameters can be increased without simultaneously 
increasing the other two. When comparing (+) RNA virus genomes, two instances where 
both genome complexity and size expanded by the introduction of a new enzyme have 
been recognized. First, an RNA helicase is encoded by all viruses with genomes larger 
than 7 kb (54). It was proposed that this enzyme may support the RdRp by removing 
double-stranded regions from the template. However, how this would directly affect 
fidelity, which depends, as explained above, on an interplay between NTP affinities and 
the chemical reaction rate, is unclear. Therefore, it cannot be excluded that there may be 
other reasons underlying the presence of a helicase in (+) RNA virus genomes.
A more straightforward explanation was proposed for a second instance of genome 
expansion. In this case a 3’-5’ exoribonuclease was acquired, which gave rise to (+) RNA 
genomes of more than 20 kb (55). A similar enzymatic activity, a 3’-5’ exonuclease, is a 
vital part of typical DNA polymerases encoded by DNA viruses and cellular organisms. 
Contrary to general believe, the intrinsic error rates of DNA polymerases are, as a matter 
of fact, not significantly lower (10-4-10-5 bp-1) than that of RNA polymerases. It is the pres-
ence of this associated exonuclease activity that enables the reduction of the error rate 













































By analogy, it was assumed and recently experimentally confirmed that the nidovirus 
exoribonuclease confers proofreading activity to the viral RTC (32;56). Furthermore, in 
reverse genetics experiments it was demonstrated that a knock-out of this proofreading 
activity led to a more than 10-fold increase of the overall error rate during MHV and 
SARS-CoV replication in cell culture (57;58). In contrast to large nidoviruses, arteriviruses 
do not encode an exoribonuclease subunit (55). Still, their genomes are substantially 
larger than those of most other (+) RNA viruses. It thus remains to be seen if another 
domain acquisition event may be linked to this expansion.
Nidovirus discontinuous RNA synthesis
As already hinted at, the transcription mechanism of nidoviruses is unique in the virus 
world (Figure 3). Although several non-nidovirus families utilize sg mRNAs, none gener-
ates those by a mechanism equivalent to that of most nidoviruses, involving discontinu-
ous (-) subgenome-length RNA synthesis (roni- and toroviruses do not or only in part 
employ this mechanism) (59). In contrast to, for example, alphavirus sg mRNA synthesis 
that is driven from an internal promoter in the full-length negative strand, nidovirus 
sg  mRNAs are transcribed from several co-terminal (-)  subgenome-length  RNAs of 
different lengths. Essential protagonists in the still not well understood mechanism to 
produce those templates are so-called transcription-regulating sequences (TRSs), which 
are conserved AU-rich elements of a length – depending on the virus – of 5-18 nucleo-
tides located near the genome’s 5’ end (leader TRS) and upstream of most of the 3’ ORFs 
(body TRSs). During negative-strand synthesis, which always initiates at the genome’s 
3’ end, the viral RdRp may pause at one of these sequences. Subsequently, the part of 
the template between the body and leader TRS is skipped before RNA synthesis resumes 
at the genome’s 5’ end at the so-called leader sequence. How exactly this skipping oc-

















Figure 3: Discontinuous negative-strand transcription model. Transcription-regulating sequences are indi-
cated by gray (positive strands) or black (negative strands) boxes. Leader and anti-leader regions are labeled 









































involved since co-infection experiments with two different MHV strains showed that the 
leader sequence may derive from a different template than the rest of the transcribed 
product (60). Also base-pairing between the leader and anti-body TRS is important since 
the amount of each sg mRNA correlates with the calculated stability of the respective 
TRS duplex (61-64). However, it was speculated that base-pairing may not be the only 
factor involved. For instance, it was also shown that TRSs serve a function independent 
of base-pairing, potentially in secondary structure-dependent recruitment of specific 
proteins (59). Three viral proteins that were implicated in arterivirus transcription regu-
lation are nsp1 (65;66), the nidovirus-wide conserved helicase nsp10 (67;68), and the 
endoribonuclease nsp11 (69). For these proteins, mutations either altered the balance 
between genome replication and transcription or selectively abolished sg mRNA syn-
thesis altogether. Since genome replication requires the synthesis of full-length nega-
tive strands, and hence a read-through through all TRSs, these results indicated that the 
three proteins are directly or indirectly involved in the discontinuous step. Interestingly, 
nsp1 as well as nsp10 contain a zinc-binding domain that may be instrumental in estab-
lishing interactions with the RNA or proteins of the RTC to serve this regulatory function.
As a consequence of discontinuous RNA synthesis, all nidovirus mRNAs, except the 
smallest, are structurally polycistronic. However, with a few exceptions, only the 
most 5’-located ORF is actually translated, meaning that the mRNAs are functionally 
monocistronic (70). Thus, the question arises what the advantage of this complicated 
transcription mechanism is compared to structurally monocistronic mRNAs expressed 
from multiple promoters or polycistronic mRNAs enabling internal ribosome entry or 
other non-canonical translation initiation mechanisms frequently employed by other 
viruses. Obviously, the nidovirus mechanism ensures that all RNAs carry the same 5’- 
and 3’-terminal sequences as the genome or anti-genome. This could be advantageous 
if regulatory elements are located at the ends. For example, sequences of negative 
strands may be required to initiate positive-strand synthesis or capping. It would also 
be possible that the genome ends contain translational enhancers (59). Finally, those 
elements could also serve to discriminate viral from host RNAs. In view of the notion 
that all vertebrate nidoviruses encode an endoribonuclease (55), whose substrate is still 
elusive but may well be a host RNA, this possibility is especially intriguing.
Means to an end: nidovirus mRNA modification
Given the complexity of ribosomes, comprising 80 proteins and 4 rRNAs in higher eu-
karyotes (71), RNA viruses cannot encode information for their components. To ensure 
that viral mRNAs are translated in the host cell, a variety of strategies is employed by 













































lular mRNAs, a 5’ cap structure and a 3’ polyA tail. Alternatively, viral mRNAs may contain 
special secondary structures, called internal ribosome entry sites (IRESs) or 3’  cap-
independent translation enhancers (3’ CITEs), that allow the non-canonical recruitment 
of the translational apparatus. Finally, some viruses encode proteins that may replace 
certain cellular translation initiation factors. Their mRNAs may thus lack some of the 
modifications of host mRNAs, for instance the cap-1 or polyA tail (72-74).
Where characterized, the 3’ ends of positive-stranded RNAs of a number of nidoviruses 
contained polyA tails (53;75-79). Furthermore, a cap-1 (mGpppNm) structure was found 
to be present at the 5’ end of the genome and/or sg mRNAs of equine torovirus (80), the 
coronavirus MHV (81;82), and the arterivirus simian hemorrhagic fever virus (83). Based 
on common ancestry, it is thus assumed that all nidoviruses equip their mRNAs with 
these modifications, which would allow them to enter the cellular translation pathway. 
In line with this hypothesis, it was shown that MHV infection leads to phosphorylation of 
the cap-binding translation initiation factor eIF4E, which is required for the cellular path-
way (84). This phosphorylation, which is a known regulatory mechanism in eukaryotic 
cells to strengthen the interaction between the cap and the protein, in turn increased 
the translation efficiency of viral mRNAs. Furthermore, overexpression of an inhibitor 
of eIF4E, 4E-BP, abolished replication of human coronavirus 229E in HeLa cells (85). 
Nevertheless, contradicting evidence with regard to the nature of its 5’ end has been 
brought forward for the arterivirus lactate dehydrogenase-elevating virus, whose ge-
nome appeared to be devoid of a cap and instead was monophosphorylated (86). Given 
this result and the fact that none of the members of the Roniviridae and Mesoniviridae 
was characterized so far, care should be taken in assuming that all nidovirus mRNAs 
carry the same 5’ end modification. Such a deviation in respect to translation strategy 
was also observed in the Flaviviridae, whose members may utilize cap-dependent or 
-independent mechanisms (87;88). In addition to cap-dependent translation initiation, 
IRES elements may, at least in coronaviruses, drive expression of a second gene product 
from a single sg mRNA (89-91).
In the host cell cap-1 and polyA tails are strictly generated in the nucleus during and 
shortly after RNA polymerase  II-dependent transcription (92). Since nidoviruses and 
many other (+)  RNA viruses replicate in the cytoplasm, they cannot benefit from this 
cellular machinery. Instead the polyA tail may be synthesized by (one of ) the viral 
RdRp(s) – coronaviruses are believed to encode a main RdRp (nsp12) and an accessory 
RdRp (nsp8) (93-95). How exactly this is achieved was not investigated so far. However, 
since negative-stranded RNAs were shown to contain a short polyU stretch at their 5’ 









































tively, SARS-CoV nsp8 in complex with nsp7 was shown to possess terminal transferase, 
that is, non-templated extension activity, on single-stranded RNAs (95).
In contrast to polyA-tail addition, the assembly of the cap-1 structure appears to be bet-
ter understood in regard to the proteins involved, at least in large nidoviruses. In general 
the synthesis of the cap involves four steps and three different enzymatic activities that 
may be present in a single subunit with multiple domains or in multiple individual 
proteins (97;98). In case of the conventional capping pathway, which is employed by all 
eukaryotes and a number of viruses, the triphosphate end of a newly synthesized RNA 
is trimmed back to a diphosphate by an RNA-triphosphatase (RTPase). As this activity is 
mechanistically identical to the cleavage of NTPs, the NTPase domains of a viral helicase, 
if encoded, may execute it. In the second step, a guanylyltransferase (GTase) transfers a 
GMP-moiety to the RNA diphosphate end. In contrast to nucleotide bonds established 
by polymerases, this bond is formed via a 5’-5’ linkage to generate a GpppN-RNA struc-
ture. While this unusual bond cannot be cleaved by regular exo- and endoribonucleases, 
specially regulated cytoplasmic host decapping enzymes are employed for the removal 
of cap structures (99). As a consequence, capping confers protection against 5’-3’ ex-
oribonucleases, and hence capped RNAs exhibit much longer half-lives than uncapped 
ones. In order to make the second step irreversible, a methyl group is attached to the 
N7-position of the guanine by an N7-methyltransferase (N-MT). Although this so-called 
cap-0 structure is due to the specific recognition of the methyl group by eIF4E the basic 
requirement for translation initiation (100), a second methylation usually occurs at the 2’ 
oxygen of the ribose of the first (cap-1) or second (cap-2) nucleotide following the cap. 
This second methylation step, which is catalyzed by a 2’-O-methyltransferase (O-MT) 
that may or may not be different from the domain utilized for N7 methylation, is con-
nected to host mRNA surveillance mechanisms for self versus non-self discrimination 
(101;102). Next to this conventional pathway, alternative viral mechanisms have evolved 
that include a different order of steps leading to the same mature cap structure (98).
It has been proposed that nidoviruses employ the canonical pathway of cap synthesis 
described above (98). However, this hypothesis is far from proven especially with respect 
to the universal conservation of this pathway in all nidoviruses. For instance, the GTase 
has not been identified in any of the nidoviruses, while RTPase activity was demonstrated 
for only two coronavirus helicases (nsp13) (103;104). Whether or not this enzyme, which 
belongs to the most conserved proteins of the order, actually exerts this activity in the 
context of capping, however, remains to be verified. Finally, two methyltransferases 
(MTases) residing in nsp14 (N-MT) and nsp16 (O-MT) have been experimentally identi-
fied in coronaviruses (105-108). Interestingly, while other large nidoviruses – with the 













































both MTases (55), neither of them was identified in arteriviruses. Since arteriviruses 
encode a unique protein (nsp12) at a genome position equivalent to that of coronavirus 
nsp16, the capping mechanism could be another example of biochemical variability 
within the diverse Nidovirales order.
OUTLINE OF THIS THESIS
The work described in this thesis addresses several poorly or uncharacterized (domains 
of ) nsps that are likely involved in one or multiple steps during RNA replication and/or 
transcription of the prototypic arterivirus EAV. After the above short introduction on 
the nidovirus replication cycle and known molecular details of the unusual transcrip-
tion and mRNA processing mechanisms, chapter  2 presents the crystal structure of 
the enzymatically active EAV helicase nsp10, which was obtained and analyzed in close 
collaboration with Chinese colleagues. Interestingly, a strong resemblance between 
this viral protein and the conserved cellular helicase Upf1, in particular with respect to 
their N-terminal zinc-binding domains, became obvious. Since this cellular helicase is 
implicated in a number of eukaryotic post-transcriptional quality control mechanisms, 
a role for nsp10 and its nidovirus homologs in genome expansion is proposed. This and 
other potential functions of the nidovirus helicase in RNA replication, transcription, 
and translation, as well as virion biogenesis are further discussed in chapter 3, which 
presents a review of our current knowledge about nidovirus helicases. Special emphasis 
is placed on gaps that still remain, facts that cannot be easily reconciled with our current 
understanding of the nidovirus replication mechanisms, and questions that need to be 
addressed in future.
Chapters  4 and 5 focus on one of the central arterivirus replication proteins, nsp9, 
which harbors the RdRp domain. Chapter  4 describes a carefully controlled study to 
investigate different polymerase activities that nsp9 may have, including a previously 
claimed primer-independent RdRp activity. Despite considerable efforts, involving ex-
periments with different preparations of nsp9 and assays performed in the presence of 
putative polymerase co-factors, no in vitro activity was observed that could be clearly 
attributed to this protein. Moreover, circumstantial evidence suggested that the previ-
ously reported activity may have been caused by a contamination of the recombinant 
nsp9 preparation with the T7 RNA polymerase used to drive its expression in E.  coli. 
In arteriviruses, the RdRp domain is located in the C-terminal two-thirds of nsp9. In 
chapter 5, it is now described for the first time that the RdRp domain is flanked at its 
N-terminus by another domain that is conserved in all nidoviruses. However, unlike the 









































RNA viruses. This domain is thus proposed to be a second marker for the Nidovirales 
order, besides the N-terminal zinc-binding domain of the helicase subunit. Residues that 
are part of three conserved sequence motifs were without exception associated with 
a newly discovered nucleotidylation activity of recombinant nsp9. It is thus proposed 
that this activity could play a role in the modification of the 5’ end of viral RNAs through 
either RNA ligation, protein priming of RNA synthesis, or guanylyl transfer during RNA 
capping. Further research is required to definitely tie nsp9 to one of these pathways. 
Nevertheless, alanine substitution of any of the conserved residues was either lethal to 
EAV and SARS-CoV or severely crippled these viruses, eventually resulting in reversion 
of the mutation. These results thus demonstrate the essential nature of this domain for 
virus replication, whatever its exact function will turn out to be.
Two MTase activities, commonly required for capping of mRNAs, were previously identi-
fied in two ORF1b-encoded coronavirus proteins, nsp14 and nsp16. While the former 
has no counterpart among the arterivirus nsps, the latter and the arterivirus C-terminal 
subunit nsp12 occupy equivalent positions in the ORF1b-encoded part of the replicase 
although the two proteins share no detectable sequence similarity. It is thus a long 
standing question, how arteriviruses may catalyze the 5’  end modification of mRNAs, 
and we therefore performed a first characterization of the entirely uncharacterized 
EAV nsp12 subunit (chapter 6). Based on the genomic position of its coding sequence, 
sequence alignment, and secondary structure prediction it is hypothesized that nsp12 
might represent a unique arterivirus MTase, which has diverged from its homologs 
beyond sharing appreciated similarity. To test this hypothesis, recombinant nsp12 was 
expressed in and purified from E. coli and tested alone and in combination with poten-
tial co-factors for N-MT and O -MT activity. Although positive controls represented by the 
SARS-CoV MTases (nsp14 and the nsp10:nsp16 complex) demonstrated the functionality 
of the assay, no activity was detected for EAV nsp12. Guided by the sequence alignment, 
an extensive set of EAV mutants was generated and characterized with respect to their 
plaque phenotype and progeny titer, as well as their protein expression. These reverse 
genetics experiments revealed a number of phenotypes ranging from wild-type-like via 
non-spreading to replication-incompetent, which indicated that nsp12 is essential for 
viral replication.
The above chapters describing biochemical properties of selected proteins may ulti-
mately contribute to the identification of drug targets to combat nidovirus infections. In 
chapter 7 the prerequisites under which the marketing of such an antiviral drug would 
be economically viable are analyzed. This project was realized under guidance of several 
specialists of one of the industrial partners, Janssen Infectious Diseases, of the EUVIRNA 













































longed. This study concludes that, at the moment, none of the circulating nidoviruses 
constitutes a sufficiently sized market to warrant the considerable investments required 
for drug development. The situation may be different if a new highly-pathogenic virus 
would emerge, as exemplified in 2002 by SARS-CoV or 2012 by MERS-CoV. In view of 
such threats, pre-pandemic drug stockpiling could be considered. However, also under 
those circumstances, it seems likely that the inherent financial risk would preclude an in-
dependent private initiative, even though market parameters and approval procedures 
appear to be favorable.
Finally, chapter  8 connects some of the main findings described in this thesis with 
previously described data. In particular, potential differences between small and large 
nidoviruses on the level of the molecular mechanisms of RNA synthesis initiation and 
mRNA capping are highlighted. To this end, alternative mechanisms are considered that 
would be consistent with the data on arteriviruses presented in this thesis and else-
where. Furthermore, potential roles of cellular helicases in nidovirus replication and the 
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Structural basis for the regulatory 
function of a complex zinc-binding 
domain in a replicative arterivirus 
helicase resembling a nonsense-




























































All positive-stranded RNA viruses with genomes larger than ~7 kilobases encode heli-
cases, which generally are poorly characterized. The core of the nidovirus superfamily 1 
helicase (HEL1) is associated with a unique N-terminal zinc-binding domain (ZBD) that 
was previously implicated in helicase regulation, genome replication, and subgenomic 
mRNA synthesis. The high-resolution structure of the arterivirus helicase (nsp10), alone 
and in complex with a polynucleotide substrate, now provides first insights into the 
structural basis for nidovirus helicase function. A previously uncharacterized domain 
1B connects HEL1 domains 1A and 2A to a long linker of the ZBD, which further consists 
of a novel RING-like module and treble-clef zinc finger, together coordinating three Zn 
atoms. On substrate binding, major conformational changes were evident outside the 
HEL1 domains, notably in domain 1B. Structural characterization, mutagenesis, and bio-
chemistry revealed that helicase activity depends on the extensive relay of interactions 
between the ZBD and HEL1 domains. The arterivirus helicase structurally resembles the 
cellular Upf1 helicase, suggesting that nidoviruses may also employ their helicases for 














































Helicases and nucleic acid translocases are ATP-dependent motor proteins capable of 
moving along their nucleic acid substrates while either unwinding duplexed regions 
(helicases) or performing other functions (translocases), including protein displacement 
and the nucleation of larger RNA-protein complexes (1,2). These enzymes are known 
to be critical players in a wide variety of biological processes and are encoded by all 
organisms, as well as positive-stranded (+) RNA viruses with genomes larger than about 
7 kilobases (kb) ((3); for reviews, see (4-6)). On the basis of sequence comparisons, heli-
cases/translocases have been classified into six superfamilies (SF1 to SF6) (7,8), with (+) 
RNA viral helicases belonging to SF1, SF2, or SF3. Based on the direction of translocation, 
helicases of various superfamilies have been divided into (biochemical) classes A and B, 
which translocate along their nucleic acid substrates in the 3’-5’ or 5’-3’ direction, respec-
tively (7). In the case of SF1 helicases (9,10), structurally characterized cellular enzymes 
of class B (SF1B) are further divided into the phylogenetically compact Pif1-like (Pif1, 
RecD2), UvrD/Rep, and Upf1-like (Upf1, Ighmbp2) groups, with the latter being able to 
unwind both DNA and RNA duplexes (11).
Helicase SF1 also includes a large number of (putative) helicases from a dozen (+) RNA 
virus families belonging to two diverse phylogenetic lineages, known as the alphavirus-
like (or Sindbis virus-like) supergroup (12) and the order Nidovirales (13). More detailed 
studies on the SF1 helicases of two alphavirus-like viruses have recently been published. 
The helicase domain of the dendrolimus punctatus tetravirus (an insect virus from 
the Alphatetraviridae family) was found to have dsRNA-unwinding activity with 5’-3’ 
directionality (14). The helicase domain of the plant tomato mosaic virus (ToMV; family 
Virgaviridae) was not characterized enzymatically, but its crystal structure revealed the 
two canonical RecA-like α/β domains (1A and 2A) of the helicase core (15). Accessory 
domain insertions, an otherwise frequently observed phenomenon among cellular SF1 
helicases, are lacking in the ToMV helicase. The SF1 helicases of nidoviruses, one of 
which is the focus of this study, were characterized in some detail using bioinformatics, 
molecular genetics, and biochemistry (see below), but structural information was lack-
ing thus far.
Nidoviruses constitute an order of (+) RNA viruses comprised of virus groups target-
ing a wide variety of mammalian, avian, and invertebrate hosts. In mammals nidovirus 
infection can be associated with severe respiratory disease, as in the case of porcine 
reproductive and respiratory syndrome (PRRS) (16), one of the leading swine diseases 
(caused by arteriviruses), and zoonotic coronavirus infections in humans, like severe 









































(18). The continuing outbreak of the latter disease is currently attracting worldwide 
attention, in particular because of its ~40% case fatality rate. Besides their pathogenic 
properties, nidoviruses have been studied for their extraordinary large RNA genomes; 
even the shortest nidovirus genome (the 12.7 kb RNA of the arterivirus equine arteritis 
virus, EAV) outranks almost all other mammalian (+) RNA virus genomes, whereas coro-
navirus genomes (26.3-31.7 kb) are larger than those of any other RNA virus group. Their 
large genome size enabled nidoviruses to evolve substantial genetic complexity, which 
is evident from (among other properties) the acquisition of a variety of enzymatic activi-
ties and accessory proteins, many of which are lacking or rare in other (+) RNA viruses 
(19). These proteins appear to contribute to the regulation of the complex RNA synthesis 
of nidoviruses, which occurs exclusively in the cytoplasm of the infected cell, and to the 
elaborate array of virus-host interactions needed to support efficient virus replication 
(13,20). For example, nidoviruses with genomes larger than 20 kb employ a proofread-
ing 3’-5’ RNA exonuclease that is proposed to promote the fidelity of viral RNA synthesis 
(19,21-27). However, it is completely unknown whether and how nidoviruses deal with 
translational quality control during the expression of their large multicistronic genomic 
RNAs, which also serve as mRNAs for the synthesis of the viral replicative enzymes.
Compared to other (+) RNA viruses, nidovirus replicase genes encode an exceptionally 
large number of nonstructural proteins (nsps) (19,24,25,28). Nidovirus nsps are expressed 
from open reading frames (ORFs) 1a and 1b, which make up the 5’-proximal 65-75% of 
the genome RNA. ORF1a encodes polyprotein 1a (pp1a; size ranging from 1728 to 4550 
amino acids) and following a -1 ribosomal frameshift pp1a can be extended with the 
ORF1b-encoded polyprotein to give pp1ab (3175 to 7183 amino acids) (29) (Figure S1). 
Both polyproteins are subject to extensive proteolytic processing by multiple internally 
encoded proteinases (19,30). The nidovirus replicase backbone consists of a conserved 
array of domains, arranged in a nidovirus-specific order and including the ORF1b-en-
coded RNA-dependent RNA polymerase (RdRp) and helicase domains, the core enzymes 
needed for genome RNA synthesis (replication) and subgenomic (sg) mRNA production 
(transcription). The latter process yields an extensive nested set of sg mRNAs, which is 
used to express up to a dozen structural and accessory proteins from smaller ORFs in 
the 3’-proximal part of the genome (31-33). In both corona- and arteriviruses, sg mRNAs 
contain a common leader sequence that is identical to the 5’ end of the genome. Their 
generation from subgenome-size negative-stranded templates involves a mechanism 
of discontinuous negative-strand RNA synthesis (31,32).
Previous studies identified the nsp carrying RNA helicase activity (arterivirus nsp10 and 
coronavirus nsp13) as one of the two most evolutionarily conserved nidovirus proteins. 













































very similar enzymatic properties, including nucleic acid-stimulated ATPase and 5’-3’ du-
plex unwinding activities on both RNA and DNA substrates containing 5’ single-stranded 
regions (34,35). A unique nidovirus helicase feature is the presence of an N-terminal 
(predicted) complex zinc-binding domain (ZBD) of 80-100 residues. The ZBD includes 
12 or 13 conserved Cys/His residues (36) and is a nidoviral genetic marker not found in 
any other RNA virus group (19). The ZBD is separated from the downstream helicase core 
domains (HEL1) by an uncharacterized domain that varies in size and sequence between 
arteri- and coronaviruses (37). For the arterivirus prototype EAV, the significance of the 
nsp10 ZBD was evaluated extensively using site-directed mutagenesis in combination 
with biochemical assays and reverse genetics. Amino acid substitutions in the ZBD or 
the adjacent “spacer” that connects it to the downstream domain can profoundly affect 
EAV helicase activity and RNA synthesis, with most replacements of conserved Cys or 
His residues yielding replication-negative virus phenotypes (36,37). Intriguingly, some 
mutations in the spacer region selectively inactivated transcription while not affecting 
replication (36,38), strongly suggesting a specific role for nsp10 in the unique mecha-
nism of discontinuous sg RNA synthesis.
Despite its importance as a key replicative enzyme and antiviral drug target (39), no 
three-dimensional structural information has been reported for any nidovirus helicase. 
To understand the regulatory role of the ZBD and the protein’s interaction with nucleic 
acids, we characterized the structure of a helicase-competent derivative of EAV nsp10, 
alone and in complex with poly(dT). The multi-domain nsp10 includes the canonical 
1A and 2A core domains of a SF1 helicase, a flexible accessory domain that is sensitive 
to nucleic acid binding, and a complex ZBD displaying a novel structural organization. 
Strikingly, the protein was found to bear structural resemblance to the eukaryotic Upf1 
helicases, which are multi-domain proteins involved in RNA quality control, including 
nonsense-mediated mRNA decay (40). Thus, our study not only highlights how nidovirus 
helicase activity depends on the extensive relay of interactions between the ZBD and 
HEL1 domains but also provides a framework to propose and explore a role for the 
enzyme in the post-transcriptional quality control of nidovirus RNAs.
RESULTS
C-terminally truncated EAV nsp10 retains ATPase and helicase activity
Full-length EAV nsp10 and a series of truncated variants were overexpressed in and puri-
fied from E. coli. After extensive crystallization trials, diffracting crystals could only be 









































simplicity, we will hereafter refer to this protein as nsp10Δ, which was used throughout 
this study unless otherwise specified. To verify that nsp10Δ, which contained all charac-
teristic SF1 helicase sequences (motifs), is enzymatically active, we performed in vitro 
enzyme assays to compare full-length and truncated nsp10. In agreement with previ-
ously published results (35), full-length nsp10 displayed only weak ATPase activity in 
the absence of nucleic acid but was strongly stimulated by the addition of poly-uridine 
(polyU). In the absence of polyU nsp10Δ showed a five-fold higher ATPase activity than 
the full-length protein (Figure 1A), yet this increased ATP turnover did apparently not 
translate into increased helicase activity. Unwinding of a partially double-stranded DNA 
substrate by nsp10Δ was incomplete but went to completion when using full-length 
nsp10 (Figure  1B). As expected, replacement of the conserved lysine of the Walker A 
motif, which is essential for ATP hydrolysis (35), with glutamine (mutant K164Q) com-
pletely abolished ATPase and consequentially also helicase activity. This confirmed that 
the observed activities could be completely attributed to the recombinant EAV proteins 
used rather than to potential trace amounts of contaminating bacterial enzymes.
The observed enzymatic differences between nsp10 and nsp10Δ may be caused by the 
latter’s truncation and could, in principle, be explained by one or multiple defects, like 
decreased unwinding velocity and/or processivity, loss of affinity towards the substrate, 
or uncoupling of ATPase from helicase activity. The results of the ATPase assay lead us 
to propose that the observed reduction of duplex unwinding may be due to unproduc-
tive ATP hydrolysis, originating from the fact that the ATPase reaction is independent 
of nucleic acid substrate binding. Accordingly, the input ATP in the nsp10Δ assay may 
have been depleted before complete unwinding was achieved. Regardless of which 
Figure 1. EAV nsp10 in vitro enzymatic activity assays. (A) ATPase activity of full-length EAV nsp10, the C-ter-
minally truncated nsp10Δ (amino acids 1-402) and respective active site mutants carrying a Lys-164 to Gln 
substitution in their Walker A box were analyzed as described in Supplementary Experimental Procedures. 
In the absence of nucleic acid, ATPase activity was measured by incubation at 20°C for 0, 5, 15 and 30 min, 
respectively. ATPase activity was strongly stimulated by the presence of poly-uridine (polyU), as measured 
by incubation at 20°C for 5 min. (B) Helicase activity of full-length nsp10 and nsp10Δ, and their respective 
K164Q mutants. Activity was determined with the indicated DNA substrate (the asterisk marks the position 
of the radioactive label). Samples were incubated for 0 or 30 min at 30°C. Control samples without protein 













































interpretation is correct, the C-terminal 65 amino acids clearly are dispensable for the 
helicase activity of EAV nsp10. This result is in good agreement with the fact that the 
truncated protein retained all HEL1 key domains (Figure  2A) previously shown to be 
evolutionary conserved and essential in both in vitro enzyme assays and in vivo studies 
with virus mutants.
The crystal structure of EAV nsp10Δ reveals a multi-domain organization of the 
arterivirus replicative helicase
Since three-dimensional structures of orthologous proteins were not available, we took 
advantage of the zinc-binding properties of nsp10 and used the zinc multiple-wave-
length anomalous diffraction (MAD) method (42) to solve the EAV nsp10Δ structure. 
The presence and position of three zinc atoms were established with anomalous data 
collected from the zinc absorption edge (Table 1). The final model included EAV nsp10 
residues 1-401, 3 zinc ions in the N-terminal ZBD, 5 sulfate ions, and 267 water molecules.
Two RecA-like α/β domains (1A and 2A) form the structure’s C-terminal part (Figure 2B; 
cyan and green) and constitute the helicase core (HEL1). Domain 1A contains a paral-
lel five-stranded β-sheet that is sandwiched by three α-helices on one side and two 
Figure 2. Overall structures of EAV nsp10Δ and the nsp10Δ-DNA binary complex. (A) Domain organization 
of EAV nsp10 depicting the N-terminal zinc-binding domain (ZBD; yellow), the two RecA-like domains 1A 
(green) and 2A (cyan) of HEL1, and an additional regulatory domain 1B (magenta). Structure of (B) free 
and (C) nucleic acid-bound nsp10Δ. Also the Fo−Fc differential electron density map of the bound single-
stranded part of a partially double-stranded DNA substrate at 2.5 σ is presented. The putative ATP binding 









































α-helices on the other. Domain 2A contains a parallel four-stranded β-sheet with five 
α-helices on the side facing domain 1A. Upstream of domain 1A, we identified an addi-
tional domain with a characteristic β-barrel fold (Figures 2A and 1B; magenta). It consists 
of five β-strands arranged as two tightly packed anti-parallel β–sheets and is juxtaposed 
to domain 1A (Figure 2B). The location of this domain in the protein sequence and its 
orientation relative to the HEL1 domain resemble those of domain 1B in helicases of 
the SF1B Upf1-like subfamily (Figures 3B and 3C), and it was therefore named accord-
Table 1. Data collection and refinement statistics of nsp10Δ and the nsp10Δ-DNA complex*.
Data collection Zn-Peak Zn-edge Zn-remote nsp10Δ nsp10Δ-DNA
Wavelength 1.2827 1.2831 1.0000 1.0000 1.0000
Space group P21212 P21212 P21212 P21212 P1
Cell dimensions
a,b,c( Å) 89.1,90.6,56.9 89.1,90.6,56.9 89.1,90.6,56.9 89.8,91.0,57.7 56.6,88.8,128.8
α,β,γ (˚) 90,90,90 90,90,90 90,90,90 90,90,90 81.7,90.0,71.4










Rmerge (%) 8.7 (38.9) 9.0 (39.9) 9.3 (42.8) 7.4 (67.0) 10.0 (73.2)
I/σ 15.2 (2.2) 15.5 (1.9) 17 (2.8) 42.0 (2) 25.6 (3.4)
Completeness (%) 97.6 (87.2) 98.8 (84.5) 99.1 (89) 97.8 (86.1) 96.1 (95.3)






No. of reflections 30451 (1874) 62140 (4421)










Bond lengths (Å) 0.008 0.007
Bond angles (º) 1.17 1.22
Ramachandran Plot ( %)§ 93.9/6.1/0/0 83.3/15.9/0.8/0
*Three crystal experiments for each structure. † Statistics for highest resolution shell.














































ingly in our nsp10Δ structure. The domain has no counterpart in the only other solved 
structure of a viral SF1 helicase, that from ToMV (Figure 3A) (15), whereas its counterpart 
in helicases of the Pif1-like subfamily is inserted in domain 2A (Figure 3D) (48).
Our structure further revealed that the N-terminal ZBD (Figure 2; yellow) has a compact 
fold containing three structural zinc atoms. Based on secondary structure analysis with 
DIAL (49), we could partition the ZBD into three elements (Figure 4). Two adjacent and 
structurally different zinc fingers, an N-terminal RING-like module (residues 1 to 40, 
pink), and a treble-clef zinc finger (residues 41 to 65, red) constitute the main body of 
the ZBD. The third element is a C-terminal linker region (Linker1) that includes the long 
loop L7, which crosses the entire domain, and helix α4 (residues 66 to 82, yellow), which 
connects the two zinc fingers with domain 1B (Figure 4A). This classification is further 
supported by the observation that the connecting residues between the RING module 
and treble-clef zinc finger are disordered (Figures S2 and 4D). Only 12 out of the 13 Cys/
His residues are involved in zinc binding rather than all 13 residues as proposed previ-
ously ((36); Figures 4B and 4C). Not involved is His34, which is not conserved in other 
arteri- and coronaviruses (Figure S3B).
The N-terminal RING-like module has a notable binuclear structure with a cross-brace 
topology involving six Cys and two His residues that coordinate two zinc ions (Figure 4A). 
A three-stranded antiparallel β-sheet (β1-β3) sits in the center and packs against helix α1 
following β2 (Figure 4B). The first zinc ion (Zn1) is coordinated by four cysteine residues 
(Cys4, Cys7, Cys22, and Cys25) within a treble-clef zinc finger-like motif. Residues Cys4 
and Cys7 are provided by the zinc knuckle within loop L1 whereas Cys22 is positioned at 
the C-terminus of β2 and Cys25 comes from the N-terminus of helix α1. The second zinc 
ion (Zn2) is coordinated by residues Cys17, Cys33, His29, and His32, which are arranged 
in an αββ zinc finger-like motif. The second pair of the zinc-coordinating residues of both 
Figure 3. Structural comparison of EAV nsp10Δ with selected SF1 helicases. (A) ToMV-HEL (pdb code: 
3vkw), (B) EAV nsp10Δ, (C) hUpf1 (pdb code: 2wjy) and (D) RecD2 (pdb code: 3gp8). Domain colors are the 









































zinc-binding motifs of the RING module may include both His and Cys residues in other 
arteri- and coronaviruses. Overall, the RING module of these viruses can be described 
by a characteristic, conserved Cys2A-CysB-CysA-[His/Cys]A-[His/Cys]3B pattern (where 
applicable, A and B refer to residues chelating the first and second zinc ion, respectively; 
brackets indicate positions at which either His or Cys can be present).
Figure 4. Structural characterization of the EAV nsp10Δ ZBD. (A) Topology of the ZBD with its RING-like 
module (pink), treble-clef zinc finger (red), and Linker 1 (yellow) indicated. (B) Structure of the RING-like 
module and (C) treble-clef zinc finger. The residues coordinating the Zn2+ ions are shown as sticks. (D) In-
teractions between the RING-like module and the treble-clef zinc finger. (E) Superposition of the RING-like 
modules of EAV nsp10 (pink) and hUpf1 (pdb code: 2wjy; gray). (F) Sequence alignment of ZBD with the 













































The C-terminal zinc finger of the ZBD adopts a treble-clef fold distinct from that of the 
RING module (see above; Figure 4C). Two one-turn helices α2 and α3 are stabilized by a 
zinc atom (Zn3) that is chelated by residues Cys42 and His44 of a Zn-knuckle within loop 
L5 while Cys53 and Cys56 originate from L6 and α3, respectively. An extensive array of 
hydrogen bonds is observed between the main chains of residues in loop L7 and Thr54 
in α3 (Figure 4D). These multiple hydrogen-bonding interactions play a major role in the 
formation of a compact zinc finger. Arteri- and coronaviruses appear to tolerate replace-
ments (Cys for His or vice versa) at the second and fourth residues of this finger (36,37), 
which can be described by the characteristic, conserved Cys-[His/Cys]-Cys-[His/Cys] pat-
tern. Finally, Linker1 includes only one structured element (α4), but it plays a central role in 
the interaction between the main body of the ZBD and HEL1, as detailed below.
The structural basis for the essential role of the ZBD in EAV nsp10 helicase 
function
Previously, ZBD mutagenesis demonstrated the in vitro and in vivo importance of this 
domain for nsp10 enzyme activities, genome replication and transcription, and arteri-
virus viability. The solved structure now provides us with a structural basis for these 
observations. The ZBD packs against the HEL1 domain through extensive hydrophobic 
and hydrophilic interactions (Figures 5A and 5B). Specifically, residues Leu138, Val141, 
Val143, Leu147, Pro247, Val248, Leu280, and Trp281 in domain 1A together with residues 
Ile71, Leu72, Leu75, Leu76, and Ile79 from α4 in the ZBD create an extensive hydropho-
Figure 5. Inter-domain interactions of the ZBD and HEL1 domains 1A and 1B. (A) Overview of the spatial 
orientation of the essential interaction helix α4 of the ZBD. (B) Close-up view of the domain interface. Resi-
dues engaged in interactions are shown as sticks. Domain colors are the same as in Figure 2A. (C) DNA-
binding assay of EAV nsp10Δ mutants with reduced Zn2+-binding capabilities. Position of free DNA and 









































bic surface. The total interface area between the ZBD and HEL1 is 1019 Å2, as determined 
by Protein Interfaces, Surfaces, and Assemblies (PISA) (50). A major part of this interface 
involves the α4 helix, which is located in a groove formed by two helices and a loop of 
domain 1A while making extensive contacts to the main body of the ZBD and, to lesser 
extent, domain 1B (Figure  5). The interface areas between α4 and domain 1A, on the 
one hand, and the ZBD fingers (including zinc ions) on the other hand, are 558.1 Å2 
and 402.4 Å2, respectively. In addition, four hydrogen bonds between the ZBD and HEL1 
enhance the interaction (Figure 5B), and a salt bridge is observed between His78 in the 
ZBD and Asp136 in domain 1B (Figure 5B). The large size of these interface surfaces and 
the large number of interactions suggest the existence of a signaling network through 
which the ZBD could affect both the fold and activity of HEL1.
The proposed signaling network can now be used to rationalize, in a structural con-
text, the previously reported phenotypes of EAV ZBD mutants carrying replacements 
of residues not directly involved in zinc-binding. For instance, a replication-negative 
phenotype was described for mutant D45A (36). It is now clear that Asp45 forms two 
hydrogen bonds with the main and side chain of Thr35 and electrostatically interacts 
with the side chain of His34, which both belong to the RING-like zinc finger (Figure 4D). 
Replacement of Asp45 may thus greatly reduce these interactions and disrupt ZBD in-
tegrity, potentially affecting the structural integrity of HEL1. Another residue, Ser59, was 
probed extensively by mutagenesis after the finding that a virus mutant (EAV030F) car-
rying a S59P mutation replicates its genomic RNA with wild-type efficiency while being 
completely defective in sg mRNA synthesis (38). This transcription-negative phenotype 
was attributed to the severe structural constraints exerted by Pro residues on the local 
conformation of the proposed hinge region, since various substitutions of Ser59 alone 
(to Ala, Cys, Gly, His, Leu, or Thr) yielded virus mutants with a wild-type phenotype while 
combining the neutral S59G mutation with a P60G substitution reproduced the specific 
defect in sg mRNA synthesis (36). This interpretation is now further supported by the 
nsp10Δ structure in which Ser59 and Pro60 are located in the hinge connecting the 
treble-clef zinc finger and α4 of the ZBD. The main chain of Ser59 forms three hydrogen 
bonds with the treble-clef Thr54, which is also connected to the Pro60 side chain and 
Lys61 main chain (Figure 4D). Due to the unique properties of the Pro residue, the Ser59-
to-Thr54 bonds are likely disrupted by the S59P mutation but are not affected by the 
alternative replacements tested. Consequently, also due to the main chain rigidity as-
sociated with the introduction of a Pro residue, the orientation of α4 relative to 1A and/
or the main body of the ZBD is likely affected in mutant S59P, which carries adjacent Pro 
residues at positions 59 and 60. Likewise, the introduction of two Gly residues at these 
positions (double mutant S59G/P60G; (36)) probably gives rise to excessive flexibility of 













































To further explore the role of the ZBD, we tested the effect of four mutations (C25A and 
H29A in the RING-like module; H44A and C53A in the treble-clef zinc finger) expected to 
affect the ability to bind Zn1, Zn2, or Zn3, respectively. In agreement with the proposed 
structural role of these zinc ions, soluble His-tagged proteins containing these muta-
tions could not be obtained, and only low yields of GST-nsp10 fusion proteins carrying 
the same mutations could be recovered. For mutants C25A and H29A, band shift analysis 
revealed a complete loss of binding to a partially double-stranded DNA substrate con-
taining a 5’ single-stranded poly(dT) overhang (substrate 5’-DNA-T10; Figure 5C, lanes 
3 and 4). These results complement previous findings showing a complete loss of both 
ATPase and helicase activity for these mutants (37). In contrast, the level of nucleic acid 
binding by mutants H44A and C53A was comparable to that of the wild-type protein 
(Figure 5C, lanes 5 and 6), consistent with nsp10-H44A retaining a limited level of ATPase 
and helicase activity (37). Upon further testing, we observed that the addition of 40 mM 
EDTA altered the overall conformation of nsp10Δ, as detected by changes in circular 
dichroism (Figure S4A), and reduced its binding to 5’-DNA-A10 (Figure S4B). In summary, 
these results reveal that the ZBD interacts extensively with the HEL1 domain and that its 
integrity is an essential determinant of nsp10Δ properties in in vitro assays.
Structural resemblance between EAV nsp10Δ and mRNA decay factor Upf1
Next we analyzed the existence of structural similarity between EAV nsp10Δ and other 
proteins by scanning a protein data bank using the DALI server (51). The structure of 
the nsp10Δ HEL1 domain was found to be most similar (Z score, 20.9; root-mean-square 
deviation (RMSD), 3.5 Å) to the helicase core of nonsense-mediated mRNA decay factor 
Upf1 and its homolog Ighmbp2 (Z score, 19.9; RMSD, 3.0 Å), which both belong to the 
Upf1-like helicase subfamily (11). Further comparisons revealed that this resemblance 
extends into the respective N-terminal zinc-binding domains. The binuclear RING-like 
module of the nsp10Δ ZBD was found to be most similar to RING-like module 1 in the CH-
domain of Upf1 (Figure 4E). This similarity was rather limited (Z-score of 1.9 and RMSD of 
2.2 Å) because only six out of the eight zinc-chelating residues in the two domains could 
be juxtaposed (Figure 4F) and because loops L1, L3 and helix α1 in nsp10Δ are shorter 
than the corresponding elements in Upf1. We did not detect significant similarity of the 
treble-clef zinc finger with other proteins although we note that the Upf1 CH-domain 
also has a zinc finger (but of a different fold) downstream of the RING1 module. Thus, the 
EAV nsp10 ZBD prototypes a novel and complex multi-domain zinc finger with distinct 
structural properties. On the other hand, EAV nsp10 and Upf1 share a similar domain 
organization, including structurally similar RING and helicase domains. These similarities 









































these helicases and likely extend to other nidovirus helicases in view of the observed 
sequence conservation (Figure S3B).
Structure of EAV nsp10Δ in complex with a nucleic acid substrate
We proceeded to solve the crystal structure of nsp10Δ in complex with a nucleic acid 
substrate. Nidovirus RNA helicases, including EAV nsp10, were previously found to lack 
the ability to discriminate between RNA and DNA substrates, a property shared with 
only a few other helicases (34,35). This substrate promiscuity allowed us to use a partially 
double-stranded DNA substrate (5’-DNA-T10) containing a 5’ single-stranded poly(dT) 
overhang for crystallographic studies. The binding of this substrate was deduced from 
an increase of the protein’s Stokes radius in gel filtration chromatography (Figure S5). 
The binary complex diffracted to a resolution of 2.65 Å in space group P1 and was solved 
by molecular replacement (Table 1). Continuous electron density was found in the en-
zyme’s binding pocket (Figure 2C), which apparently corresponded to seven thymidine 
residues. This part presents in an extended conformation and lies in a channel formed 
by domains 1A, 1B, and 2A, with its 5’ end in domain 2A and its 3’ end in domain 1A. 
The remaining three unpaired thymidines and the entire double-stranded portion of 
the substrate could not be located. The asymmetric unit contained four nsp10Δ-DNA 
binary complexes with a Matthews coefficient of 2.73 Å3/Da, corresponding to a solvent 
content of 55%. These complexes shared a remarkably similar spatial arrangement with 
the RMSD of their Cα atoms being only 0.8 Å. Several connecting residues between sub-
domains were missing in the structure of the complex, indicating apparent structural 
flexibility of these residues.
Nucleic acid binding induces profound conformational changes outside the 
HEL1 domain of nsp10Δ
The Cα atoms of domains 1A and 2A of free nsp10Δ and the nsp10Δ-DNA complex can 
be superimposed with an RMSD of 0.6 Å, indicating that the relative orientations of 
these core domains are barely affected by DNA binding (Figure 6A). However, outside 
these domains the effect of DNA binding was considerable, with the RMSD between 
the Cα atoms of the two forms of nsp10Δ increasing to 1.8 Å. Particularly large con-
formational changes were observed in domain 1B, which rotates approximately 28º 
towards the ZBD in the nsp10Δ-DNA complex (Figure 6A). The RMSD between the Cα 
atoms of the two forms of domain 1B is 1.8 Å, with loop residues being affected most 
profoundly (Figure S6A). Both width and height of the polynucleotide substrate channel 
formed by domains 1A and 1B (originally about 5 and 11 Å, respectively) are increased 













































single-stranded nucleic acids although it remains too narrow for a nucleic acid duplex 
(Figure  6B). Consequently, double-stranded nucleic acids must be unwound at the 
entrance of the substrate channel to let a single-stranded chain enter. Besides this large 
conformational change, temperature factor calculations suggest that the regions at the 
surface of domain 1B not directly involved in DNA binding may become flexible (Fig-
ure S2). For example, domain 1B residues Arg95, Gly125, and Ala131 become disordered 
after DNA binding (Figures 2C, 3B, and S2).
Upon DNA binding, a structural change was also observed in the treble-clef zinc finger 
of the ZBD, as reflected by its relatively high temperature factor (compared to that of do-
mains 1A and 2A) in the nsp10Δ-DNA complex as opposed to nsp10Δ alone (Figure S2).
Substrate recognition by EAV nsp10Δ is sequence-independent
As outlined above, the single-stranded part of the DNA substrate is bound to a nucleic 
acid-binding channel formed by domains 1A, 1B, and 2A (Figure  2C). The backbone 
phosphates of the poly(dT) are located on top of domains 1A and 2A, with the thymine 
bases exposed to the solvent (Figure S7A). The majority of contacts with the bound DNA 
are made via the phosphodiester backbone and nonspecific protein-base interactions 
as depicted in Figure 7.
Consistent with this observation, the base orientation varies in the four EAV nsp10-
poly(dT) complexes of the asymmetric unit while the position of the DNA backbone is 
rather rigid (Figures S7B and S7C). Several key residues from domains 1A and 2A contact 
the DNA backbone in the channel of the protein (Figures 7A and 7B). Base T1, the most 
5’ one, is exposed to the solvent and protrudes outwards, causing a bend in the DNA 
backbone between T1 and T2. The bases T2 and T3 as well as T5 and T6 stack with each 
Figure 6. Conformational changes of EAV nsp10Δ upon nucleic acid binding. (A) Comparison of the free 
and DNA-bound states of nsp10Δ. The arrow indicates the movement of domain 1B (cartoon) in the DNA-
bound state compared to the free state. (B) Surface model of the channel formed by domains 1A and 1B 
in the DNA-bound state and (C) the DNA-free state. Domain colors are the same as used in Figure 2A. Note 









































other at an average distance of 3.7 Å. In contrast, base T4 is almost perpendicular to 
T3, with its edge exposed to protein side chains that make specific contacts. Val271 in 
domain 1A forms van der Waals contacts with the base and the sugar ring of T4 and thus 
stabilizes the DNA conformation. Moreover, the binding is stabilized by several hydro-
gen bonds between His186, His339, Thr348, Ser351, and the backbone of the DNA and 
by van der Waals contacts between Thr185, Leu227, Val230, Tyr338, and the phosphate 
groups of the DNA. While the interactions described above do not involve specific bases, 
six further interactions specific for thymine were found. For example, the backbone NH 
of Arg102 forms a hydrogen bond with the O4 atom of T6. The O2 and O4 atoms of 
base T3 form hydrogen bonds with the side chains of Asp350 and Tyr81. Also, several 
residues, such as Arg374 and Gln229, interact with both the base and the sugar ring. 
However, no interaction was observed between nsp10Δ and position C2’ of the ribose 
ring of the DNA substrate. This observation may explain why EAV nsp10 has the ability 
to unwind both DNA and RNA, in agreement with the substrate specificity observed for 
other helicases (52,53) possessing or lacking the ability to interact with the 2’ OH moiety 
of the RNA backbone.
DISCUSSION
Among (+) RNA viruses, whose RdRps generally have a high error rate, nidoviruses stand 
out for their large to very large genome size (13 to 32 kb). Consequently, the replication 
fidelity of nidoviruses, in particular coronaviruses, has been the subject of intense study. 
Most recently, the identification of a unique 3’-5’ exoribonuclease (ExoN) activity has 
provided the basis for the hypothesis that a primitive proofreading mechanism operates 
Figure 7. Interactions between EAV nsp10Δ and a DNA substrate. (A) Stereo view of the nucleic acid-
binding pocket of nsp10Δ. Bound single-stranded DNA and the interacting residues are shown as sticks. 
Nucleotides are numbered (T1 to T7) in the 5’-3’ direction and are shown in orange. Residues are colored 
according to their domain origin as indicated in Figure 2A. (B) Schematic representation of the contacts 













































to promote the fidelity of RNA-dependent RNA synthesis in nidoviruses with  >20 kb 
genomes (21-27).
Despite this recent progress, the two central subunits of the nidovirus replicase, the 
RdRp and the unique ZBD-containing RNA helicase, have remained poorly character-
ized, also due to the lack of structural information. Remarkably, our present analysis of 
the arterivirus helicase structure revealed a number of important similarities to Upf1 
helicases, eukaryotic enzymes involved in quality control of RNAs through multiple 
pathways, including nonsense-mediated mRNA decay (54-56). In contrast to the ExoN-
driven control of replication fidelity (see above), the possibility of post-transcriptional 
quality control of nidovirus mRNAs has not been considered thus far. Yet, replicase 
ORF1ab is extremely large (from 3175 to over 7000 codons) and its correct expression 
by translation of the viral genome is a critical first step in the production of the enzymes 
directing genome replication and expression. Therefore, our study not only provides the 
first insights into the structural basis for nidovirus RNA helicase function but also creates 
a basis to propose a role for this protein in the post-transcriptional quality control of viral 
mRNAs. This role may be common to all nidoviruses, regardless of their genomes size, 
which would distinguish it from the ExoN-based proofreading mechanism that appears 
to be restricted to nidoviruses with a >20 kb genome. On the time scale of nidovirus 
evolution, the acquisition of ZBD-HEL1 may have been a critical event to facilitate the 
genome expansion of ancestral small-sized nidoviruses thus setting the stage for the 
subsequent ExoN-driven expansion towards even larger nidovirus genomes (19,57).
EAV nsp10 represents a multi-domain helicase conserved in nidoviruses
Previously, using bioinformatics, biochemistry, and molecular genetics, it was estab-
lished that nsp10 of arteriviruses and its orthologs in other nidoviruses are multi-domain 
proteins. Of its domains the ZBD and HEL1 domains are critical for the enzyme’s ATPase 
and helicase activities in vitro and for the regulation of viral replication and transcription 
in infected cells. Our structural and biochemical studies extended the characterization 
of known domains and delineated two hitherto uncharacterized domains: one (domain 
1B) flanked by the ZBD and HEL1, and the other (C-terminal domain) located down-
stream of HEL1, with its structure remaining to be solved. Our data show that, along 
with the ZBD, these two non-enzymatic domains may regulate HEL1 function. Given 
that nsp10/nsp13 is one of only three proteins whose nidovirus-wide conservation can 
be detected at the sequence level (19,24,25,28), the nsp10Δ structure should be ap-
plicable to other nidovirus helicases, including those of PRRS viruses and coronaviruses. 
However, considerable size differences exist between arteri- and coronaviruses in the 









































appreciable sequence conservation. Thus, helicase structures from other small- and 
large-genome nidoviruses will be required to fully understand the enzyme’s function.
The nsp10 C-terminal domain: coupling ATPase and helicase activities?
While attempting to solve the EAV nsp10 structure, we were confronted with the low 
stability of the full-length recombinant protein expressed in E. coli. We solved this prob-
lem by characterizing the C-terminally truncated nsp10Δ, which lacks the 65 residues 
(C-terminal domain) downstream of the known HEL1 motifs. This protein was found to 
bind partially double-stranded DNA and display the previously reported in vitro ATPase 
and helicase activities. Since, compared to full-length nsp10, nsp10Δ appeared to be 
somewhat more active as an ATPase but somewhat less active as a helicase, the C-ter-
minal truncation may have affected the coupling of these two enzymatic activities. This 
suggests that the C-terminal domain may have evolved to (co-)regulate nsp10 helicase-
mediated functions in vivo, implying that it must be able to communicate with the nsp10 
active site. This could be achieved either directly, by interacting with the nucleic acid- or 
ATP-binding site (the nsp10Δ C-terminus is separated by ~22.5 Å from the active center; 
Figure  2C), or indirectly, through a protein signal transduction network. Importantly, 
the C-terminal domain is poorly conserved among arteri- and coronaviruses in terms of 
both sequence and size (Figure S3A and data not shown), arguing that such a putative 
regulatory function could be executed in a virus- and, possibly, host-specific manner.
The nsp10 structure: defining a complex ZBD
Our characterization of the EAV nsp10 structure verified and revised a model of the N-
terminal ZBD based on prior studies (36,37,58). It resolved the uncertainty about the 
number of zinc ions bound (now established to be three) and the fold of this domain (a 
unique structure combining a RING-like module fused with a treble-clef zinc finger). Fur-
thermore, it redefined the C-terminal border of the ZBD and placed it thirteen residues 
downstream to include a third, hitherto unrecognized, structural element (helix α4). Pre-
viously, we analyzed a variety of EAV nsp10 ZBD mutants in which putative zinc-binding 
residues were replaced in a manner (Cys→His or His→Cys) that could preserve zinc bind-
ing (36,37). From the solved structure, it is now apparent that the replication-negative 
phenotypes of these virus mutants can likely be attributed to the detrimental impact 
of the respective mutations on ZBD integrity and, through the extensive interaction 
network, the HEL1 domain. It presently remains unclear why the replacement of His44 
by Cys in the treble-clef zinc finger was partially tolerated. On the other hand, structural 
superposition of the RING-like modules of nsp10 and hUpf1 (Figure 4E) reveals how the 













































His (found in the equivalent position in hUpf1), could be accommodated by nsp10. The 
RING-like module 1 of Upf1 also shares structural similarity with RING-box domains of E3 
ubiquitin ligases (59), and the involvement of this module in self-ubiquitination of Upf1 
was indeed demonstrated (60). It would be interesting to see whether these results are 
relevant for nsp10 and its ZBD. Recently, arterivirus papain-like protease 2 was found to 
have deubiquitinase activity, which suppresses the innate immune response in infected 
host cells (61,62).
The nsp10-nucleic acid complex: towards the dsRNA unwinding mechanism
To understand how nsp10 unwinds its natural dsRNA substrates, we analyzed a complex 
of nsp10Δ with a partially double-stranded DNA substrate. Only seven thymidine resi-
dues could be confirmed in the structure of that complex (Figure 2C). The DNA-bound 
nsp10Δ structure revealed two possible RNA-binding clefts at the surface of nsp10, 
which are formed by domain 1B and the ZBD (named putative exit site 1), and 1A and 
the ZBD (putative exit site 2), respectively (Figure S8). Both have continuous positively 
charged surfaces, with the latter (Figure S8, right panel) being sufficiently large to bind 
a ssRNA longer than ten base pairs, which could be especially suited for unwinding 
complex secondary structures. This organization suggests that, after unwinding, one of 
the separated RNA chains would be guided through the narrow nucleic acid substrate 
tunnel formed by domains 1A, 1B, and 2A while the path of the other strand remains 
to be defined. No matter which cleft is actually used for RNA binding, the positively 
charged ZBD, and especially its RING-like module, would be involved.
Like the protein-binding surface of the Upf1 CH domain (54), the ZBD has a putative 
protein interaction surface composed of two major hydrophobic zones that are almost 
perpendicular to each other (Figure 8). Nucleic acid binding induced a conformational 
change (Figure S6B) of these two zones. In addition, the temperature factor of the treble-
clef zinc finger was higher and several residues are disordered in the structure of the 
nsp10Δ-DNA complex (Figure S2). Together these findings imply that these two zones 
are readily accessible for interactions with other proteins, which may further influence 
nucleic acid binding.
Substrate binding by nsp10 is accompanied by structural changes in domain 1B and 
the treble-clef zinc finger, which may be recognized by yet-to-be identified interaction 
partners modulating nsp10 function. The treble-clef zinc finger is fairly distant from the 
bound substrate, suggesting long-distance signal transduction within nsp10, possibly 
involving helix α4, which interacts with 1A, 1B, and nucleic acid and is directly connected 









































finger and helix α4 is likely compromised by the previously described S59P and S59G/
P60G mutations that, importantly, were found to impair viral sg mRNA synthesis but 
not genome replication (36). Consequently, the described inter-domain communication 
channel may be used by nsp10 and its partners for switching from a role in genome 
replication to directing viral transcription, a hypothesis that will be the subject of future 
studies.
Nidovirus helicase: a role in post-transcriptional quality control of viral mRNAs?
The observed structural similarity between the EAV nsp10 and Upf1 helicases is most 
remarkable, in particular since it extends to include the multi-domain organization es-
sential for helicase function. This organization is only found in Upf1 of all eukaryotes (59) 
and nidovirus helicases (19,24,25,28). For Upf1, its conservation was linked to the pro-
tein’s universal role in post-transcriptional quality control of eukaryotic RNAs through 
multiple pathways, including nonsense-mediated mRNA decay (54-56). Upf1 interacts, 
commonly through its CH and 1A domains, with proteins that can modulate its func-
tion. For the nidovirus helicase subunit, the functional basis of its domain conservation 
remains to be firmly established although ZBD – like CH in Upf1 (63) – affects helicase 
activity (36,37).
If the nidovirus helicase possesses some of the properties of Upf1, this could explain the 
exclusive conservation of the ZBD in nidoviruses, which stand out for their large to very 
large single-stranded RNA genomes. For instance, by providing post-transcriptional 
Figure 8. Putative protein interaction surfaces of the EAV nsp10Δ ZBD. (A) Overview of surface charges of 
nsp10Δ. The putative protein interaction surfaces are indicated by a yellow circle. (B) Close-up view of zone 
1 (orange) and zone 2 (magenta). Hydrophobic residues are shown as sticks. (C) Surface representation of 













































quality control of genomic RNA, i.e. detection of non-sense and/or other mutations 
and elimination of defective molecules, the nidovirus helicase could alleviate the con-
sequences of the generally low fidelity of RNA virus genome replication. Such a role of 
ZBD-HEL1 may have protected an ancestral nidovirus from the mutational meltdown of 
its expanding genome, quite similar to the proposed fixation of the proofreading ExoN 
domain at a later stage of nidovirus evolution (19,24,25,28). Subsequently, the enzyme 
would have facilitated expansion to the genome size observed in contemporary arteri-
viruses and remained a critical factor in the further ExoN-driven genome expansion to 
evolve middle- and large-sized nidoviruses. Thus, the proposed Upf1-like role of the 
nidovirus helicase can be accommodated in a meaningful evolutionary scenario incor-
porating several of the structural and functional observations made in this study. The 
structural similarity between nsp10 and Upf1 establishes a new connection between 
research on viral and cellular helicases, which could be mutually insightful for under-
standing the evolution and function of this group of vitally important enzymes.
MATERIALS AND METHODS
Cloning, expression, and purification of soluble EAV nsp10
Nsp10 of the EAV-Bucyrus isolate (NCBI Reference Sequence NC_002532) is comprised 
of amino acids 2371 to 2837 of replicase pp1ab, which will throughout this study be 
referred to as nsp10 residues 1 to 467. The full-length nsp10 sequence or a C-terminally 
truncated version comprising residues 1 to 402 (nsp10Δ) were cloned into a modified 
pET28a vector with a tobacco etch virus (TEV) protease cleavage site. Mutations were 
generated using the QuikChange protocol and confirmed by DNA sequencing. The 
proteins were overexpressed at 37°C in E. coli strain BL21 (DE3) grown to an OD600 
of about 0.8 in Luria–Bertani medium in the presence of 50 µg/ml kanamycin. Protein 
expression was induced with 0.2 mM isopropyl β-D-1-thiogalactopyranoside for 12 h at 
16°C. Cell pellets were resuspended in lysis buffer (20 mM HEPES pH 7.0 for nsp10Δ or 
pH 8.0 for full-length nsp10, 500 mM NaCl and 30 mM imidazole), supplemented with 
protease inhibitor cocktail (Roche) and disrupted by sonication. Lysates were clarified 
at 20,000g for 30 min, and the soluble fraction was applied to a Ni2+ chelating column. 
After sample loading, the column was washed (20 mM HEPES, pH 7.0 or 8.0, 500 mM 
NaCl and 60 mM imidazole), and the protein was eluted (20 mM HEPES, pH 7.0 or 8.0, 
500 mM NaCl and 400 mM imidazole). Proteins intended for ATPase or helicase assays 
were dialyzed against storage buffer (20 mM HEPES, pH 7.0 or 8.0, 100 mM NaCl, 50% 
glycerol) and stored at 20°C. Truncated protein for crystallization studies was digested 









































by size-exclusion chromatography using a Superdex 200 column (GE Healthcare) with 
GF buffer (20 mM HEPES, pH 7.0, 500 mM NaCl). The peak fraction was collected and 
analyzed by SDS-PAGE.
Crystallization and data collection
Purified nsp10Δ was concentrated to 10 mg/ml and initial crystallization trials were 
performed at 16°C using the sitting-drop vapor-diffusion method by mixing 1 µl protein 
solution with 1 µl reservoir solution. The conditions were then optimized and high-
quality crystals were obtained in 1.6 M (NH4)2SO4, 0.1 M HEPES, pH 7.1, 25 mM KCl and 
20% ethylene glycol. To obtain crystals of the protein-DNA complex, purified protein 
and partially double-stranded DNA with a 5’ single-stranded poly-thymidine overhang 
(the two partially complementary sequences were 5’-TTTTTTTTTTGCAGTGCTCG-3’ and 
5’-CGCGAGCACTGC-3’) were mixed in a 1:1.5 molar ratio and incubated at 4°C overnight. 
The complex was further purified by size-exclusion chromatography (Superdex 200, GE 
Healthcare) and concentrated to 5 mg/ml. The condition for obtaining crystals was 14% 
PEG 3350, 0.1 M HEPES, pH 7.0, and 0.2 M calcium acetate. For data collection, crystals 
were cryoprotected in mother liquor containing 25% (v/v) ethylene glycol and flash 
cooled to 173°C.
The MAD data for intrinsic zinc atoms were collected on beamline 1W2B at the Beijing 
Synchrotron Radiation Facility. The data for EAV nsp10Δ and its complex with DNA 
were collected at beamline NE3A at Photon Factory (KEK) and beamline BL17U1 at the 
Shanghai Synchrotron Radiation Facility. Data was indexed, integrated and scaled using 
HKL2000 (41). Data collection and processing statistics are summarized in Table 1.
Structure determination
The structure of nsp10Δ was determined by the MAD method. Initial phases were 
calculated by SOLVE, and phases were subsequently improved using RESOLVE (42). 
The figure of merit from the MAD phasing was 0.36, and the Z score was 15.7. Several 
segments of the protein could be automatically modeled into the electron-density map 
by RESOLVE although in part only as poly-alanine chains. Manual rebuilding was per-
formed in COOT (43), and refinement was performed with REFAMC5 (44). Further rounds 
of refinement were done with Translation/Libration/Screw (TLS) refinement (45). The 
structure was refined to 2.0 Å with an Rwork of 19.5% and an Rfree of 22.4%.
Using the structure of free nsp10Δ without domain 1B as input model, the structure 













































The initial model was obtained by MOLREP from the CCP4 program suite (46). A good 
match for domains ZBD, 1A, and 2A with electron density was found. Domain 1B was 
manually added with the aid of 2Fo–Fc and Fo–Fc maps using COOT (43). DNA molecules 
were included in the final stages of refinement. Difference Fourier maps clearly showed 
electron densities for seven bound deoxyribonucleotides. The final model was refined to 
2.65 Å with an Rwork of 23.2% and an Rfree of 25.7%. All figures in this article displaying 
molecular structures were made using PYMOL (47).
ACCESSION NUMBERS
The coordinates and structure-factor amplitudes of EAV nsp10D and EAV nsp10D–DNA 
complex have been deposited in the Protein Data Bank with accession codes 4N0N and 
4N0O, respectively.
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Supplementary Data are available at NAR online, including Supplementary References 
(64-66).
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All DNA oligonucleotides were purchased from Invitrogen. Radioactive labeling of the 
5’ end of single-stranded DNA was done with T4 polynucleotide kinase (Invitrogen) and 
[γ-32P]ATP according to the manufacturer’s protocol. DNA duplexes used for crystal-
lization, helicase assays, and electrophoretic mobility shift assays were annealed in a 
buffer containing 10 mM Tris-HCl pH 8.0 and 100 mM NaCl. Annealing was performed 
by first heating the mixture at 90°C for 5 min and then slowly letting it cool to room 
temperature in 2 h.
ATPase assay
ATPase activity of full-length nsp10 and nsp10Δ was assayed in 5 µl reactions containing 
100 nM purified recombinant protein, 1 mM ATP (including 250 nCi [α-32P]ATP, 3000 Ci/
mmol), 20 mM Tris-HCl, pH 7.5, 2 mM MgCl2, 1 mM DTT, 0.01 mg/ml BSA. Additionally 
5% glycerol and 10 mM NaCl were introduced by the protein storage buffer. Where indi-
cated 1 µM poly-uridine RNA with a length of 30 nucleotides was added. Samples were 
incubated for up to 30 min at 20°C before 1 µl 500 mM EDTA was added to stop the 
reaction. A 0.25 µl aliquot of each sample was analyzed by polyethyleneimine cellulose 
thin-layer chromatography with 0.45 M ammonium sulfate as mobile phase. Plates were 
dried and analyzed using storage phosphor screens, which were subsequently scanned 
on a Typhoon 9410 variable mode imager (GE Healthcare). ATP turnover was quantified 
using ImageQuant TL software (GE Healthcare).
Helicase assay
100 nM protein and 1 nM of radioactively labeled partially double-stranded DNA (Hel1, 
5’-TTTTTTTTTTGCCTCGCTGCCGTCGCCACC-3’; Hel3, 5’-*GGTGGCGACGGCAGCGAGGC-3’; 
asterisk indicates the position of the radioactive label) were incubated for 10 min at 30°C 
in a buffer containing 20 mM Tris-HCl, pH 7.5, 10 mM NaCl, 2 mM MgCl2, 0.01 mg/ml BSA, 
and 0.01% Triton X-100. Additionally 5% glycerol and 10 mM NaCl were introduced by 
the protein storage buffer. After the initial binding phase, unwinding was started by 
addition of 5 mM ATP, and incubation continued at 30°C for up to 30 min. Reactions 
were stopped by mixing with an equal volume of loading buffer (20 mM Tris-HCl, pH 8.0, 
50 mM EDTA, 60% glycerol, 0.5% SDS, 0.1% bromophenol blue). To prevent re-annealing 
of the unwound radioactively labeled strand, an excess of unlabeled oligonucleotide 









































DNA were separated by 12% native PAGE (acrylamide:bis-acrylamide 19:1) run in ice-
cold 1×TBE (89 mM Tris, 89 mM boric acid, 2 mM EDTA). Gels were dried and analyzed 
using storage phosphor screens, which were subsequently scanned on a Typhoon 9410 
variable mode imager (GE healthcare).
Electrophoretic mobility shift assays
For EMSA, unless stated otherwise, 20 μM DNA was incubated with 30 μM nsp10Δ in 10-
µl reactions containing 20 mM HEPES, pH 7.0, 100 mM NaCl at 25°C for 2 hours. Samples 
were then analyzed on 8% native polyacrylamide gels (acrylamide:bis-acrylamide 19:1) 
containing 0.5×Tris-borate buffer and visualized by staining with ethidium bromide.
Circular dichroism analysis
Circular dichroism spectra were measured at beamline 4B8 at the Beijing synchrotron ra-
diation facility. Spectra of EAV nsp10Δ were collected at 1 nm intervals ranging from 250 
to 190 nm in a 0.0007 cm optical path length at 16°C in 0.1 M HEPES, pH 7.0, 50 mM NaCl. 
Far-UV CD spectra of 3 mg/ml EAV nsp10Δ with or without 40 mM EDTA were scanned. 
A pure solvent baseline was measured with the same cell and subtracted. All spectra 
were processed using the CD tool software package(64). The machine unit (mdeg) was 
converted into the per residue molar absorption unit, delta epsilon (Δε) in M/cm, by 













































Figure S2. Overall B-factors of the nsp10Δ-DNA complex, color-coded on the basis of the calculated B-
factors. The colors range from blue to red corresponding to increasing fluctuations. Dashed lines mean that 
residues have not been resolved.
Figure S1. Schematic representation of the proteolytic processing of the EAV multidomain replicase poly-
proteins pp1a and pp1ab. The nsp1/2 and nsp2/3 cleavage sites (cleaved by the nsp1 and nsp2 autoprote-
ases) are highlighted by red arrows, all other sites (indicated with black arrows) are cleaved by the 3CL pro-
tease in nsp4. Abbreviations: 3CL, serine/3C-like protease; RdRp, RNA-dependent RNA polymerase; HEL1, 











































Figure S3. (A) Alignment of nsp10 from different arteriviruses. The zinc-binding domain (ZBD), 1B, 1A, 
and 2A domains are colored yellow, magenta, green, and cyan, respectively. (B) Alignment of the helicase-
associated ZBD of selected arteri- and coronaviruses. RING-like module (pink), treble-clef zinc finger (red), 
and Linker1 (yellow) are indicated. Residues now known (EAV) or predicted to be involved in chelating 
Zn1, Zn2, and Zn3 are colored red, blue, and green, respectively. The residues involved in nucleic acid bind-
ing are highlighted with red background. The sequences were aligned using the program T-Coffee (65). 
The ALSCRIPT program (66) was used to prepare the figure. Sequence numbering and secondary structure 
designations are according to the EAV nsp10 sequence and structure. The sequences used are from: EAV, 
equine arteritis virus (GenBank accession number X53459); LDV, lactate dehydrogenase-elevating virus 
(U15146); PRRSV, porcine reproductive and respiratory syndrome virus (JX317648); SHFV, simian hemor-
rhagic fever virus (AF180391); SARS-CoV, severe acute respiratory syndrome coronavirus (AY291315); HCoV-














































Figure S4. Effects of EDTA on folding and DNA-binding activity of EAV nsp10Δ. (A) Superposition of far-
UV CD spectra of EAV nsp10Δ with or without EDTA. Error bars show the standard deviation. (B) EMSA of 
nsp10Δ with 5’-DNA-A10 as substrate in absence or presence of EDTA. The control lane shows the position 
of free DNA.










































Figure S6. Overlay of (A) 1B and (B) the ZBD in presence and absence of a bound DNA substrate. The 
DNA-free state is shown in gray. For the DNA-bound state, the 1B domain is shown in magenta, the RING-
like module in pink, treble-clef zinc finger in red, and Linker1 in yellow. The hydrophobic zone formed by 
residues V12, V26, P27, I46, V64, and P65 is shown in magenta ellipse.
Figure S7. Overlay of the substrate channels of the four nsp10-DNA complexes of the asymmetric unit. (A) 
Surface and (B) ribbon representation of the four binary complexes in the asymmetric unit. Poly(dT) is shown 













































Figure S8. Proposed nucleic acid binding sites of EAV nsp10Δ. Electrostatic surface representation of EAV 
nsp10Δ (left), a 90°-rotated view (right) and a top view (lower). Note that the regions around the 3’ end of 
the resolved single-stranded part of the nucleic acid substrate are rich in positive charges. The double-
stranded nucleic acid unwinding site and another putative single-strand exit site are indicated by a red-
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Helicases are versatile NTP-dependent motor proteins of monophyletic origin that are 
found in all kingdoms of life. Their functions range from nucleic acid duplex unwinding 
to protein displacement and double-strand translocation. This explains their participa-
tion in virtually every metabolic process that involves nucleic acids, including DNA 
replication, recombination and repair, transcription, translation, as well as RNA process-
ing. Helicases are encoded by all plant and animal viruses with a positive-stranded RNA 
genome that is larger than 7 kb, indicating a link to genome size evolution in this virus 
class. Viral helicases belong to three out of the six currently recognized superfamilies, 
SF1, SF2, and SF3. Despite being omnipresent, highly conserved, and essential, only 
a few viral helicases, mostly from SF2, have been studied extensively. In general, their 
specific roles in the viral replication cycle remain poorly understood at present. The 
SF1 helicase protein of viruses classified in the order Nidovirales is encoded in replicase 
open reading frame 1b (ORF1b), which is translated to give rise to a large polyprotein 
following a ribosomal frameshift from the upstream ORF1a. Proteolytic processing of 
the replicase polyprotein yields a dozen or so mature proteins, one of which includes 
a helicase. Its hallmark is the presence of an N-terminal multi-nuclear zinc-binding 
domain, the nidoviral genetic marker and one of the most conserved domains across 
members of the order. This review summarizes biochemical, structural, and genetic data, 
including drug development studies, obtained using helicases originating from several 
mammalian nidoviruses, along with the results of the genomics characterization of a 
much larger number of (putative) helicases of vertebrate and invertebrate nidoviruses. 
In the context of our knowledge of related helicases of cellular and viral origin, it dis-
cusses the implications of these results for the protein’s emerging critical function(s) in 
nidovirus evolution, genome replication and expression, virion biogenesis, and possibly 
also post-transcriptional processing of viral RNAs. Using our accumulated knowledge 
and highlighting gaps in our data, concepts, and approaches, it concludes with a per-














































1. HELICASES: CONSERVED BUT VERSATILE PLAYERS IN BIOLOGICAL 
PROCESSES UTILIZING NUCLEIC ACIDS IN VIRUSES AND HOSTS
Cellular life forms in all kingdoms, as well as positive-stranded (+) RNA viruses with a 
genome larger than 7  kb and a number of DNA viruses, encode (predicted) helicases 
on which they depend in various ways (1;2). Helicases are widely recognized for their 
capability to resolve base pairs in nucleic acid duplexes in an NTP- and metal-dependent 
manner (Figures 1A and D). Additionally, some helicases were shown to displace proteins 
present in polynucleotide-protein complexes (Figure  1B) (3) and to translocate along 
double-stranded DNA or RNA without unwinding it (Figure  1C) (3;4). Besides replica-
tion, their unwinding activity may be utilized in many other processes including, but 
not limited to, DNA repair, transcription, RNA maturation and splicing, and translation. 
Thus, it is not surprising that as much as 1% of all prokaryotic and eukaryotic genes were 
estimated to encode helicases (5).
1.1 Helicase classification and domain organization
Helicases are classified into six evolutionary compact and interrelated superfamilies 
(SFs  1-6), which were established using statistically significant sequence similarity, 
corroborated and extended by subsequent structural analyses of selected members 
(3;5). Among the SF members classified are relatively few characterized helicases and 
numerous related proteins, whose number has steadily increased along with genom-
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Figure 1. Schematic representation of NTP-dependent helicase activities. (A) Unwinding of a nucleic acid 
duplex. (B) Displacement of protein bound to nucleic acid. (C) Translocation along a double-stranded nu-
cleic acid without unwinding. (D) Typical result of a biochemical nucleic acid unwinding assay. Shown is 
the helicase activity of equine arteritis virus (EAV) nsp10 and a corresponding active site mutant carrying 










































ics projects. The helicase SFs are distinguished by characteristic conserved sequences 
(motifs) that are often used to identify new members. Helicases of the two larger su-
perfamilies, SF1 and SF2, are characterized by their monomeric or dimeric state and the 
presence of up to twelve conserved sequence motifs involved in NTP and nucleic acid 
binding and the coordination thereof (2;3;7). In contrast, SFs 3-6 require the formation 
of hexamers or dodecamers in order to be active and contain just three to four signature 
motifs. Only some of these motifs are specific to a particular superfamily, while oth-
ers may be conserved in a more or less diverse group of proteins. For instance, motifs 
I and II (or the Walker A and B boxes, respectively (8)), are common to all helicase SFs 
and are also conserved in many NTPases that lack helicase activity, attesting to the fact 
that helicases form an evolutionary lineage within a very diverse class of NTP-utilizing 
enzymes. All motifs are embedded in a catalytic core. In SF1 and SF2, it is formed by two 
RecA-like domains, designated 1A and 2A, that emerged by duplication and extensive 
divergence (9-11). In contrast, members of SFs 3-6 employ a helicase core composed of 
a single RecA-like domain. It is this helicase core which essentially allows the conversion 
of chemical energy stored in NTP phosphodiester bonds to mechanical energy that 
fuels the directional movement of the protein along a nucleic acid strand. SF1 and SF2 
members typically include additional domains that may be located upstream and/or 
downstream of 1A and 2A, or inserted within those domains. In some helicase proteins, 
the size of these accessory domains exceeds that of the actual helicase core domains. 
Such insertions are thought to govern specific protein functions, including helicase 
activity per se, by engaging in protein-protein and protein-nucleic acid interactions or 
through additional enzymatic activities. This modular design contributes importantly to 
the versatility of this enzyme group and serves to achieve specificity (2;3;12).
1.2 SF1 helicases
The SF1 helicases, which are the focus of this review, have been further subdivided into 
three distinct families using structural and biochemical considerations (Table 1) (3). Each 
family was named after its most prominent members of the moment: UvrD/Rep, Pif1-like, 
and Upf1-like. The most striking difference between these families is the direction of 
translocation along their nucleic acid substrate. Relative to the single strand with which 
they associate, members of the first family traverse their substrate in the 3’-5’ direction 
(type A), whereas members of the other two families are moving from 5’ to 3’ (type B). A 
second distinguishing feature is the nucleic acid substrate preference, which is thought 
to be exclusive for DNA for the UvrD/Rep and Pif1-like families. In contrast, the Upf1-like 
family comprises members that may unwind either DNA or RNA, and in some cases both 
without a clear preference. As mentioned, the number of helicases identified through 













































and structurally characterized helicases. Consequently, it remains uncertain whether 
the above regularities faithfully reflect a different mode of nucleic acid binding in these 
families (2) or are due to a sampling bias of the characterized helicases.
1.3 SF1 helicases of RNA viruses
Viral helicases belong to one of three superfamilies, SF1 (e.g., alphavirus-like viruses, nido-
viruses, herpesviruses), SF2 (e.g., flaviviruses, herpesviruses), or SF3 (e.g., picornavirus-like 
viruses), with their role in the viral replicative cycle remaining largely unknown for any 
RNA virus (5;38;39). Given the apparent correlation between genome size and the pres-
ence of a helicase (1), it was speculated that these enzymes could either reduce nucleotide 
misincorporation (40) or assist in unwinding of long double-stranded regions during 
replication of (+) RNA viral genomes above a certain size threshold (41). Thus, expression 
of a helicase protein may be particularly important for viruses of the order Nidovirales, 
comprising the families Arteriviridae, Coronaviridae, Mesoniviridae, and Roniviridae, which 
are characterized by having large to very large (+) RNA genomes (13-34 kb) (42-44).













UvrD/Rep family              
UvrDb + - + - + n.d. 3’-5’
Repc + - + - + n.d. 3’-5’
PcrAd + + + + + n.d. 3’-5’
Pif1-like family              
Pif1e + + + + + n.d. 5’-3’
RecDf + + n.d. n.d. + n.d. 5’-3’
Ddag + - + - + n.d. 5’-3’
Upf1-like family              
Upf1h + - + - + + 5’-3’
Nidovirus helicasesi + + + + + + 5’-3’
Alphavirus nsP2j,k + + + + - + 5’-3’
Hepevirus Helk,l + + + + - + 5’-3’
Alphatetravirus Helk,m + + + + - + 5’-3’
n.d. not done; aconsidered negative if activity  <10% of ATPase activity; b(13-15); c(16-18); d(19); e(20;21); 
f(22) g(23;24); h(25;26); i(27-32); j(33-36); kbased on biochemical properties and a high structural similarity of 
domains 1A and 2A of tomato mosaic virus Hel to those found in Upf1 we propose to classify the related 










































In this review, we will summarize the state of the art of our knowledge and recent ad-
vances in our understanding of these nidovirus enzymes. In particular, we will emphasize 
similarities and differences between nidovirus helicases and other viral and non-viral 
SF1 helicases and their implications for helicase functions in the nidovirus replication 
cycle. We will start with a summary of our understanding of the structural organization 
and enzymatic activities of SF1 helicases, which is based on the analysis of few cellular 
enzymes. In our comparative analysis, we will frequently refer to SF1 helicases of the 
alphavirus-like supergroup, the only other large group of (+) RNA viruses that uniformly 
encodes a SF1 helicase (45). Among this supergroup, which includes a dozen animal and 
plant virus families with (+) RNA genomes in the size range of 7-20 kb, the helicases of 
the animal alphaviruses Semliki Forest virus (SFV) and chikungunya virus (CHIKV), the 
hepevirus hepatitis E virus (HEV), as well as the plant tobamovirus tomato mosaic virus 
(ToMV) have been biochemically characterized to some extent (33-35;45-47). To limit the 
scope of this review, comparisons are restricted to data on these proteins while the large 
body of literature on the genetics of helicase mutants of alphavirus-like plant viruses 
(e.g. see (48)) is not discussed.
2. THE STRUCTURAL BASIS FOR HELICASE TRANSLOCATION, 
DIRECTIONALITY, AND UNWINDING
When characterizing helicases enzymatically and structurally, some of the major ques-
tions asked address the type of substrate used, the direction of movement, rate and 
processivity, the coupling of helicase properties to specific biological functions, and the 
regulation of the enzymes’ activities. In this section, we will briefly summarize our un-
derstanding of mechanisms of SF1 helicase unwinding and directional movement along 
a nucleic acid. Helicases may unwind polynucleotides that are either fully or partially 
double-stranded, including DNA/DNA, DNA/RNA, or RNA/RNA duplexes (Figure  1A). 
Since they provide the initiation sites for unwinding, single-stranded overhangs of 
these substrates, if present, may provide specificity to the enzyme-substrate interaction 
through their sequence, size, or structure or a combination thereof. SF1 and SF2 include 
helicases with diverse biochemical properties, including directionality and substrate 
preference; these properties, e.g. 5’-3’ directionality of movement, may thus have evolved 
more than once (convergent evolution). In comparative terms, they are less conserved 
than the sequence motifs that define a superfamily. Consequently, understanding the 
underlying selection pressure that drives the conservation of these motifs may provide 













































2.1 Functions of conserved sequence motifs
As outlined above, despite sequence conservation and similar fold of the core domains, 
a fundamental difference must exist in the way in which helicase proteins of SF1A and 
SF1B interact with their nucleic acid substrate in order to achieve translocation, and thus 
unwinding, with a defined polarity. To shed light on the mechanistic basis of this differ-
ence, we first need to understand the general molecular mechanism by which direc-
tional movement is generated driven by the energy originating from NTP hydrolysis. As 
one would expect, the elements involved in this essential NTPase activity are generally 
conserved among SF1 helicases (Figures 2A and B) and (in part) beyond, reflecting con-
siderable evolutionary constraints (2). The most notable of these motifs are motifs I and 
II, which harbor key residues necessary for the direct interaction with the NTP:Mg2+ and 
NDP:Mg2+ complexes. Furthermore, motif II contains a conserved glutamate thought to 
act as catalytic base during hydrolysis by accepting a proton from the water molecule 
that subsequently attacks the NTP (11). Other motifs vary in respect to sequence con-
servation and diversity of helicases with whom they are associated. Motifs Ia, III, IV, V, Va, 
and VI are found in SF1 and SF2. Of these, motifs III, IV, V, Va, and VI are most conserved, 
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Figure 2. Conservation, structure, and function of the SF1 helicase core domains 1A (tan) and 2A (red). 
Shown are properties of nidovirus helicases, which may deviate from other SF1 helicases. (A) Relative posi-
tions of motifs and secondary structure elements of a consensus nidovirus helicase. Secondary structures 
were predicted by Jpred (53) using a multiple sequence alignment of 31 representative nidoviruses that 
was assisted by tools in the Viralis software platform (54). Motifs as defined by Fairman-Williams et al. (2) 
are colored according to their predominant biochemical function. Green, NTP binding and hydrolysis; blue, 
nucleic acid binding; purple, coupling between NTP and nucleic acid binding sites. (B) Sequence conser-
vation of helicase signature motifs of representative nidoviruses depicted using WebLogo (55). Motifs Q 
(LNxxQ) and Vb (xxxxVR) are absent in nidoviruses. (C) Position of sequence motifs in the tertiary structure 










































Additionally, motif IIIa is found exclusively in SF1 helicases while motifs Q, Ib, Ic, and Vb 
may be specific to different subsets of SF1 helicases. For instance, motifs Q and Vb are 
apparently absent in nidovirus helicases (Figure 2).
Additional nucleotide-binding residues reside in motifs Q, IIIa, and VI. The first two of 
these seem to be specifically important for the recognition of ATP. Thus, it is not surprising 
that the Q motif and a conserved tyrosine in motif IIIa that provides stacking interactions 
with the adenine base may be lacking in helicases without nucleotide specificity, such 
as that of ToMV (45). Moreover, a highly conserved arginine residue in motif VI, termed 
“arginine finger”, specifically interacts with the γ-phosphate of the incoming NTP. Rela-
tive to motifs I, II, and Q this residue is located on the opposite side of the NTP-binding 
cleft formed by domains 1A and 2A (Figure 2C). This position enables it to fulfill a critical 
function in opening and closing of the cleft in response to NTP binding and hydrolysis, 
which triggers a conformational shift at the NTP binding site that is translated into a 
rotation of domain 2A towards 1A (49-51). Although this domain movement is a com-
mon feature, the exact mechanism and kinetics of hydrolysis and product release may 
differ between helicases, possibly in response to specific physiological roles (52).
 To translate the rotation into movement along a nucleic acid track, the majority of the re-
maining (partially) conserved motifs is primarily devoted to nucleic acid binding (motifs Ia-c, 
IV, IVa, V, and Vb). These motifs are located exclusively on the opposite face of the helicase 
core relative to the nucleotide binding site, resulting in a nucleic acid-binding channel 
involving both core domains on the one side and additional protein-specific domains on the 
other. Interestingly, while SF1A helicases are thought to establish contacts mainly via base 
stacking, members of SF1B seem to bind predominantly to the phosphate-sugar backbone. 
This would suggest that SF1A helicases are strongly inhibited by base lesions while SF1B 
members would not tolerate backbone modifications (50). Moreover, the crystal structure 
of the DNA-specific Pif1-like helicase RecD2 revealed a C3’ endo conformation of the sugar 
backbone of a bound DNA. As this conformation appeared to be heavily stabilized by amino 
acid side chain interactions, it was speculated that this binding mode may be the basis for 
discrimination against RNA, whose 2’-OH would prevent establishing these interactions 
(50). In further support of this hypothesis, similar interactions are conserved in other DNA 
helicases like Rep, PcrA, and RecB while they cannot be found in Upf1, which can utilize both 
DNA and RNA (10;49;51;56). Finally, motifs III and Va contact both NTP and nucleic acid bind-
ing sites to promote the coupling of the binding processes (2). Thus, it is not surprising to 













































2.2 General models of translocation: how the energy of NTP-hydrolysis is 
converted into directional movement
In an effort to explain the sequence of events that enables the conversion of the NTP 
hydrolysis-induced domain rotation into a directional movement, two hypotheses have 
been brought forward: the Brownian motor hypothesis (59) and the ‘backbone stepping 
motor’ model (18;60). The former, based on the observation that the SF2 helicase (NS3) 
of Hepatitis C virus (HCV) has lower nucleic acid affinity in the NTP-bound state than in 
the free state, explains the directional translocation on the basis of Brownian motion 
and a ‘power stroke’ caused by NTP-hydrolysis. Furthermore, it assumes an asymmetric 
sawtooth-shaped energy profile for helicase binding to nucleic acids over the length of 
the single strand. In the absence of NTP, the enzyme would bind strongly to the nucleic 
acid and thus be incapable of any movement, a state characterized by a local energy 
minimum. Conversely, once NTP binds, the enzyme’s affinity for nucleic acid decreases, 
which triggers either the dissociation of the protein or its random movement covering 
a certain number of bases. During this stage, existing energy barriers may be fully or 
partially overcome. When the NTP is hydrolyzed and the enzyme’s affinity for its nucleic 
acid substrate is restored, the protein may either fall into a neighboring local energy 
minimum or return to the original one. However, since the energy profile is assumed 
to be asymmetric, i.e. a shorter, steeper barrier exists on one side of the helicase, the 
enzyme would be more likely to overcome a local energy maximum in one direction 
than the other, resulting in a net forward motion. Although this model presents a simple 
thermodynamic perspective on protein translocation, it has remained unclear which 
protein or nucleic acid properties would play a role in creating the required asymmetric 
energy profile (59).
Two main variants have been proposed for the ‘backbone stepping motor’ model, which 
also relies on sequential NTP-dependent affinity changes: the ‘active rolling’ model by 
Wong and Lohman (60), and the ‘inchworm’ model, originally from Yarranton and Gefter 
(18) and extended by Velankar et al. (51). Although these models are quite similar, there 
is one decisive difference: the proposed number of binding sites per enzyme. The former 
model proposes the existence of a single nucleic acid binding site per helicase subunit, 
which allows binding to either single- or double-stranded nucleic acids. Thus, in order 
to engage simultaneously with the transition region between duplex and single strand, 
the so-called “fork”, at least a functional enzyme dimer is required. Upon NTP hydrolysis, 
the individual subunits of this dimer are then assumed to “roll” over each other, resulting 
in a constant replacement of the leading molecule. This model thus implies a step size, 
defined as the distance that a helicase moves forward during a single catalytic cycle, at 









































nism postulates the existence of two binding sites within the same helicase subunit, al-
lowing the protein to “slide” along a nucleic acid. Therefore, neither the oligomerization 
state nor the unwinding step size would be subject to any constraints.
In support of the latter model, all helicase crystal structures currently available show a 
monomeric protein, even in those cases where the co-crystallized nucleic acid would 
have allowed binding of a second subunit (51). Furthermore, biochemical data demon-
strating step sizes of one base pair exist for several helicases (61;62), which is difficult 
to reconcile with the active rolling model unless it would include a backward motion 
at some point in the reaction cycle. As this would imply a deliberately low efficiency of 
unwinding, this is unlikely to be the case. An additional conflict with the active rolling 
model derives from studies with PcrA, which was not found to dimerize yet displayed a 
higher affinity for substrates comprised of single- and double-stranded regions than for 
those containing exclusively either of these states (19). This essentially argues against 
the strict temporal separation of single- and double-strand binding. It should be noted 
that the kinetic data derived from studies with Rep and UvrD that served as the basis for 
the rolling model are consistent with the inchworm mechanism as well.
2.3 The structural basis for directionality
Given the large body of experimental data supporting it, the inchworm model is now 
widely accepted. The model (Figure  3, top panel) based on the SF1A helicase PcrA 
proposes two intermediate steps that are characterized by different affinities for a DNA 
substrate, a feature controlled by the binding and hydrolysis of NTPs. Initially, the heli-
case protein binds to a single strand in the 3’-5’ orientation, utilizing all binding pockets 
present in the 1A and 2A domains. Of special importance is a phenylalanine in motif Ia, 
located in domain 1A and conserved in the UvrD/Rep subfamily of SF1 (63) but replaced 
by different residues in nidoviruses (2nd residue in motif Ia of Figure 2B). It fulfills the 
role of gatekeeper for the second of three base acceptor pockets within this domain 
(named A to C in the 3’-5’ direction) (Figure 3, top panel). Once NTP binds to the NTP 
binding site, inducing the closure of the binding cleft, the conformational change is 
relayed to this residue and causes the displacement of the base residing in pocket  B 
into pocket A. At this point, only two of three binding sites of 1A are occupied and thus 
the overall affinity for DNA is reduced. Since domain 2A retains its grip on the DNA and 
both core domains rotate towards each other, 1A is pulled along the substrate in 3’-5’ 
direction. Subsequently, NTP hydrolysis triggers the re-opening of pocket B and allows 
the next base to enter. Ultimately, binding of a base to the vacant binding pocket in 1A 













































1A. In conjunction with the re-opening of the NTP binding cleft, 2A is now pushed away 
from 1A, completing the translocation step in 3’-5’ direction (51).
In order to change the direction of translocation to fulfill alternative cellular functions, 
two variations of this mechanism would be conceivable: the helicase could bind to nucleic 
acids in the opposite orientation or the order of binding events could be reversed. Using 
the SF1B prototype helicase RecD2 Saikrishnan et al. (50) demonstrated that the latter is 
true for this protein. Although the overall binding site and its location resemble those of 
SF1A helicases, subtle differences in what seems to be an otherwise remarkably similar 
mechanism became apparent (Figure  3, bottom panel). In particular, it is noteworthy 
that the conserved phenylalanine of motif Ia is not present in SF1B helicases but is, as in 
SF2 helicases, often replaced by a conserved proline (64). While this replacement results 
in the loss of the gatekeeping function for this residue, the pocket mentioned above 
still plays a major role during translocation. Before NTP binding, it is occupied by a base, 
which has to flip out of the stacked conformation with its neighboring bases in order to 
bind. Together with several other contacts with the DNA backbone, this leads to a firm 
interaction between domain 1A and the single strand. As soon as NTP is bound and cleft 
closure induced, the conformational change of the NTP-binding cleft translates directly 
into several alterations and concomitant strengthening of the interaction network of 
2A. However, as a number of contacts are made with the downstream base compared 
to the NTP-free state, it seems that, in contrast to the mechanism for 3’-5’ translocation, 
2A becomes the dominant binding domain only after the domain movement has been 
completed. In parallel, the base in the motif Ia pocket moves back into a stacked con-
formation, releasing the mechanical block on 1A movement. This conformational switch 
may be facilitated by relaxation of the DNA as 2A moves towards 1A. Finally, as the NTP 
is hydrolyzed, the binding cleft re-opens and pushes 1A towards the 3’ end, concluding 
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Figure 3. Mechanistic models of helicase translocation with different polarities. Schematic representation 
of major conformational changes upon ATP binding and hydrolysis based on crystal structures of PcrA (top) 
and RecD2 (bottom). Domains with the relatively weaker binding affinity are depicted in lighter colors and 









































Although both models offer a compelling mechanism for the directional movement of 
helicases, it needs to be stressed that both are based on the analysis of just two crystal 
structures, one in the absence and one in the presence of NTPs, which were obtained 
for very different helicases representing SF1A and SF1B, respectively. Thus it is possible 
that, when more structures become available, additional transition states might be 
identified in the catalytic cycle, possibly leading to revision or elaboration of the pro-
posed mechanisms. Also, these mechanisms must be correlated with the evolutionary 
conservation of key residues, which will require insights that may not be deducible from 
the helicase family classification (SF1A and SF1B) founded on structural and biochemical 
considerations.
2.4 Mechanisms of strand separation: do helicases play an active or passive 
role?
As the translocation of a helicase strictly occurs along a single strand, the energy spent 
on this process could, in principle, also account for strand separation when the helicase 
reaches a double-stranded region simply by excluding the other strand from entering 
the binding site and prying the duplex open. In fact, the amount of energy released 
by hydrolysis of any NTP (~10 kcal/mol) should be more than sufficient to separate an 
average base pair under physiological conditions (~1.6 kcal/mol) (65). Still, the question 
whether the actual unwinding is actively supported by the protein or occurs passively 
depending on thermal fraying, that is, spontaneous opening and closing, of double 
strands is still an unresolved issue. In order to clarify the use of active and passive in 
this respect, it should be made clear that this terminology relates to the mechanism by 
which strand opening is achieved and not to the overall enzyme activity, which is by 
definition always active in the biochemical sense as it requires NTP hydrolysis.
In a passive unwinding model, the helicase would temporarily pause when it encounters 
a double-stranded region and move forward once the base pair opens, thereby prevent-
ing re-annealing of the single strands (57). Although estimates on the fraying frequency 
are as high as 1000 s-1, this model would not account for helicase proteins or complexes 
that possess higher unwinding rates, for example RecBCD (66;67). Thus, at least some 
helicases seem to employ an active mechanism for duplex destabilization (12;68). Sup-
port for such a mechanism was again obtained from the crystal structure of PcrA (51). 
In this case the optional domains 1B and 2B play a critical role by specifically binding 
to double-stranded DNA in the context of the NTP-bound state. Once the NTP is hydro-
lyzed, their binding affinity is lost, and contacts with the DNA are predominantly limited 
to both core domains. Thus, NTP binding does not only start translocation, it also leads 













































the first four to five base pairs at the junction start to open, which allows stabilization of 
the newly generated single-stranded region by the forward motion of the protein.
In contrast to the duplex opening, the translocation mechanism described with the 
inchworm model implies that PcrA progresses by a single base per NTP hydrolyzed. 
Therefore, it is possible that translocation and unwinding are not coupled during every 
hydrolysis cycle in PcrA (51), a hypothesis that would also explain unwinding step sizes 
of more than one base pair seen with some other helicases. This theoretical concept was 
supported by findings for HCV NS3, which suggested that three successive hydrolysis 
events trigger the sudden unwinding of three base pairs in a so-called spring-load 
mechanism (69). Thus, it is important to distinguish between translocation step size, 
which may be fixed at one nucleotide per NTP, and the size of individual unwinding 
steps, which may involve hydrolysis of several NTP molecules.
From the study of multiple members of different helicase superfamilies, it has now 
become apparent that introduction of some kind of mechanical strain into the double-
stranded region, to ease its opening up, may be a common part of helicase action. 
However, as the participation of non-conserved domains already implies, the exact 
mechanism of strand separation may vary between helicases. Particularly, the element 
responsible for the destabilization, called pin or wedge, may be part of different domains 
and vary in size (51;56;64;70).
3. THE NIDOVIRUS HELICASE: A MULTI-FUNCTIONAL ENZYME CONTROLLING 
KEY STEPS IN VIRAL REPLICATION
The presence of a helicase in nidoviruses was recognized already in the late 1980s by 
comparative genomics involving the first sequenced nidovirus genome, that of the avian 
infectious bronchitis coronavirus (71), along with known bacterial helicases, for example 
UvrD. These findings led to the original proposal to establish SF1, the first among the 
helicase superfamilies, and to classify the corresponding nidovirus protein domain as 
putative helicase (7;72;73). Subsequent genomic studies of other nidoviruses reported 
conservation of this domain and its characteristic helicase motifs, strongly supporting 
the helicase function in nidoviruses.
The multidomain helicase subunit (hereafter referred to as helicase) of nidoviruses 
ranges in size from 50 to 70 kDa and is called nsp10 in arteriviruses and nsp13 in corona-
viruses, which are the only nidovirus families that were characterized in respect to this 









































nonstructural polyprotein (pp1ab) that results from ORF1a/1b ribosomal frameshifting 
(Figure 4). Comparative sequence analysis indicated that the nidovirus helicase subunit 
consists at least of an N-terminal zinc-binding domain (ZBD; known also as zinc-binding 
module, Zm, or complex zinc-finger), the helicase core domains, and an as yet undefined 
C-terminal part. Despite considerable size differences, it is one of the three ubiquitous 
and evolutionary most conserved proteins encoded by nidoviruses. The other two are 
the chymotrypsin-like protease (3CLpro or main protease Mpro), responsible for most of 
the proteolytic processing of pp1a and pp1ab, and the RNA-dependent RNA polymerase 
(RdRp) that is thought to synthesize the genome as well as a set of subgenomic (sg) 
mRNAs (41;42). The helicase is genetically segregated with the RdRp in ORF1b, and mu-
tation of specific conserved residues can either negatively impact or block replication of 
the arterivirus equine arteritis virus (EAV) (74;75), the only nidovirus for which reverse 
genetics analysis of the helicase was performed so far. These genetic and genomics 
observations established the helicase as an essential protein for viral replication.
ZBD 1B 1A 2A C
Figure 4. Genomic organization and key replicase domains of four nidoviruses. The coding regions are 
partitioned into ORF1a (yellow), ORF1b (purple), and the 3’ ORFs (blue), which also differ in their expres-
sion mechanism or template as indicated on top. Black squares, ribosomal frameshift sites. Within ORFs 
(white rectangles), colored patterns highlight domains identified in: all nidovirus replicases [transmem-
brane domain 2 (TM2), transmembrane domain 3 (TM3), 3C-like protease (3CLpro), RNA-dependent RNA 
polymerase (RdRp), and Zn-binding domain fused with helicase domain (ZmHEL1)], light and dark blue; 
large nidoviruses [exoribonuclease (ExoN), 2’-O-methyltransferase (OMT)], orange; certain clades [N7-
methyltransferase (NMT), endoribonuclease (NendoU)], red; ronivirus-specific domain (RsD), light green; 
arterivirus-specific domain (AsD), dark green. Genomic organizations are shown for Beluga whale coro-
navirus SW1 (corona), gill-associated virus (roni), Nam Dinh virus (mesoni), and porcine respiratory and 
reproductive syndrome virus, North American genotype (arteri). Domain organization of ZmHEL1 is shown 













































Biochemically, helicase activity was first demonstrated for a coronavirus and an arteri-
virus (30;31) just few years before the 2003 SARS (severe acute respiratory syndrome) 
pandemic, which sparked renewed interest in nidoviruses in general and coronaviruses 
in particular. By now biochemical data are available for helicases originating from severe 
acute respiratory syndrome coronavirus (SARS-CoV) (27;32;76-78), human coronavirus 
229E (HCoV-229E) (29;31;79), porcine reproductive and respiratory syndrome virus 
(PRRSV) (28), and EAV (6;30;74). Furthermore, as mentioned above the latter was also 
extensively probed in reverse genetics studies (74;75), and the crystal structure of a 
truncated variant was reported recently (6). In contrast, putative helicases originating 
from the invertebrate families Roniviridae and Mesoniviridae have not been experimen-
tally characterized calling for caution with respect to generalization of results available 
exclusively for vertebrate nidoviruses. For the sake of clarity, the source of the described 
data, that is, either from an arterivirus or a coronavirus, is stated throughout this paper 
unless a general conclusion applicable to all vertebrate nidoviruses is drawn.
3.1 Three different enzyme activities with contrasting substrate requirements
3.1.1 A promiscuous NTPase sensitive to the presence of polynucleotides
As discussed in section 2, helicase translocation is driven by the energy released upon 
hydrolysis of phosphodiester bonds of NTPs. Accordingly, mutation of the conserved 
lysine of motif I (G/A)x(A/P)GxGK(S/T), which binds ATP, abolished all NTPase activity of 
the nidovirus helicases probed thus far (29-31;76). Additionally, a number of labs char-
acterized the nucleotide specificity of these proteins (28;29;32;76). However, a direct 
comparison of the kinetic constants obtained in these studies is complicated by differ-
ent experimental conditions used regarding pH, incubation temperature, and presence 
of homopolymeric RNAs.
In general, like the SF1 helicases of the alphavirus-like viruses CHIKV nsP2 (Togaviridae) 
(33) and HEV ORF1 protein (Hepeviridae) (34), none of the nidovirus enzymes tested 
seemed to be able to strongly discriminate between any of the ribo- or deoxynucleotides. 
EAV nsp10 was found to utilize both tested nucleotides, ATP and GTP, with comparable 
efficiency (30). Similarly, PRRSV nsp10 was able to hydrolyze all NTPs with a preference 
for purines over pyrimidines and with UTP being the least favorite substrate (28). The 
same order of substrate preferences was deduced in one SARS-CoV nsp13 study, where 
the obtained kcat/Km values ranged from 1.9 µM-1s-1 for ATP and GTP to 0.4 µM-1s-1 for UTP 
(76). Yet, a second study by Tanner et al. (32) on the same protein carrying a different 
affinity tag reported an almost twofold difference between ATP (kcat/Km 57.9  mM-1s-1) 









































of the influence of affinity tags and choice of expression system on enzyme activities 
see below). Again UTP was the least efficiently used substrate (kcat/Km 19.1  mM-1s-1). 
However unlike other studies, the latter research was performed in the presence of a 
polynucleotide, polyuridine (polyU). As such homopolymeric co-factors are known to 
affect the NTPase rate of a number of helicases (19;25;80), this difference in experimental 
set-up may explain the observed variation in the relative order of substrate preference 
(see also below). Finally, also the HCoV-229E helicase behaved similarly in terms of NTP 
selectivity, with again ATP being the most and UTP the least preferred substrate (kcat/
Km 0.9  µM-1s-1 and 0.3  µM-1s-1, respectively) (29). Furthermore, besides the differences 
observed in the two SARS-CoV nsp13 studies, for which a possible reason was discussed 
above, all groups examining coronavirus helicases reported that different dNTPs and 
NTPs could be utilized with the same overall relative preference. What discriminated 
them was an up to threefold lower efficiency of the utilization of dNTPs compared to 
NTPs. Given the general resemblance between the data obtained with helicases of 
selected coronaviruses and arteriviruses, it is tempting to speculate that this lack of 
specificity is conserved in these two distantly related families of vertebrate nidoviruses. 
It remains unknown whether this property may also be conserved in the invertebrate 
nidoviruses, whose helicases have not been characterized at all.
Interestingly, the observations described above suggest that neither base-specific 
side chains nor the 2’-OH contribute significantly to nucleotide binding. Instead, the 
mere presence of a 5’ triphosphate may be the sole prerequisite for promoting NTPase 
activity. This interpretation is further supported by a three-dimensional model of the 
highly conserved helicase core domains 1A and 2A of SARS-CoV nsp13, computed by 
Hoffmann et al. (81) based on structures of the PcrA, Rep, and RecB DNA helicases. 
After molecular dynamics simulation and energy minimization of ATP binding, six 
hydrogen bonds between the β- and γ-phosphates of the ATP and the side chains of 
(partially) conserved residues (T286 motif I, K288 motif I, R443 motif IIIa, R567 motif VI) 
were predicted. Moreover, an additional hydrogen bond may be established between 
the 3'-OH of the sugar and E540 (motif Va). Additionally, the base may be involved in a 
stacking interaction with H290 (extended motif I) and a cation-p interaction with R442 
(motif IIIa). In contrast, no interactions that would be specific for the adenine base could 
be identified. Finally, a hydrogen bond was predicted to be present between the 2'-OH 
of the ribose and K569 (motif VI). With respect to the experimental data, the presence of 
this single interaction, as compared to the nine interactions that are not specific for the 














































In section 2, we mentioned the stimulation of the NTPase activity of eukaryotic and 
bacterial SF1 and SF2 helicases by single-stranded nucleic acids. This effect was also 
observed for the nidovirus helicases of EAV, SARS-CoV, and HCoV-229E (30-32). All stud-
ies recorded the strongest stimulation by poly(U), poly(dT), and poly(dA). A remarkable 
finding was the unusual magnitude of the increase, 15- to 20-fold for EAV, 15- to 25-fold 
for SARS-CoV, and ~50-fold for HCoV-229E, which is similar to the enhancement observed 
for viral SF2 helicases, like HCV NS3, which could be stimulated up to 15-fold (39;82). In 
contrast, the nucleic acid-stimulated enhancement of NTP hydrolysis by SF1 helicases of 
viruses of the alphavirus-like supergroup was generally found to be minor, mostly about 
twofold (33;34;83;84). SARS-CoV nsp13 helicase activity was furthermore stimulated by 
more than 15-fold by poly(A) and poly(dC). While HCoV-229E nsp13 activity was also 
significantly increased by the presence of poly(C) (32-fold), neither poly(A), poly(G), nor 
tRNA induced a more than fivefold stimulation. Similarly, EAV nsp10 NTPase activity was 
only enhanced up to fourfold by tRNA and homopolymeric RNAs other than poly(U). The 
observed variation in the scale of stimulation of NTPase activity depending on the type 
of polynucleotide raises the question of its molecular basis. On the one hand, it could 
merely reflect a higher affinity for certain nucleic acid substrates compared to others, 
which would imply sequence-dependent helicase activity. Yet, as the affinity towards 
nucleic acids has not been evaluated for any of the nidovirus helicases so far and little is 
known about the exact means by which these allosteric activators may influence NTPase 
activity, alternative explanations should also be considered. For instance, based on crys-
tal structures of HCV NS3, Frick et al. (85) suggested that electrostatic changes inside the 
NTP-binding site could be caused by a subtle rotation of domain 2A upon nucleic acid 
binding. From computer simulation of the ionization states of amino acid side chains, 
it appeared that this conformational change would lead to a switch of the protonation 
states of the conserved lysine in motif  I and the conserved aspartate of motif II and 
would thus directly influence the NTPase rate. Therefore, the magnitude of nucleic acid 
stimulation may be indirectly governed by the relay of conformational changes from the 
nucleic acid binding channel in the vicinity of domains 1A and 2A to the NTP binding 
cleft between these domains. In this line of reasoning, different nucleic acids may differ 
in respect to their ability to induce conformational changes rather than their binding 









































3.1.2 A DNA and RNA helicase with stringent requirements for its partially double-stranded 
substrate
3.1.2.1 A helicase without nucleic acid preference
After confirmation of their NTPase activity, the next question was whether the putative 
nidovirus helicases are indeed functional and capable of unwinding nucleic acid du-
plexes, presumably the double-stranded RNAs that are formed during viral replication. 
HCoV-229E nsp13 and EAV nsp10 were the first proteins for which this question was 
addressed in a so-called “all-or-nothing” assay, which only records unwinding events 
that result in complete strand separation (30;31). In these pioneering studies, published 
in short succession by Seybert et al., both proteins were able to unwind not only partially 
double-stranded RNA but also DNA substrates containing a single-stranded region at 
one or both of the 5’ ends, irrespective of the additional presence of 3’ tails. In contrast, 
no activity was observed with substrates containing only an unpaired region at one 
of the 3’  ends or with blunt-ended substrates. These findings demonstrate that the 
nidovirus helicase recognizes and binds single-stranded RNA and DNA (see section 3.2 
for the structural basis for this lack of specificity) before proceeding to unwind in 5’-3’ 
direction. Later the same polarity was also established for SARS-CoV nsp13 (32;76;77) 
and PRRSV nsp10 (28), confirming the classification of nidovirus helicases as members 
of SF1B. In comparison, the helicases of CHIKV nsP2 and HEV ORF1 protein did share the 
5’-3’ polarity on RNA substrates but were incapable of unwinding DNA (33;34), indicat-
ing that these properties could be uncoupled.
The assays employed in the initial studies mentioned above were based on a multiple-
turnover approach, which assesses and compares the ratio of single-stranded products 
to double-stranded substrates at a defined reaction end point. Therefore, they disregard 
multiple unwinding events involving the same substrate but different helicase mol-
ecules and, in these particular studies, also product re-annealing (30;31). Thus, differ-
ences in binding affinity, processivity, and velocity of the enzyme when comparing the 
two substrates may have been masked. Addressing the basis of the apparent lack of 
substrate specificity, the unwinding kinetics of RNA and DNA substrates with identical 
sequences have been examined more closely for SARS-CoV nsp13 using a single-cycle 
assay, which prevents re-binding of proteins that have dissociated from the nucleic acid 
or that are not bound when the reaction is started by ATP addition (27). Strikingly, also in 
this single-turnover experiment no difference was observed between the unwinding of 
RNA and DNA substrates. On the one hand, this lack of specificity may reflect a structural 
property (see section 3.2) that has evolved due to the lack of selection for discriminating 













































virus. On the other hand, while RNA unwinding may be employed during replication 
and/or transcription of viral RNAs, the helicase could specifically exert its DNA unwind-
ing activity on host nuclear DNA as proposed for the SF2 helicase of HCV, which even 
showed a preference for DNA over RNA substrates in absence of protein co-factors (86). 
However, no nidovirus helicase was found to be traveling to the nucleus, which stands 
in contrast to a few other nonstructural proteins, for example nsp1 of EAV (87). Alterna-
tively, the hypothesis could be modified to propose that the nidovirus helicase might 
target host mitochondrial DNA, a possibility that has not been discussed in the literature 
to the best of our knowledge. Finally, the biochemical properties described above were 
determined using in vitro assays utilizing purified recombinant helicases and may be 
only partially applicable to helicases within viral replication complexes, which include 
other proteins and co-factors.
3.1.2.2 The influence of sequence and size of single-stranded nucleic acids on helicase activity 
and oligomeric state
Next to the nature of the sugar, the sequence of the single-stranded region used to 
initially bind the protein may provide specificity for certain substrates. Therefore, 
again Seybert et al. (31) investigated the unwinding of DNA duplexes containing 10-
nt long homopolymeric tails at one of their 5’ ends. Although HCoV-229E nsp13 could 
utilize substrates with a dA, dC, or dT tail, it showed a marked preference for the two 
pyrimidines. In contrast, dG-containing duplexes were not unwound. However, this may 
not be due to a specific discrimination against guanine but rather to the formation of 
higher order structures in this particular substrate, which, as the authors speculated, 
may interfere with helicase activity. Later, it was also demonstrated that SARS-CoV 
nsp13 is able to initiate unwinding on tails with random sequences (27). Despite this 
apparent lack of sequence specificity in these in vitro assays, the function of the nido-
virus helicase in infected cells may require loading at specific nucleic acid sequences or 
higher-order structures. Thus, it would be interesting to investigate binding affinities 
towards, for example, sequences located within the untranslated region of the genome, 
the antigenome, or any of the transcription-regulating sequences (TRSs) that direct the 
production of nidoviral sg RNAs (see section 3.3.2). Furthermore, it is conceivable that 
one (or more) of the other nonstructural proteins may interact and target the helicase to 
specific genome regions if it indeed would not possess any specificity itself.
In addition to the sequence, also the length of the 5’ overhang is important for binding 
of the protein to its nucleic acid substrate. Besides revealing the minimal spatial require-
ments for helicase binding, characterization of this property may more importantly 









































merization of SF1 helicases, which possibly leads to cooperativity. However, it should be 
noted that the NTP-binding motifs of the two SF1 core domains face each other to form 
an intact NTP-binding site in each protein subunit. Therefore, proteins of this superfam-
ily are not per se dependent on oligomerization. In contrast, in SF3-6 members, whose 
binding motifs are localized on distant sides of the protein, assembly of a functional NTP 
binding site requires two subunits (3). Nevertheless, it has been shown for individual 
SF1 members that dimerization is needed at different stages of the enzymatic cycle. For 
instance, the E. coli helicase UvrD requires dimerization to initiate and sustain unwinding 
but not to translocate along DNA (88-91).
To shed light on the oligomerization requirements of nidovirus helicases, unwinding 
of DNA substrates with the same double-stranded region but progressively shorter 
tails was tested for SARS-CoV and HCoV-229E nsp13 (27;31;77). In agreement with the 
results summarized above, unwinding was observed in all studies if the DNA contained 
an overhang of ten or more nucleotides. In contrast, the results of experiments using 
substrates with shorter 5’ overhangs and SARS-CoV nsp13 were less consistent between 
different groups but suggested that the minimal length required for binding may be in 
the range of five to seven nucleotides. However, it is important to note that all factors 
that may influence the extent and frequency of the fraying of the double-stranded part 
of the substrate, like temperature, sequence, or salt concentration, may have influenced 
the outcome of these experiments.
Given the need for only short binding sequences, it is possible that multiple helicase 
molecules bind simultaneously to a single substrate molecule with a longer tail region, 
giving rise to cooperativity effects. Interestingly, the data from Lee et al. (77) suggests 
that such a scenario could be possible for nidovirus helicases. While unwinding of DNA 
comprising a 50-base pair duplex region and tails of 15 or less nucleotides was inefficient 
(<7.5% unwound) in a single-cycle all-or-nothing assay containing a 40-fold excess of 
protein over DNA, the ratio of single-stranded to double-stranded DNA increased step-
wise to 18%, 55%, and 95% when the tail was extended to 20, 30, or 40 nt, respectively. 
Although this result could also be explained by an increasing affinity between a single 
protein and its substrate and therefore by more frequent initiation of unwinding, the 
absence of a direct correlation between tail length and activity makes it tempting to 
speculate that a second molecule entered the reaction once the tail exceeded a certain 
length, most likely 20  nt (77). Additionally, in the same study it was shown by cross-
linking experiments with DMS (dimethyl suberimidate) that SARS-CoV nsp13 can form 
dimers, trimers, and possibly also larger oligomers in solution in the absence or pres-
ence of ATP and DNA. Notwithstanding a possibility of forming artificial oligomers by 













































two-hybrid screen indicating an nsp13 self-interaction (92). Nevertheless, none of the 
studies has addressed the question whether helicase molecules indeed form oligomers 
during unwinding. Likewise, it is unknown whether oligomer formation affects biophysi-
cal properties of the individual monomers to reveal typical indicators of cooperativity, 
such as coordinated substrate binding or translocation activities (93). Accordingly, Lee 
et al. (77) postulated that the higher net product formation is plausible if at least one of 
the independently operating helicase molecules stayed attached to the substrate until 
unwinding was completed.
3.1.2.3 The size of double-stranded regions of the substrate affects helicase processivity
The fact that a comparable tail length-dependent increase of unwinding was not 
observed in two other studies using a similar design but employing polynucleotides 
with slightly shorter duplex regions underlines the importance of another feature of 
helicases, their processivity. This feature is defined as either the average number (N) 
of base pairs that a helicase can unwind without dissociating from its substrate or as 
the probability (P) that a helicase proceeds with unwinding after each catalytic cycle. 
This property should not be mistaken for rate of translocation that is defined as number 
of base pairs unwound per second (57). In general, processivity can be influenced in 
two ways; first, by the protein’s affinity for a nucleic acid, and second, by preventing 
re-annealing of freshly separated strands. The latter can be achieved by simultaneous 
binding of additional proteins behind the helicase irrespective of having a physical 
interaction with it. Additionally, this would also reduce the rate of backward movement, 
called slippage (94). Thus, the mere presence of a second nsp13 molecule, as opposed 
to true biochemical cooperativity, could also explain the data obtained by Lee et al. (77) 
with duplexes containing successively longer tails.
To assess the processivity of the SARS-CoV helicase, DNA substrates with a 20-nt tail and 
increasingly longer double-stranded parts were assayed in single-cycle experiments. 
As expected, the percentage of unwound double strand decreased with increasing 
duplex length (27;77). After correction for spontaneous melting of the last eight to ten 
base pairs, which is frequently observed in the presence of helicases (95), Adedeji et al. 
calculated a processivity (expressed as probability) of 0.80 ± 0.03, which appears to be 
surprisingly low given the 32-kb genome size of SARS-CoV (27). With this value nsp13 
would rank far below the highly processive E. coli heterotrimeric complex RecBCD (pro-
cessivity ~1), which contains two functional SF1 helicases, but slightly above T4 phage 
Dda with a processivity of 0.73 (95;96) that unwinds a dsDNA genome of a size compa-
rable to that of coronaviruses. However, in the context of a viral replication complex this 









































complex towards RNA and prevention of re-annealing. The kinetic step size, defined as 
the number of base pairs separated per enzyme cycle, hence not necessarily per NTP 
hydrolyzed, was estimated to be 9.4 ± 2.1 bp. The catalytic rate for unwinding of DNA 
was determined to be 30 steps per second (27). No parameters were calculated by Lee 
et al. (77).
Strikingly, although comparable DNA substrates were used in both studies (27;77), the 
unwinding kinetics differed substantially. In one case the fraction of unwound substrate 
plateaued after approximately 100 to 500 s (77) while in the other it took less than 1 s 
(27) for all duplex lengths. Conveniently, the authors of the latter study also provided the 
explanation for this difference when they compared three different recombinant nsp13 
fusion proteins containing either a GST (glutathione S-transferase), MBP (maltose-
binding protein), or hexahistidine moiety at their N-termini (27;97). Besides the fusion 
partner, a second difference was that the GST version was expressed in eukaryotic cells 
with the help of a baculovirus vector while the other two were expressed in E. coli. Simi-
lar to the his-tagged bacterially expressed protein from Lee et al., they found a several 
hundred-fold lower ATPase rate compared to GST-nsp13 originating from baculovirus 
(0.2 s-1 compared to 104.1 s-1) for proteins which were expressed in E. coli, regardless of 
the tag used. At the same time, however, DNA binding properties remained unaffected. 
When considering this difference, it is interesting to note that neither the GST nor the 
MBP moiety could be removed from SARS-CoV nsp13, nor the His tag from its HCoV-229E 
homolog (27;31;76). This may suggest that each of these foreign sequences was similarly 
closely associated with the N-terminal domain of the viral protein and hence inacces-
sible for a protease. Thus, it seems likely that not the identity of the foreign sequence 
was the cause of the inhibition in the study by Lee et al. (77) but rather the expression 
in a bacterial host that may have resulted in misfolding. Therefore, the numbers cited 
above should be taken with caution and the design of any future experimental studies 
seeking to determine biophysical parameters of nidovirus helicases should take this 
effect into account.
3.1.3 RTPase: an enzymatic activity not required for helicase function
Many RNA viral helicases of SF1 and SF2 were shown to possess RNA 5’-triphosphatase 
(RTPase) activity, that is, the capability to specifically cleave the phosphodiester bond 
between the β- and γ-phosphate of the most 5’ nucleotide of newly synthesized RNA 
(35;47;98;99). This activity was shown to be the first of four consecutive steps in the 
conventional RNA capping pathway (reviewed in (100)) leading to the addition of an 
mGpppNm-cap to the 5’ end of mRNA. It is employed for mRNA capping by all eukaryotes 













































flaviviruses and alphaviruses utilizing their NS3 and nsP2 helicases, respectively (35;99). 
To test whether this activity is also shared by the helicases of nidoviruses, which also 
employ capped genomes (101-103), short RNA substrates were in vitro transcribed in the 
presence of [γ-32P]GTP. After incubation with SARS-CoV or HCoV-229E nsp13 (29;76) or 
most recently EAV nsp10 (our unpublished data), the radioactive phosphate was released 
while the RNA stayed otherwise intact. Conversely, when the same assay was performed 
with RNAs transcribed in the presence of [α-32P]GTP, none of the helicases was able to 
release the radioactive label, indicating that they do not possess general phosphatase 
activity. As, from a mechanistic perspective, the RTPase activity is very similar to the 
already reported NTPase activity, the next question was whether both activities would 
utilize the same active site. To this end, an alanine substitution mutant of the conserved 
lysine located in motif I was shown to abolish both NTPase and RTPase activities for the 
above mentioned coronaviruses (29;76). Thus, the authors concluded that the utilization 
of both substrates depends on the same active site. To further support this conclusion, 
competition experiments between both activities were performed. In agreement with 
their conclusion, ATP acted as potent inhibitor for RTPase activity while AMP had almost 
no effect. These results imply that nidovirus helicases may also be involved in the control 
of the translation of their mRNAs.
3.2 Structure: interplay between enzyme core, ZBD, and a new accessory 
domain revealed upon polynucleotide binding
Recently, EAV nsp10 became the first nidovirus helicase (and only the second RNA 
viral SF1 helicase after that of ToMV (45)) for which a three-dimensional structure was 
reported (6). The structure was solved for a somewhat truncated version of the helicase, 
which did not include the most C-terminal 65 amino acid residues, after the full-length 
protein failed to form any crystals. This truncation did not involve any of the conserved 
helicase motifs, and neither ATPase nor helicase activity were abolished, supporting 
the relevance of the structure of this truncated nsp10 version. In fact, compared to 
the full-length wild-type protein, this engineered protein variant showed an increased 
ATPase activity in the absence of homopolymeric RNA. Nevertheless, its unwinding 
activity seemed to be moderately lower than for the full-length protein, indicative of 
less efficient coupling between ATPase and helicase activities. This may suggest that 
the C-terminal domain, which is not conserved among nidoviruses, is not only flexible 
but perhaps also exerts a regulatory function on the helicase core, facilitating coupling 
between NTPase and polynucleotide binding activities.
Overall the EAV nsp10 structure revealed an organization comprising four domains 









































like domains (1A and 2A, together designated HEL1) containing all conserved helicase 
motifs in line with prior analyses (2;72;73). In comparison to representative members of 
the three SF1 helicase families, this organization is most similar to that of Upf1, which 
contains three accessory domains, an N-terminal zinc-binding domain followed by 1B, 
and 1C inserted into the 1A core domain (49). In contrast, UvrD and RecD2 of the UvrD/
Rep and Pif1-like families, respectively, comprise insertions, designated 1B and 2B, in 
both core domains. While these insertions are the only additional domains for UvrD, 











PcrA (2PJR) RecD2 (3GP8) hUpf1 (2WJV)




Figure 5. Three-dimensional models of prototypic prokaryotic and eukaryotic (top) and viral (bottom) SF1 
helicases. Depicted are the prototypic helicases PcrA (UvrD/Rep family), RecD2 (Pif1-like family), hUpf1 
(Upf1-like family), as well as the currently only available structures of viral SF1 helicases of tomato mosaic 
virus (ToMV) and equine arteritis virus (EAV). Also shown is a structure prediction of severe acute respira-
tory syndrome coronavirus (SARS-CoV) nsp13 obtained with Phyre2 (104). Based on sequence and struc-
tural comparisons nidovirus helicases are classified into the Upf1-like family. Domain colors correspond to 
those used for the domain organization schemes depicted below each structure. Same coloring of domains 
other than 1A and 2A does not imply any evolutionary relationship. Zn2+ ions are depicted as pink spheres. 
Dashed domains in the organization schemes represent parts that could not be modeled. Domain sizes are 













































(Figure 5) (50;105). At this point, it is important to note that an equivalent designation 
does not imply a divergent evolutionary relationship of accessory domains if these 
domains are associated with distantly related helicases.
Domain 1A (residues 138-293) of the EAV nsp10 structure folds as a parallel five-stranded 
β-sheet sandwiched between three and two α-helices on the sides. Conversely, domain 
2A (residues 294-401) is comprised of a parallel four-stranded β-sheet and five α-helices 
facing domain 1A. Comparison of the domain structure with all protein structures cur-
rently available yielded the closest similarity to the SF1B helicase Upf1 and its close ho-
molog Ighmbp2 with Z-scores of 20.9 (RMSD 3.5 Å) and 19.9 (RMSD 3.0 Å), respectively. 
Likewise, the newly discovered 1B domain (residues 83-137), which contains a two- and 
a three-stranded antiparallel β-sheet arranged into a β-barrel fold, resembles a domain 
found in the Upf1-like helicase subfamily in terms of its location and orientation relative 
to the helicase core and was thus named accordingly. Finally, the ZBD (residues 1-82) co-
ordinates three zinc ions with its twelve conserved cysteine and histidine residues and 
folds as two distinct zinc-binding modules, which are connected by a disordered region 
(Figure 6). The larger N-terminal module (residues 1-40) coordinating two zinc ions can 
be classified as RING-like with a binuclear structure with cross-brace topology. Within 
this structure a treble-clef zinc finger-like motif, involving four cysteines in the case of 
EAV nsp10, chelates the first metal ion while the second ion is embedded in an αββ 
zinc finger-like motif containing two cysteines and two histidines in EAV nsp10. Based 
on nidovirus-wide sequence conservation the signature residues of this RING-like motif 
can be described with the formula Cys2A-CysB-CysA-[His/Cys]A-[His/Cys]3B (with A and 
B designating the chelated zinc ions, residues in brackets indicating alternative amino 
acids, and numbers indicating the number of times the residue occurs in succession). 
The more distal zinc-binding module (residues 41-65), which is built by three cysteines 
and one histidine in EAV, has a treble-clef fold that is different from the one of the RING 
module. Its conservation pattern can be described as Cys-[His/Cys]-Cys-[His/Cys]. The 
residues outside of these zinc-binding modules are part of either a long loop, which 
enables extensive hydrogen bonding with the latter module and may thus contribute 
substantially to the overall rigidity of the ZBD, or an α-helix connecting the zinc-binding 
modules with the remainder of the protein. As for the other domains, the closest similar-
ity of the RING-like module was again found to the N-terminal and similarly complex 
zinc-binding CH-domain of Upf1 (Z-score 1.9, RMSD 2.2 Å). This similarity included struc-
tural equivalents for six of the eight chelating residues. In contrast, EAV nsp10 and Upf1 
have structurally different zinc-binding modules downstream of the RING-like module, 










































The presence and conservation of a putative complex zinc-binding domain, located 
between an RdRp upstream and an SF1 helicase downstream, were among the initially 
recognized specific features of the group of viruses, including coronaviruses and later 
also arteriviruses, that has now been united in the order Nidovirales (38;106). To date, this 
domain has been identified as uniquely associated with all known nidoviruses, which 
resulted in its recognition as a molecular marker of the order (41;107). The significance 
of this observation for nidoviruses is highlighted by the fact that all other conserved 
protein or polynucleotide domains are either conserved also in other RNA viruses, e.g., 
RdRp, HEL1, or 3CLpro, or not conserved in some nidoviruses, e.g., an endoribonuclease 
(NendoU) or an 3’-5’ exoribonuclease (ExoN).
Interestingly, all mutant helicases expressed as N-terminal fusions to MBP were reported 
to have the same solubility as the wild-type protein while His- or GST-tagged mutants 
clearly were less soluble (6;74). Likewise, Seybert et al. (74) demonstrated that zinc ions 
are an essential structural co-factor required for proper folding of EAV nsp10 as well 

























Figure 6. Structural comparison between the EAV nsp10 ZBD and hUpf1 CH-domain. Structure and topol-
ogy of the N-terminal domains of EAV nsp10 (PDB accession number 4N0N) and hUpf1 (PDB accession 
number 2WJV). Both domains possess a RING-like zinc-binding module of similar fold (bright green) and 
a second module of different fold. Linker regions are colored in light and dark gray. Residues coordinating 













































role to the ZBD, which could influence the function of the helicase core by affecting 
its structure. The latter interpretation was further substantiated by the identification of 
an extensive interface area of 1019 Å2 between these domains, which may be part of a 
signaling network (6) (see below for more on function).
To elucidate the basis for the lack of specificity for its nucleic acid substrate but also to 
gain first insights into its potential unwinding mechanism, a second crystal structure of 
nsp10 was solved in complex with a partially double-stranded DNA but in the absence 
of NTPs (Figure 2C) (6). Electron density for seven of the ten thymidines of the single-
stranded loading region was identified within a channel formed by domains 1A, 1B, 
and 2A. As biochemical data indicated, the majority of the protein DNA contacts was 
established either with the phosphodiester backbone or non-specifically with the base. 
Furthermore, none of the amino acid side chains was found to be in a position that would 
enable an interaction with the 2’ hydroxyl group of RNA. Although we cannot exclude 
that binding of an RNA substrate might induce such a contact, this structural feature 
may explain the lack of discrimination between DNA and RNA, which all currently tested 
nidovirus helicases share with some cellular members of the Upf1-like family. In agree-
ment with the proposed unwinding model based on RecD2 (50), the 5’ and 3’ ends of 
the substrate were located in domain 2A and 1A, respectively. Taking the demonstrated 
polarity of unwinding into consideration, this implies that domain 1A must be leading 
during translocation. The remaining three nucleotides of the single strand as well as the 
double-stranded part of the substrate could not be resolved, which indicates a certain 
degree of flexibility of the complex. Interestingly, superposition of the Cα atoms of the 
helicase core domains of the free and substrate-bound structures revealed that the 
overall conformation of these domains is not profoundly affected by DNA binding (RMSD 
0.6 Å). Conversely, outside domains 1A and 2A the structural change was significantly 
greater with an RMSD of 1.8 Å. Especially remarkable is an approximately 29° rotation of 
the 1B domain towards the ZBD upon nucleic acid binding. At the same time, the part 
of the nucleic acid substrate channel that is formed by domains 1A and 1B assumes an 
open conformation that is 2 Å wider than in the absence of the substrate. Nevertheless, 
the channel remains too narrow for entry of a duplex. This may suggest that unwind-
ing is achieved by a structural element at the entrance of the substrate channel that 
destabilizes the duplex and makes one of the strands available for being pulled into the 
channel. In line with this model, the area around the entry site for the nucleic acid strand 
appeared to be heavily positively charged (Figure 7) and may thus be utilized to bend 
the duplex during active unwinding, as seen for PcrA, or to guide the displaced strand. 
However, as the double-stranded part of the DNA could not be modeled, neither the 
presence nor the identity of the putative element that facilitates unwinding of double-









































1B and the ZBD that are not part of the substrate channel itself were substantially af-
fected by DNA binding. Thus, it seems plausible that these two domains have a direct 
role in the presumably substrate-dependent binding of interaction partners.
In conclusion, the crystal structure of EAV nsp10 reinforces a common notion that ni-
dovirus helicases may have evolved N- and/or C-terminal extensions in order to utilize 
the central helicase core’s enzymatic activities in many processes of the viral replication 
cycle (see section 3.3. for functional implications). Of special interest is the presence of 
an N-terminal ZBD representing a novel complex zinc-binding fold and having structural 
similarity to the CH-domain of the cellular helicase Upf1, which is known to be involved 
in a number of RNA quality control pathways (108). This virus-host similarity is striking 








Figure 7. Surface electrostatic potential of an EAV nsp10-DNA complex. Both entry and exit side of the 
protein’s nucleic acid binding channel are predominantly positively charged, potentially providing bind-
ing surfaces for nucleic acid. Electrostatic potential mapped onto the molecular surface of 4N0O. Ribbon 














































Indeed, the size differences between the ZBDs of different nidovirus families are con-
siderable, and just a dozen invariant residues mostly involved in zinc binding are shared 
by ZBDs. In line with these observations, replacement of EAV nsp10 residues 4 to 63 by 
the orthologous nsp10 ZBD sequence from PRRSV, another arterivirus, results in a total 
of 31 substitutions and six deletions and was not compatible with EAV viability (75). 
Thus, it may be possible that the interaction network between the ZBD and the helicase 
core is species-specific and may, especially in the large ZBDs of coronaviruses, impose a 
more complex regulation on the helicase core than is now apparent from the EAV nsp10 
data. Moreover, it cannot be excluded that larger ZBDs may harbor additional structural 
elements that may further expand their functional repertoire.
3.3 Helicase function: a protein with diverse properties critically involved in 
several processes
Our understanding of the functions of helicase proteins in the nidovirus replication 
cycle has been and continues to be informed by functional studies using different 
techniques. Some of these studies, e.g., those dealing with the characterization of the 
genome, enzymatic activities, and helicase structure, were already reviewed in the sec-
tions above. They will be mentioned below to the extent that is sufficient to connect 
them to other nidovirus studies, primarily employing reverse-genetics and molecular 
biology techniques, and also to functional paradigms in the helicase field.
3.3.1 Helicase and genome replication
Due to its genetic segregation with the RdRp, helicases of single-strand RNA viruses 
could be considered principally replicative helicases. As such, they might function in 
a manner reminiscent of better studied DNA helicases that participate in the replica-
tion of the double-stranded genomes of prokaryotes and eukaryotes. Obviously, this 
parallel is only valid if it also accounts for specifics of the replication and transcription of 
the single-stranded RNA genomes of nidoviruses. In this context, several helicase roles 
can be envisioned. First, the enzyme could support the polymerase by removing any 
obstacles the replication complex may encounter, for instance secondary structures, in 
single-stranded templates, thereby increasing polymerase processivity (39). This model 
assumes proximity of or even interaction between the RdRp and helicase, which was 
shown for a number of helicases, for example SARS-CoV nsp13 and SF2 HCV NS3, to con-
siderably stimulate their activity (27;109-111). Still, since template-based nucleic acid 
synthesis proceeds in the 5’-3’ direction, and polymerases thus translocate with the op-
posite polarity along the template, only helicases with a 3’-5’ polarity will be able to stay 









































same single strand (Figure 8A). Thus, the 5’-3’ polarity of the helicases of nidoviruses and 
also alphaviruses (28;30-33;76) seems to be incompatible with the conventional model 
of the active helicase associating with a polymerase using a single-stranded template, 
as became clear immediately when this polarity was first described (31). Alternatively, 
the RdRp alone may be capable of unwinding short stretches of secondary structure in 
single-stranded templates during RNA synthesis (Figure  8B) while the helicase would 
separate the strands of dsRNA. In this model RdRp and helicase may not collide and could 
even cooperate as they would move in the same direction but along the complementary 
strands to exercise their respective activities (Figure 8C). Since molecules resembling ei-
ther blunt-ended replicative forms (RFs) or 3’ polyA-tailed replicative intermediates (RIs), 
which are expected to be formed during replication and/or transcription (see below) 
by different mechanisms, did not support the activity of nidovirus helicases tested so 
far in in vitro experiments (30-32;76), the model depicted in Figure 8C depends on the 
involvement of other co-factors. For instance and obviously, cooperation of the helicase 
with other proteins that bind double-stranded RNA may facilitate its interaction with 
RFs/RIs as a step towards initiating unwinding once thermal fraying occurs.
To formally establish interactions with other (nonstructural) proteins, two-hybrid 
screens of SARS-CoV proteins were conducted. These identified three possible interac-
tion partners of nsp13: the accessory protein 3b encoded by an sg RNA, the RdRp nsp12, 
and a domain of the transmembrane nsp3, which is the largest nonstructural protein 
of coronaviruses and was also shown to bind to several other enzymes implicated in 
RNA replication, like the RdRp, the ExoN and N7-methyltransferase (N-MT) (nsp14), and 
the 2’-O-methyltransferase (O-MT) (nsp16) (92;112;113). Additionally, nsp13 was found 
to localize to presumably endoplasmic reticulum-derived membranous replication 
structures in infected cells (76), which is very similar to the localization of most other 
nonstructural proteins of related nidoviruses (114;115). These findings indicate that 
nsp13 is, as expected, most likely part of the membrane-bound replication complex, an 
assumption further supported by findings from a complementation assay. Using EAV 
replicons, mutants deficient in nsp10 activity could not be complemented in trans by 
either simultaneous or exclusive expression of wild-type nsp10 from an internal ribo-
some entry site element inserted downstream of the replicase gene (75). The most likely 
explanation, besides technical reasons, is the apparently aberrant cytoplasmic localiza-
tion of ectopically expressed nsp10. This suggests that nsp10 needs to be expressed in 
the context of the replicase polyprotein, which likely enables correct complex forma-
tion, in order to fulfill its role during virus replication. On the other hand, it cannot be 
excluded at present that nsp10-containing cleavage intermediates may have a separate 
function early in virus replication (75;116). Regardless which interpretation is true, both 































































































Figure 8. Schematic representation of possible functions of the nidovirus helicase (HEL) in cooperation with the viral 
polymerase (RdRp) during genome replication and transcription. (A) Abortive replication and unwinding. Simultane-
ous RNA synthesis and unwinding of secondary structures of the template strand would lead to collision due to op-
posite polarities of HEL and RdRp with respect to a single-stranded template. (B) During the first round of continuous 
RNA synthesis on a single strand HEL may not be required. Note that this model assumes that the RdRp is able to 
remove secondary structures from the template strand. (C) Unwinding of double-stranded replication intermediates 
after the first round of RNA synthesis enables HEL and RdRp to traverse in the same direction along different strands: 
HEL along the positive strand (black), RdRp along the negative strand (gray). Note that nidovirus HEL is unable to 
initiate at blunt ends in vitro and thus presumably would require additional loading factors. (D) During discontinuous 
negative-strand RNA synthesis the RdRp may stall at a body TRS (dashed and stop symbol). Associated inactive HEL 
may subsequently facilitate switching to the leader TRS thus enabling addition of the anti-leader sequence without 
dissociation of RdRp and nascent strand. After completion of negative-strand synthesis, the RdRp becomes inactive. 
In order to increase HEL processivity, the RdRp stays associated with HEL that is traversing along the template strand 
(black) to separate the negative-stranded subgenome-length RNA. Additional proteins required for circularization 
were omitted from the scheme for clarity. Inspired by (121). (E) HEL may trail behind the synthesizing RdRp. Once RNA 
synthesis stalls at a body TRS, continued translocation along the nascent strand would lead to removal of this strand 
from the RdRp active site once HEL and RdRp collide. The 3’ end of the released nascent strand, carrying the body 
TRS complement, may subsequently base-pair with the leader TRS. Finally, the same or a second RdRp molecule may 
add the anti-leader sequence. Additional proteins required for circularization and potentially TRS base-pairing were 









































was expected from the co-segregation of the respective genetic loci. In line with these 
considerations, a twofold stimulation of unwinding rate and almost doubling of the ki-
netic step size was detected upon addition of the cognate polymerase to the SARS-CoV 
helicase while the ATPase rate remained unchanged (27). Conversely, addition of the 
non-cognate RdRp of foot-and-mouth disease virus (3Dpol, Picornaviridae family) had no 
effect on any of the nsp13 parameters, indicating that a specific interaction between 
RdRp and helicase is required to spur this enhanced activity.
3.3.2 Helicase and genome transcription
To rationalize the above observations, it may be informative to recapitulate the main 
facts on the unusual transcription mechanism of nidoviruses (reviewed in (117;118)). A 
common feature of this virus order is the generation of subgenome-size templates for 
sg mRNA synthesis, which is achieved by interruption of negative-strand RNA synthesis 
at specific RNA sequences. These signals, termed body TRSs, are located immediately up-
stream of the genes in the 3’-proximal part of the genome, whose expression depends on 
the production of sg mRNAs. In most but not all nidovirus groups (see below), following 
interruption of negative -strand synthesis, the nascent strand subsequently is translo-
cated to the 5’ end of the genomic template where its 3’-terminal body TRS complement 
can base-pair with the so-called leader TRS. Next, negative-strand synthesis is resumed 
to add the complement of the genomic 5’ leader sequence. The subgenome-length 
negative strands then serve as templates for the synthesis of viral sg mRNAs, which thus 
carry the same 5’- and 3’-terminal sequences as the genome. Whereas all arteri-, corona-, 
and mesonivirus sg mRNAs appear to contain a leader that is identical to the genomic 
5’ end, ronivirus sg mRNAs and all but the largest of the torovirus sg mRNAs lack such 
a common 5’ sequence, suggesting that their subgenome-length negative strands are 
functional templates for sg mRNA synthesis immediately after their release at a body TRS 
(103;119;120). Thus, variations in the mechanism of subgenome-length negative-strand 
RNA synthesis have evolved, which differ in their ability to resume negative-strand RNA 
synthesis after its interruption at a body TRS (117;118).
Although currently neither the protein complex(es) involved nor any detailed mecha-
nisms for this process have been described, one of the explanations for the cooperativity 
between helicase and RdRp may be found in the context of this unique transcription 
mechanism. For example, both enzymes may be part of a complex that allows only one 
of the two proteins to be active at any given moment. It is conceivable that subgenome-
length negative-strand RNA synthesis is started by a complex either lacking the helicase 
or including an enzymatically silent form (Figure 8D). Once a body TRS is reached, the 













































may facilitate a template switch to the leader sequence. The latter may be positioned in 
close proximity to the original template strand if we assume that the genome is circular-
ized via a protein bridge as seen for several other viruses (122). Implicitly, this model 
proposes that the nascent strand only dissociates from the RdRp when anti-leader se-
quence synthesis is completed. At this stage RdRp activity may be silenced and helicase 
activity may be triggered, leading to unwinding of the newly synthesized strand by the 
helicase’s movement in the opposite direction (Figure  8D). In consequence, partially 
double-stranded intermediates should arise under these conditions independent from 
helicase activity if helicase and RdRp cannot associate during the pause. In an alterna-
tive model, the nidovirus helicase may trail behind the RdRp along the newly synthe-
sized strand similar to the transcription termination factor Rho (123) (Figure 8E). Upon 
encountering a body TRS, the RdRp could stall until the lagging helicase reaches it. At 
this stage, the helicase would be in the position to pull the negative strand out of the 
RdRp active site and thereby potentially allows polymerase dissociation. The nascent 
negative strand may then, possibly under guidance of additional proteins, base-pair 
with the leader TRS (again assuming genome circularization). Subsequently, the same or 
a second RdRp molecule may engage in extending the nascent negative strand with the 
anti-leader sequence. This model could also be modified to complete the synthesis of 
the negative strand using the original RdRp molecule assisted by an enzymatically inac-
tive helicase molecule as depicted in Figure 8D. The models in Figures 8D and 8E could 
also be adapted to the utilization of sg  mRNAs, rather than the genome, as template 
for the synthesis of complementary strands of other, smaller sg  mRNAs, as described 
for coronaviruses (124;125). Once subgenome-length negative strands are produced, 
they may function as template for the respective sg mRNAs, according to the model in 
Figures  8B and 8C. Thus, the above considerations envision differential requirements 
for helicase activity and helicase interaction with the RdRp in the continuous and 
discontinuous modes of RNA synthesis that operate during nidovirus replication and 
transcription. These processes may also recruit host helicase(s) (126), indicating that the 
proposed models may be modified as a result of future experimental probing.
To shed light on the validity of these hypotheses, it should be insightful to identify 
proteins or protein complexes that are modulated upon encountering a body TRS. Re-
markably, the functional profile of a single-point mutant of EAV nsp10 showed that 
this protein may have properties compatible with the requirements of the template 
switching model (Figure 8D). This mutant, with a replacement of residue S2429 of the 
replicase polyprotein (subsequently referred to as S59 of nsp10) by a proline, displayed 
a selective reduction of negative- and positive-stranded subgenome-length RNA syn-
thesis by ~100-fold while genome synthesis and polyprotein processing remained un-









































thought to be located at the border between the ZBD and the helicase core, by replacing 
it with alanine, cysteine, glycine, histidine, leucine, or threonine led to no significant 
difference compared to wild-type nsp10 (75). Already at that time it was speculated that 
the special structural properties of proline in combination with a localization within a 
proposed hinge-region connecting the ZBD and the helicase core might be the cause of 
the mutant phenotype.
This hypothesis was recently verified and further refined on the basis of the EAV nsp10 
crystal structure (6). It is now evident that this region of the protein appears to be an 
integral part of both the ZBD and a linker to the downstream region. S59, which notably 
is followed by another proline (P60), is located immediately downstream of the second 
zinc-binding module of the ZBD (Figure 6) and contributes three main chain hydrogen 
bonds to the interactions with this module. These interactions are likely maintained in 
many mutants as long as the general backbone conformation of this loop is not sig-
nificantly altered by, for instance, the introduction of a second proline (6). In agreement 
with this interpretation, also the introduction of consecutive glycines at positions 59 
and 60, which may lead to excessive flexibility, or inversion of the serine and proline 
resulted in phenotypes similar to that of the S59P mutant (75). Interestingly, when any 
of these three mutations was introduced into recombinant nsp10, the protein’s activities 
in ATPase and helicase assays were almost indistinguishable from those of the wild-type 
protein while the respective mutant viruses were severely crippled (74;75). These obser-
vations suggested that the ZBD may have a vital function independent of the helicase 
activity per se, for example, in interacting with partners that facilitate the regulation or 
utilization of helicase functions. Remarkably, nsp10 is the third nonstructural protein 
in arteriviruses, next to nsp1 (128) and nsp11 (129), which was directly and specifically 
implicated in transcription. Given this specific effect on sg RNAs it seems plausible that 
interactions between nsp10 and other proteins play a role in discontinuous negative-
strand synthesis. Therefore, it might be possible to rescue the EAV nsp10/S59P mutant 
virus by supplying negative-stranded subgenome-length RNA templates separately.
3.3.3 Helicase and virion biogenesis
To gain insight into the function of the ZBD, its characterization was extended to point 
mutants of EAV nsp10 whose conserved zinc-binding histidine and cysteine residues 
were individually swapped. This approach was chosen with the goal of affecting but 
not impairing the protein’s function by retaining the metal binding capacity, which 
was, however, not directly measured in the study. Despite this effort, RNA synthesis in 
general was still abolished in most mutants and, consequently, the respective muta-













































loss or severe reduction (≥80%) of ATPase activity. The only mutants that were viable, 
although displaying delayed replication, a small-plaque phenotype, and lower progeny 
titers, were C25H and H44C, which in vitro had an up to 40% reduced ATPase activity and 
therefore also diminished helicase activity. Upon a more detailed investigation of their 
defects, total RNA synthesis of both mutants seemed to be severely reduced compared 
to the parental virus. Nevertheless, while C25H had apparently lower helicase activity 
than H44C, its progeny titer surprisingly was 100-fold higher. Furthermore, the 5-log 
decrease of H44C viability was not consistent with its relatively mild decrease in overall 
RNA synthesis. These results may indicate that EAV nsp10 has an additional function in 
processes downstream of RNA synthesis.
In line with the above findings, also a mutation that blocked the nsp10-nsp11 cleavage 
resulted in a lack of infectious progeny although genomic and sg  RNAs were synthe-
sized (130). Although this defect could also be explained by a late function of nsp11, it 
emphasizes the need for further investigation of the role of nsp10 in other steps than 
RNA synthesis. Such an additional function would not be unprecedented in the virus 
world as the helicase domain of the NS3 protein of several flaviviruses but not its associ-
ated enzymatic activities appears to be important for particle formation, potentially by 
providing interaction surfaces for other proteins including the core protein (131-134).
3.3.4 Helicase and translation
Next to its functions in RNA synthesis, biochemical data suggested a role for the helicase 
in translation through providing RNA 5’-triphosphatase activity implicated in mRNA 
capping (29;76). This activity was demonstrated in other RNA viruses with capped RNA, 
including alphavirus-like viruses (35;47;98;99) and flaviviruses (135;136), which also 
encode other enzymatic activities involved in the production of capped RNAs. Based 
on this parallel, nidoviruses are expected to encode all components of the enzymatic 
capping machinery which has not been demonstrated yet for any nidovirus. For coro-
naviruses, a guanylyltransferase has not been identified (137) while two other major 
nidovirus groups lack also orthologs of the coronavirus N-MT (toroviruses) or N-MT 
and O-MT (arteriviruses) (138). Thus, the RNA 5’-triphosphatase activity of the helicase 
protein may be the only enzymatic activity of the capping machinery that is conserved 
across nidoviruses. Clearly, further research focusing on different lineages is required 
to ascertain the universal link between the conservation of the RNA 5’-triphosphatase 









































3.3.5 Helicase and post-transcriptional quality control
In addition to being involved in replication, transcription, and translation, which has 
been proposed for helicases of other RNA virus families as well, nidovirus helicases may 
also engage in a unique post-transcriptional RNA surveillance and processing pathway. 
This hypothesis arose from the surprising but provocative similarities to the highly 
conserved helicase Upf1 (6), which is universally employed by all eukaryotes (Figure 9). 
As described above, those similarities involved not only the widely documented 5’-3’ 
polarity of unwinding and the lack of nucleic acid specificity but also and uniquely 
the recently solved domain organization and fold. Most remarkably, Upf1 as well as 
nidovirus helicases carry a complex bipartite multi-nuclear zinc-binding domain at their 
N-terminus and an unstructured domain at their C-terminus, which both (probably) 
exert regulatory functions on the NTPase of these proteins (6;49;139). The most con-
served ZBD/CH and the helicase core domains of these two helicase lineages, nidovirus 
and Upf1, may be of monophyletic origin while the evolutionary relationships of the 
least conserved domain are understandably untraceable. Given these parallels, it was 
speculated that, like Upf1 (108), nidovirus helicases could be involved in processes tar-
geting aberrant viral transcripts, including the genome, for degradation (6) in order to 
prevent the synthesis of potentially harmful, truncated proteins. Alternatively, nidovirus 
helicases may be employed to interfere with Upf1-dependent pathways of the host by 
directly competing for interaction partners. In theory such interference may be a means 
to either protect viral RNAs from being recognized by and targeted to Upf1-dependent 
degradation pathways or to trigger the specific degradation of antiviral host mRNAs. 
The latter would mimic the type of regulation of mRNA abundance that is mediated by 













Figure 9. Phylogeny of nidoviruses in comparison to the Tree of Life (ToL). Bayesian phylogenies of nidovi-
ruses (A) and ToL (B) are drawn to a common scale of 0.1 amino acid substitutions per position. Major lin-
eages are indicated by vertical bars and names; arteri: Arteriviridae, mesoni: Mesoniviridae, roni: Roniviridae, 
toro: Torovirinae, corona: Coronavirinae. Lineages encoding the nidovirus helicase or Upf1 are indicated. 
Rooting was according to either (A) domain-specific outgroups or (B) as described (141). Posterior prob-
ability support values and fixed basal branch points (*) are indicated. The nidovirus and ToL alignments 
include, respectively, three enzymes and 56 single-gene protein families, 604 and 3336 columns, 2.95% and 













































nidovirus helicase with the stability of viral or cellular mRNAs are available. Similarly, 
RNA signals or proteins that could assist the helicase in the critical recognition of its 
wild-type or aberrant targets, particularly those of viral origin, remain uncharacterized. 
Thus, further experimental research is clearly needed to test the above hypotheses, 
which are not mutually exclusive.
The involvement of the helicase in non-sense mediated decay of aberrant cognate 
RNAs might have been used to facilitate helicase gene fixation in the genome of an 
ancestral nidovirus. Given the restricted genome size variation in families of (+)  RNA 
viruses (41), such facilitation could be essential since the helicase locus is larger than 
1000 nucleotides and its acquisition must have increased genome size considerably. For 
nidoviruses, constraints on the genome size expansion were postulated to be linked 
to the fidelity of RNA replication and the division of labor between the three principal 
genome regions, ORF1a, ORF1b, and the 3’-proximal ORFs (42). These regions seem to 
have expanded largely in succession, with domain acquisition by ORF1b leading to the 
transition from small to large nidoviruses. Among the proteins acquired early on was 
ExoN, whose proofreading activity was likely critical for the fixation of this gene in the 
expanding ancestral genome. If it had not improved the fidelity of RNA synthesis, the 
expanded genome would have melted down due to its increased error load. The ExoN 
acquisition also relieved further genome expansions from fidelity constraints. Similar 
considerations were invoked to explain the fixation of the helicase gene in an ances-
tral nidovirus genome upon its transition from a helicase-free proto-ancestor with an 
astrovirus-like genome organization (6). It can be argued that with the helicase being 
involved in post-transcriptional mRNA quality control, progeny genomes that passed 
this quality control would carry fewer errors, an effect similar to, although likely with 
smaller impact than, that of ExoN proofreading during replication. In contrast, this effect 
would seem unlikely if the helicase were involved in the control of viral or cellular mRNA 
stability in the other two ways detailed above. Importantly, although the evolutionary 
considerations regarding the ancestral event favor one hypothesis over the other two, it 
remains to be established how this likely early specialization constrained further evolu-
tion of the nidovirus helicase. Consequently, all three hypotheses must be considered 
when studying contemporary nidoviruses.
4. NIDOVIRUS HELICASES AS DRUG TARGETS
Despite intensified drug screening efforts since the 2003 SARS pandemic, clinically ap-
proved antivirals against nidoviruses are still lacking. Reflecting their importance during 









































(nsp5 in Coronaviridae), the RdRp, and also the helicase. As we have seen in the previous 
sections, helicase activity depends on several reactions and/or interactions: NTP binding, 
NTP hydrolysis, NDP and phosphate release, nucleic acid binding, translocation, duplex 
destabilization, protein co-factor binding, and signal transduction interconnecting any 
of these steps. Each of these may, at least in theory, be targeted to prevent unwinding. 
Consequently, the diversity of candidate drug scaffolds can be expected to be extensive, 
comprising NTP analogs and other small molecules, nucleic acid competitors, as well as 
antibodies and aptamers (142). The most accessible target in the helicase subunit prob-
ably is the NTP-binding site. However, given the similarity between viral and cellular 
NTPases and the vast number of proven and putative helicase enzymes in humans, many 
of the identified hits may possess significant cytotoxicity. To address this challenge, hit 
compounds are often first screened in unwinding assays and then counter-selected for 
NTPase inhibition. In this manner, molecules targeting less conserved regions and func-
tions of the protein, for instance protein-protein interactions, which tend to be specific 
for each helicase, can be identified. Still, also this approach is hampered by the fact that 
helicase inhibition is often caused by intercalation into the nucleic acid substrate rather 
than binding to the enzyme itself (143).
Over the past years, four drug scaffolds with inhibitory effect on the SARS-CoV helicase 
and low cytotoxicity have been identified. Interestingly, the available biochemical 
data indicate that the modes of action of these inhibitors may be very different. First, 
chromone derivatives (Figure 10A) and the adamantine-derived bananins (Figure 10B) 
have a direct effect on the NTPase activity although they are not nucleotide analogs 
(144;145). While chromones were not characterized in detail, bananins seemed to 
specifically inhibit nucleic acid-stimulated NTPase activity in a non-competitive fashion. 
Furthermore, these compounds did not inhibit the E. coli SF1 helicase DnaB, which sug-
gests the presence of a non-conserved binding site on the surface of SARS-CoV nsp13. 
In agreement with this hypothesis, bananins exhibited good selectivity with an EC50 
of <10 µM and CC50 of 390 µM. Whether this site may also be present in other nidovirus 
helicases has not been tested so far. Another non-competitive inhibitor was identified 
by Adedeji et al. (146;147). In contrast to the above compounds, it neither had an effect 
on the NTPase or nucleic acid-binding activities nor was it able to bind non-specifically 
to nucleic acids. Also this compound, designated SSYA10-001 (Figure 10C) originating 
from the Maybridge HitFinder chemical library, did not inhibit the NS3 proteins of the 
two flaviviruses HCV and Dengue virus. Moreover, it was efficacious against Middle East 
respiratory syndrome coronavirus (MERS CoV), murine hepatitis virus, and SARS-CoV in 
cell culture, with EC50 values ranging from 7-25  µM while being non-toxic up to con-
centrations of 500 µM. Finally, bismuth complexes (Figure 10D) proved to be effective 













































was proposed that bismuth ions can directly compete with zinc ions for their cysteine 
binding partners within the ZBD, thereby inhibiting NTPase and unwinding activities. 
It thus seems likely that these complexes may present broad-spectrum antiviral com-
pounds against all nidoviruses.
5. CONCLUDING REMARKS: A LONG AND UNWINDING ROAD TO 
UNDERSTANDING NIDOVIRUS HELICASES
As detailed above, nidovirus helicases have been the subject of about a dozen, mostly 








































Figure 10. Antiviral compounds with low cytotoxicity targeting SARS-CoV nsp13. Representative chemical 
structures of each inhibitor family. IC50 values refer to either NTPase or unwinding activity. (A) Chromones 
are inhibitors of NTPase activity. (B) Adamantine-derived bananines inhibit nucleic acid-stimulated NTPase 
activity non-competitively while they do not affect unstimulated NTPase activity. (C) SSYA10-001 is a non-
competitive inhibitor of unwinding but has no effect on NTPase activity. (D) Bismuth complexes act by 
releasing Bi3+, which compete with Zn2+ for binding to the ZBD. Bi3+ are located above and below the plane 









































Arteriviridae and subfamily Coronavirinae. These studies established the in vitro require-
ments for processivity and unidirectional 5’-3’ movement and their dependence on 
partially double-stranded DNA or RNA substrates and NTPase activity. The 5’-3’ direc-
tionality coupled with the requirement for a single-stranded overhang to initiate duplex 
unwinding is particularly restrictive with respect to RNA synthesis models, which can 
probably accommodate the helicase only upon postulating the involvement of addi-
tional and yet-to-be characterized co-factors. This and other properties of the nidovirus 
helicases listed above are shared with closely related helicases of viral and host origin. 
The overall similarity also includes the importance of a few highly conserved residues in 
the characteristic helicase motifs as well as the typical structural organization of the two 
core RecA-like domains, as revealed by the recent crystal structure of EAV nsp10.
The latter structure was also instrumental in establishing similarities between nido-
viral and Upf1 helicases, creating a novel functional dimension that may be explored 
in future nidovirus research to assess the potential involvement of the helicase in 
post-transcriptional quality control. The helicase core domains of both the arterivirus 
nsp10 and Upf1 enzymes are covalently linked to apparently orthologous multinuclear 
zinc-binding domains, whose extensive interaction with other helicase and external 
domains may mediate signal transduction. Known as the ZBD in nidoviruses, and distin-
guished by its exclusive presence in these viruses, this domain has been characterized 
extensively by site-directed mutagenesis and reverse genetics. From these studies it 
became clear that the arterivirus helicase is required for replication, transcription, and 
virion biogenesis. How the enzyme controls and possibly interconnects these processes 
are big unknowns that may not be resolved without major advancements in several 
fields, including the high-resolution visualization and in vitro reconstitution of the virus-
specific intracellular factories that mediate major processes in the nidovirus replication 
cycle. These lines of inquiry are at the cutting-edge of the currently pursued research 
efforts (see e.g. (150;151)). Their progress may be greatly stimulated by the availability 
of temperature-sensitive and other conditional mutants, whose parallel characteriza-
tion by traditional genetics, e.g., complementation and recombination, may be equally 
insightful (152). Together, these studies are expected to uncover the temporal and 
spatial dynamics of the interactions between the helicase and its partners, which have 
remained totally obscure so far. Admittedly, the generation and characterization of 
such mutants is time-consuming and requires unique expertise. These issues must be 
urgently addressed if our understanding of nidovirus helicase functions is to approach 
the level that has already been achieved for cellular helicases involved in other complex 













































To understand the specifics of helicase functions in the different phylogenetic lineages 
and firmly establish nidovirus-wide and lineage-specific features, their experimental 
characterization must be extended beyond the currently studied small number of vi-
ruses. These studies may also address questions inspired by comparative genomics, like 
it was done with the prior verification of the helicase and ZBD assignments. For instance, 
genomics tells us that the helicase is expressed downstream of the RdRp in nidoviruses 
while it is the other way around in alpha-, flavi-, and picornavirus-like viruses. This large-
scale evolutionary difference may be linked to fundamental constraints, whose nature 
remains as unclear as 25 years ago when this difference was first established (5;38;39). 
More recently, we have learned that in a helicase-based phylogeny coronaviruses cluster 
with invertebrate nidoviruses rather than with mammalian toroviruses with whom they 
share many more characteristics and form the Coronaviridae family (138). That study also 
established the mosaic conservation of ORF1b domains, including methyltransferases, 
in the major phylogenetic lineages of nidoviruses, which questions the universal role 
of the helicase’s RTPase activity in forming the 5’ end RNA cap of nidoviruses. Resolving 
these apparent conflicts, and others that could emerge from the on-going genomic 
characterization of nidoviruses, is a challenge for future experimental research. If met, 
the integration of mechanistic and evolutionary insights may help in developing effec-
tive drugs targeting nidovirus helicases. It will also ensure that our understanding of 
the details and relative importance of helicase characteristics is informed by natural 
selection rather than formed by our perception.
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Polynucleotide polymerases are the central enzymes involved in nucleic acid-based func-
tions of all organisms and viruses. Reflecting this importance, a detailed understanding 
of their activities is crucial for deciphering biologically important processes like genome 
replication, transcription, and repair. All plus-stranded RNA viruses encode a conserved 
RNA-dependent RNA polymerase (RdRp), which was extensively characterized only in 
viruses of few families. In the order Nidovirales, which includes viruses with (very) large 
genomes, the RdRp is expressed in association with other replicative enzymes as part 
of the polyprotein encoded in open reading frame 1b (ORF1b). Based on sequence 
conservation, it was mapped to the C-terminal domain of nonstructural protein (nsp) 9 
in arteriviruses and nsp12 in coronaviruses, the two families of mammalian nidoviruses. 
Potent primer-dependent RdRp activity was demonstrated for the severe acute respira-
tory syndrome coronavirus enzyme. In contrast, the only study focusing on nsp9 of the 
arterivirus equine arteritis virus (EAV) reported de novo polymerase activity on certain 
homopolymeric RNA templates in biochemical assays. However, this activity was not 
maintained when Mn2+ ions, which are known to relieve the sequence dependency of 
polymerases, were omitted or when biologically more relevant templates representing 
viral sequences were supplied. Due to these observations, we sought to revisit the 
biochemical properties of this polymerase. We describe here the results of a carefully 
controlled study involving several preparations of purified recombinant EAV nsp9 that 
included the wild-type and a set of active site mutants, which were tested for de novo 
and primer-depended polymerase and terminal transferase activities. However, we were 
unable to reproduce the published EAV nsp9 activity as the RdRp domain of nsp9 was 
found not to be associated with any of the activities observed in these assays. Also we 
noticed a striking resemblance between the product profiles of one of the tested prepa-
rations of nsp9 and that of T7 phage RNA polymerase. Our results hence emphasize the 














































Polymerases, which catalyze the templated synthesis of polynucleotides in the 5’-3’ 
direction, are enzymes encoded by all organisms and RNA viruses, as well as some DNA 
viruses. Reflecting the principal differentiation into DNA- and RNA-based processes and 
functions, those enzymes can be grouped into four classes each possessing a distinct 
combination of specificities for their substrate (NTPs or dNTPs) and template (RNA or 
DNA) under physiological conditions. Despite these fundamental differences regarding 
the requirements for their substrates, many polymerases of the four classes, including 
all characterized RNA-dependent RNA polymerases (RdRps), employ the same catalytic 
mechanism and a similar three-dimensional fold resembling the shape of a right hand 
with finger, thumb, and palm domains (1;2). At the sequence level, these polymerases 
share two sequence motifs, motifs A and C, found in the most conserved palm domain 
(3). Few conserved residues, primarily aspartates, located in these motifs are implicated 
in (d)NTP binding and/or catalysis (4;5), and consequently their replacement should 
abolish or at least severely decrease nucleic acid synthesis (2).
Based on their requirements for initiation of nucleic acid synthesis, two types of poly-
merases are recognized: primer-dependent and de  novo-initiating enzymes (2;6). The 
latter, to our knowledge exclusively RNA polymerases (DNA- or RNA-dependent), are 
capable of positioning two NTPs, typically two purines, in a manner that allows the 
formation of a starting dinucleotide. In contrast, primer-dependent polymerases are un-
able to accommodate the required stable association between the first (d)NTP and the 
template. As a result the formation of the first dinucleotide is an energetically extremely 
unfavorable event in these proteins. To overcome this problem, short RNA primers must 
be produced and placed on the template. For this purpose, organisms and viruses have 
evolved different initiation mechanisms that are all assisted by additional proteins or 
domains. They may involve the synthesis of short RNA fragments (by e.g., eukaryotic 
DNA primase (7)), the formation of covalent RNA-protein complexes (e.g., picornavirus 
VPg-RNA complexes (8)), or the utilization of tRNAs (by lentivirus tRNA-binding domains 
(9)) or 5’ fragments of cellular mRNAs (generated by influenza virus, bunyavirus, and 
arenavirus endoribonuclease and cap-binding domains (10-12)).
For genome replication many viruses rely on a polymerase that is encoded within 
their genome. In viruses of the order Nidovirales (comprising the families Arteriviridae, 
Coronaviridae, Mesoniviridae, and Roniviridae), which are characterized by their large to 
exceptionally large single-stranded RNA genomes (13;14), a canonical RdRp possessing 
common motifs of other polymerases with right-hand structure is expressed from ORF1b 









































subunit (nonstructural protein (nsp) 9 in Arteriviridae, nsp12 in Coronaviridae) harbor-
ing conserved motifs of an RdRp in its C-terminal two-thirds is released (14;15;18;19). 
Eventually, this cleavage product becomes a key subunit of the membrane-associated 
multi-subunit replication-transcription complex (RTC) that mediates the synthesis of 
diverse viral RNAs (20-22). This complex has been characterized in  situ and through 
reconstitution of its activities in vitro. In one of these studies coronaviruses, prototyped 
by severe acute respiratory syndrome coronavirus (SARS-CoV), were proposed to ex-
press a second, non-canonical RNA polymerase subunit: the ORF1a-encoded nsp8 (23). 
In agreement with early studies describing nsp8 as an obligatory de novo polymerase 
capable of synthesizing products of less than six nucleotides (23) and nsp12 as strictly 
primer-dependent (24), it was speculated that the two proteins may work sequentially 
on the same template, with nsp8 providing the primers required by the nsp12 “main 
RdRp”. Subsequently, also recombinant feline coronavirus nsp8 and human coronavirus 
229E nsp7-10 (an nsp8-containing precursor) were reported to be able to synthesize 
RNA oligonucleotides with a length of up to six nucleotides. Upon addition of the cog-
nate nsp7, the activity of feline coronavirus nsp8 was further enhanced, generating RNA 
products of up to 67 nucleotides (25).
However, recent studies question this clear division of labor. First, it was shown that 
recombinant nsp8 expressed without any artificial terminal residues also possesses 
primer-dependent activity. Furthermore, in complex with its co-factor nsp7, this activity 
was estimated to be only 2.5-fold lower in terms of NTP incorporation per active site 
than that of nsp12 (26). Additionally, one study also reported de novo activity for nsp12 
(27). Finally, in the most recent study, SARS-CoV nsp12 showed non-processive primer 
extension activity in an in vitro assay, which was substantially enhanced by the addition 
of nsp7 and nsp8. The same combination of three proteins was also required for de novo 
initiation of RNA synthesis. A complex of just nsp7 and nsp8, on the other hand, did not 
show any activity in this study. Hence it was concluded that the nsp7-nsp8 complex 
serves as an activator and processivity factor, rather than primase, for the nsp12 RdRp 
(16). The background of the reported differences and apparent contradictions with 
respect to the properties of SARS-CoV nsp8 (in complex with nsp7) and nsp12 remain 
unknown, but technical differences are likely to play a role, especially concerning the 
expression constructs, protein purification, and templates used.
Besides SARS-CoV nsp12, RdRp activity was characterized for only one other nidovirus 
“main RdRp”, the arterivirus equine arteritis virus (EAV) nsp9 (28). In that study, de novo 
RdRp activity was reported on poly-uridine (pU) and poly-cytidine (pC) single-stranded 
RNAs while no primer extension or terminal transferase activity, that is, the untemplated 













































is restricted to de novo initiation. However, the applicability of the observed activity to 
virus replication remained uncertain since activity on templates containing appropriate 
virus-specific sequences could not be detected, and the in vitro activity required the pres-
ence of Mn2+, which is known to relieve template requirements for other polymerases 
(29). One possible explanation for the lack of initiation on virus-specific templates could 
be that additional co-factors, e.g. higher-order RNA structures or proteins, are needed 
for genuine de novo initiation in vivo. Therefore, the aim of this study was to character-
ize the RNA polymerase activity of EAV nsp9 in more detail. We report the results of a 
carefully controlled study involving several preparations of purified recombinant EAV 
nsp9 that included the wild-type protein and a set of active-site mutants, which were 
tested for de  novo and primer-dependent polymerase and terminal transferase activi-
ties. However, we were unable to reproduce the published EAV nsp9 activity as the RdRp 
domain of nsp9 was found not to be associated with any of the activities observed in 
these assays. Also we noticed a striking resemblance between the product profiles of 
one of the tested preparations of nsp9 and that of T7 phage RNA polymerase. Our results 
hence emphasize the need to employ diverse controls when utilizing highly sensitive 
biochemical assays.
RESULTS AND DISCUSSION
Expression and purification of EAV nsp9 using two vectors
Previously, the purification and de novo polymerase activity of recombinant EAV nsp9 
were described (28). In that study the viral protein (subsequently designated as nsp9/
pDEST) was cloned into a pDEST vector including a C-terminal hexahistidine tag and 
expressed in E. coli BL21 (DE3). As typical for bacterially expressed proteins, an unknown 
fraction of nsp9 may contain an N-terminal formylmethionine due to saturation of the 
endogenous protein processing pathway by nsp9 overexpression. Such an N-terminal 
extension would modify the authentic N-terminus of nsp9, which is expected to be a 
glycine residue following the proteolytic release of nsp9 from the pp1ab polyprotein by 
nsp4-mediated cleavage of the Glu1677↓Gly1678 site (30). Previously, it was reported 
for SARS-CoV nsp8 and nsp12 that artificial tags at the N-terminus may influence RdRp 
activity and stability, respectively (24;26).
To circumvent this potential problem, we decided to express EAV nsp9 as part of a ubiqui-
tin fusion protein by using a so-called pASK vector (31), the resulting protein is hereafter 
referred to as nsp9/pASK. In combination with co-expression of the ubiquitin-specific 









































this enabled us to obtain the natural glycine N-terminus of nsp9 when expressed in 
the E. coli BL21 derived strain C2523/pCG1. An additional advantage of the pASK vector 
was that its backbone allowed us to drive expression via the endogenous pool of E. coli 
RNA polymerase after induction with anhydrotetracycline. In contrast, nsp9/pDEST was 
expressed from a T7 promoter after over-expression of the T7 phage RNA polymerase. 
Although this expression system is well characterized and has proven suitable for a 
wide range of proteins, the potential presence of this phage RNA polymerase in the 
ultimate nsp9 preparations could be of concern. Indeed, since the demonstrated activ-
ity of recombinant EAV nsp9 was shown to be low (28), even trace quantities of this 
potent phage polymerase might cause a significant background activity complicating 
the interpretation of the obtained results.
Both variants of recombinant nsp9 were expressed in their respective E. coli strains un-
der identical growth conditions. They were subsequently batch purified in a single step 
using metal ion chromatography with Co2+ targeting the C-terminal hexahistidine tag 
of both polypeptides. As Figure 1A shows, both proteins could be obtained with similar 
purity, but nsp9/pASK was expressed in higher quantities than nsp9/pDEST. Attempts to 
further purify both proteins by gel filtration did not result in a significant improvement 
as judged by silver staining of SDS-PAGE gels (not shown).
T7 RNA polymerase contamination may account for de novo activity observed 
with EAV nsp9 preparations
nsp9/pDEST and nsp9/pASK preparations were tested side-by-side in a de novo polymerase 
assay in the presence of radioactive ATP using similar reaction conditions as described before 
(28). The only noteworthy difference from the published protocol was the length of the pU 
template, which was 30 nucleotides in our experiments compared to an undefined mixture 
containing RNAs of up to 300 nucleotides in the study of Beerens et al.. To our surprise neither 
of the preparations showed any activity on this template even when the ATP concentration 
was 15-fold increased to 1.5 mM with the goal to favor polymerase initiation (not shown). 
Next we tested the RdRp activity using a template whose 3’-terminal dinucleotide matched 
the CC dinucleotide that is present immediately upstream of the poly(A) tail at the 3’ end of 
the EAV genome. Indeed, as previously shown for homopolymeric pC templates, nsp9/pDEST 
exhibited some activity with this RNA template, while nsp9/pASK remained essentially inac-
tive (Figure 1B, middle and left panel, respectively, lanes R1). As noted earlier, the former and 
latter preparations differed in two respects: the presence of an artificial N-terminal residue 
in nsp9/pDEST and the induction of T7 RNA polymerase production to achieve expression of 
nsp9/pDEST. Only this expression of an additional polymerase can reasonably be linked to 













































To test this hypothesis, we extended our analysis to include also a highly diluted sample 
(0.01 U/µl final concentration) of a commercially available T7 RNA polymerase. Since this 
enzyme is DNA-dependent, we included two single-stranded DNA templates: a DNA 
variant (D1) of the RNA template used and a DNA template containing the negative-
stranded T7 promoter sequence (D4). The rationale for the second template was to pro-
vide a specific recognition signal in the template for the enzyme and thus increase the 
chances to observe its activity. Although it has been reported that this DNA-dependent 
enzyme strictly requires its cognate promoter in a double-stranded form (32), we rea-
soned that providing DNA with the same polarity as the template that is transcribed 
under physiological conditions, may at least support some residual activity. Surprisingly, 
T7 RNA polymerase was active on all of these templates under the employed conditions 
























Figure 1. Expression, purification, and de novo polymerase activity of two recombinant EAV nsp9-His prep-
arations. (A) Coomassie brilliant blue-stained SDS-PAGE gel of samples taken during metal ion chromatog-
raphy using Co2+. Insoluble and soluble: respective fractions after cell lysis; after binding: unbound protein 
after removal of Co2+ resin; eluate: elution fraction after purification. The molecular weight of nsp9-His is 
78 kDa. Size markers are depicted on the right in kDa. (B) de novo polymerase assay using nsp9 expressed 
from pASK (final protein concentration 2 µM) or pDest (final protein concentration 0.6 µM) vectors, or using 
commercial T7 RNA polymerase (0.05 U per sample). R and D indicate the use of RNA and DNA templates, 
respectively. Identical numbers indicate templates with equivalent sequences. Template sequences are 
listed in Table 2. Product lengths (nt) are indicated on the right. Note that products longer than template 
length, 30 nt for R1 and D1, result from terminal transferase activity acting on either the template or the 









































Interestingly, the product pattern from the T7 promoter-containing template was 
markedly different from the one expected. As already mentioned, de  novo initiation 
on any given template can be forced by increasing the concentration of the required 
NTPs. Likewise, decreasing the concentration of one of the NTPs will force a polymerase 
to pause and eventually dissociate from the template (or incorporate a non-matching 
nucleotide) once it encounters the complementary base. In this manner synthesis by 
enzymes with low processivity can be shifted from the production of evenly distributed 
but low-intensity products towards a few predominant, high-intensity bands. Thus, lim-
iting the concentration of one nucleotide, in this case CTP, may increase the probability 
of detecting polymerase activity if the signal-to-noise ratio is a concern. However, this 
was not evident with nsp9/pDEST (Figure 1B, right panel). While the lack of these promi-
nent bands in lanes R1 and D1 may be explained by misincorporation of nucleotides, 
favored by the high ratio between correct and incorrect NTPs as well as the presence of 
error-inducing Mn2+, the preference for synthesizing the products of a length of 12, 14, 
15, and approximately 38 nucleotides seen in lane D4 is difficult to reconcile with the 
template’s sequence. Instead it would be expected that, if at all, synthesis would termi-
nate at positions preceding a G residue in the template (nucleotides 5 (in which case 
the product would not be visible), 8, 10, 12, etc.) as incorporation of CTP is unfavorable 
under the conditions applied. A possible explanation for the observed product pattern 
could be internal initiation on this template lacking a strong promoter sequence. Thus, it 
is tempting to speculate that this particular template interacts with T7 RNA polymerase 
in a distinctive manner that may not be shared by other polymerases.
With that said, it remains to be noted that the nsp9/pDEST preparation showed the same 
overall pattern, including the preference for DNA templates, as the commercial T7 RNA 
polymerase. In line with this notion, an nsp9/pASK preparation gained de novo activity 
once it was expressed in BL21 (DE3) under addition of IPTG (not shown). Hence, this 
circumstantial evidence suggests that contaminating T7 RNA polymerase, rather than 
EAV nsp9 itself, is responsible for the de novo polymerase activity observed here.
Whether or not this contamination was also present in the nsp9 preparations described 
in Beerens et al. (28), and later on also by te Velthuis et al. (33), cannot be established 
with certainty as the experiments presented here and those published previously devi-
ated in some aspects. Particularly the previously described purification protocol could 
not be reproduced in our experiments due to technical difficulties with the described 
purification buffer, which in our hands induced protein precipitation during purification. 
Furthermore, as mentioned above, we could not observe an additional purifying effect 
of a second chromatography step. Nevertheless, we investigated whether inclusion of 













































contamination with T7 RNA polymerase (molecular weight 99 kDa) from a preparation of 
nsp9/pDEST (molecular weight 78 kDa). We found that this was not the case (not shown).
In conclusion, our results revealed that the radioactive polymerase assay used in this 
and previous studies is sensitive enough to detect trace activities of contaminating 
T7 RNA polymerase and also enables this polymerase to act on templates lacking the 
established T7 promoter requirements. Still, the fact that we did not detect any RdRp 
activity for nsp9/pDEST, and therefore also not for its suspected contaminant, on a pU 
template may be used to argue for the detection of genuine nsp9 activity in the previous 
studies. In this context it is noteworthy that the two coronavirus RdRps were addressed 
in six independent studies (16;23-27), none of which succeeded in exactly reproducing 
results of any other. This may indicate that nidovirus RdRps are highly delicate proteins 
responding to minute changes during purification or in their reaction environment.
EAV nsp9/pASK preparations possess primer-dependent polymerase and 
terminal transferase activity
Besides de novo activity, we decided to test whether EAV nsp9 may possess primer-depen-
dent polymerase activity like its larger coronavirus homolog nsp12 (16;24). To detect this 
activity, we used a similar assay as the one described above but this time providing partially 
double-stranded templates. We found that both nsp9 preparations were enzymatically ac-
tive on these templates and showed the highest extension activity if the template and 
primer were RNAs (Figure 2A, left and middle panel). This differential reaction towards the 
type of substrate showed that the measured activity was a direct response to the added 
nucleic acids, hence not to a co-purified E. coli-derived RNA or DNA template. Furthermore, 
as the presence of a DNA template significantly decreased processivity, it also demonstrated 
that the responsible polymerase was RNA dependent. Interestingly, while the use of a DNA 
primer in combination with an RNA template precluded any extension (no products in 
the size range between 20 and 39 nucleotides), a product corresponding to a length of 40 
nucleotides was detected. This suggested that the polymerase possesses terminal transfer-
ase activity but only on RNA substrates. To investigate this further, we also compared the 
elongation of single-stranded RNA and DNA substrates in an assay otherwise identical to 
the one used for measuring primer-dependent polymerase activity (Figure 2B). As expected, 
both nsp9 preparations showed a clear selectivity in favor of RNA, again emphasizing their 
dependence on this substrate type. In this context it is also noteworthy that neither the 
primer extension nor the terminal transferase assay included Mn2+ ions, which can favor ac-
tivity on sub-optimal templates (29). Together with the demonstrated DNA specificity of T7 
RNA polymerase (Figures 2A and B, right panels) this supports the reliability of these assays 









































Finally, to conclude the characterization of the polymerase, its nucleotide preference 
was examined. To this end, a primed RNA template (Figure  3A) was first elongated in 
the presence of a low concentration of radioactive ATP, resulting in frequent abortion 
of transcription after incorporation of the first nucleotide. Subsequently, either dATP 
or ATP was supplied in a concentration that should allow restarting and completion of 
the reaction (Figure 3B). As expected, addition of ATP enabled the synthesis of almost 
fully extended products while dATP did not support any extension beyond one or two 
nucleotides (Figure 3C). In agreement with the lack of DNA primer extension and the 
known inability of the prototype viral RdRp of poliovirus to further extend deoxynucleo-










































Figure 2. Polymerase assays using recombinant EAV nsp9-His expressed from pASK (final protein concen-
tration 1 µM) or pDEST (final protein concentration 0.3 µM) vectors or using commercial T7 RNA polymerase 
(0.025 U per sample). R and D indicate RNA and DNA strands, respectively. Identical numbers indicate nu-
cleic acids with equivalent sequences. Nucleic acid sequences are listed in Table 2. Product lengths (nt) are 
indicated on the left. (A) Results from primer extension assay (primer length 19 nt). Note that products 
longer than template length (29 nt for R2, 39 nt for R3 and D3) must have resulted from terminal transferase 
activity acting on either the template or the newly synthesized strand. (B) Results from terminal transferase 
assay. The signal at the very top of the gel likely represents products of >200nt that cannot be resolved in 
the high-percentage acrylamide gel used here. Note that products resulting from end-labeling with ATP 













































Reverse genetics of conserved aspartates of nsp9
To establish whether the observed activity was associated with the RdRp domain of 
EAV nsp9, we substituted several of the key residues of the (predicted) active site of the 
enzyme with alanine. Previously, EAV nsp9 residues belonging to conserved polymerase 
motifs had been identified (17;28). To further support this identification, we constructed 
EAV full-length cDNA clones encoding alanine substitution mutants of each of the four 
conserved aspartates of motifs A and C, which coordinate the essential metal ions or 
interact with the NTP’s 2’ and 3’ hydroxyl groups in the better characterized polymerases. 
After in vitro transcription, full-length RNAs representing these mutants were trans-
fected into BHK-21 cells, which were monitored for viral progeny production and protein 
expression using plaque assays and immunofluorescence microscopy, respectively. 
Polymerase activity is primarily based on a two-metal-ion mechanism involving several 
residues. In contrast to other catalysis mechanisms, which may feature a single or few 
absolutely required residues, individual amino acids rather work in concert during metal 
catalysis to provide a framework for metal ions and substrates to bind. Consequently, 
the substitution of single residues may merely reduce binding affinities and may thus, 
depending on their individual contribution, be either lethal or non-lethal for the en-
zyme’s function and thus for the virus. In agreement with the expected essential role 
and preliminary unpublished observations for equivalent SARS-CoV nsp12 mutants (not 
shown), each of the aspartate-to-alanine substitutions tested had a severe impact on 
viral replication. Whereas all double mutations tested were lethal, viruses carrying single 


























Figure 3. Stop-and-go primer extension assay using EAV nsp9-His expressed from a pASK vector and prim-
er/template R/R3 in the presence of ATP or dATP. (A) Sequence of primer/template. (B) Schematic represen-
tation of the experimental design. (C) Polymerase products after interrupted and resumed synthesis. The 









































sion to wild-type virus later in the experiment (by 48 h p.t.; Table 1). In all cases a single 
nucleotide point mutation was sufficient to restore the codon for the wild-type residue. 
Nevertheless, this finding is somewhat unexpected given the universal conservation of 
all four aspartates in positive-stranded RNA viruses. To our knowledge replication, even 
though severely decreased and undetectable until reversion had occurred, of a single 
mutant of the enzyme’s active site has not been reported for any other RNA virus thus far.
Observed primer extension and terminal transferase activities are not 
correlated with EAV nsp9
Following the results described above, we transferred the same mutations into the nsp9/
pASK expression construct to obtain negative controls for the biochemical RdRp assays 
described in the previous paragraphs. However, none of the proteins with double, triple, 
and quadruple aspartate-to-alanine substitutions tested showed a decreased primer 
extension activity compared to two independently purified batches of wild-type recom-
binant nsp9/pASK (Figure 4). Likewise, D445A and D560A mutant proteins maintained 
terminal transferase activity (not shown). Thus, the observed activities either derived 
from a second active site within nsp9, which was not targeted by mutagenesis, or may 
have originated from a different (contaminating) protein altogether. Both these expla-
nations are quite extraordinary since none of the described RdRps is known to have a 
second active site and no RdRp activity from E. coli has been reported to the best of our 
knowledge.
To discriminate between these possibilities, we asked whether it was possible to 
separate nsp9-containing fractions from biochemically active ones during purification 









of P1*16 h p.t. 24 h p.t. 48 h p.t. 72 h p.t.
wt ++ +++ cells dead cells dead large 2·107 n.d.
D445A - - + +++ large 6·105 wt
D450A - - ++ +++ large 2·105 wt
D445/450A - - - - - - n.d.
D560A - - ++ +++ large 6·107 wt
D559/560A - - - - - - n.d.
IFAs were done with antibodies directed against nsp3 and N proteins; -, negative; +, few, separated positive; 
++, clustered positive; +++, all positive; p.t., post transfection; n.d., not done; *P1 was generated by infec-













































of the quadruple mutant of nsp9/pASK. To this end, the wash steps of the previously 
established purification protocol were modified in either of two ways; first, a decreasing 
salt gradient was introduced to weaken (disrupt) hydrophobic interactions between a 
contaminant and nsp9, and second, an increasing imidazole gradient was employed in 
order to eliminate any contaminant from the Co2+-resin. As shown in Figure 5, the NaCl 
elution fraction and wash steps 2 and 3 of the imidazole gradient contained almost iden-
tical amounts of nsp9-His, as judged by SDS-PAGE, while two of these three fractions 
were inactive in the polymerase assay. This partial correlation between the presence of 
p+20
p+1
Figure 4. Primer extension assay on primer/template R/R3 using wild-type EAV nsp9-His expressed from 
a pASK vector and mutants in which essential aspartate residues of the RdRp domain were replaced with 
alanine (D445 and D450 of motif A, D559 and D560 of motif C). The sizes of primer extension products are 













































































Figure 5. Correlation between EAV nsp9-containing fractions and primer extension activity. (A) Coomassie 
brilliant blue-stained SDS-PAGE gel of samples taken during the purification of nsp9/pASK by Co2+ affinity 
chromatography using wash buffers with either a decreasing NaCl concentration or an increasing imidaz-
ole concentration. Size markers are depicted on the left in kDa. (B) The samples shown in A were examined 














































recombinant nsp9-His and primer extension activity could be due to either the presence 
of two forms of nsp9, enzymatically active and defective, or the presence of a second 
enzyme responsible for the activity. Resolving the remaining uncertainty is challeng-
ing since bacteria are, to our knowledge, not known to encode RNA-dependent RNA 
polymerases, and the nature and origin of the possible heterogeneity of nsp9 remained 
elusive.
Concluding remarks
In a final effort to activate the polymerase activity of recombinant EAV nsp9, we included 
several potential protein co-factors in our primer extension assays. For these experi-
ments we chose the poorly characterized arterivirus subunits encoded immediately up-
stream of the ORF1a/1b ribosomal frameshift site, at the genomic position equivalent to 
those of the proven coronavirus nsp12-RdRp co-factors nsp7 and nsp8 (16). Although 
the proteins of the distantly related corona- and arterivirus families share little similarity, 
they might have diverged beyond recognition while retaining similar functions. These 
poorly characterized arterivirus proteins include nsp6, a 22-amino acid peptide in EAV, 
nsp7α (123 amino acids in EAV), nsp7ß (102 amino acids in EAV), and nsp8 (50 amino 
acids in EAV), the subunit located immediately upstream of the frameshift site that 
corresponds to the N-terminus of nsp9. Additionally, as these four subunits are known 
to be contained in, in part, long lasting cleavage intermediates (nsp6-7α, nsp6-7, nsp6-
7-8, nsp7, nsp7-8) (35;36) also those were tested. Finally, the EAV helicase nsp10 was 
included since its SARS-CoV homolog (nsp13) was shown to interact with its cognate 
RdRp nsp12 (37;38). Unfortunately, neither of these subunits had any positive impact 
on the polymerase activity of recombinant EAV nsp9/pASK (not shown) or showed 
any evidence of interaction with nsp9 in native gel and cross-linking experiments (not 
shown). However, we should note that we did not probe this possibility exhaustively 
using different experimental conditions to facilitate complex formation or maybe even 
co-expression of multiple partners. Hence, there is certainly room to explore the co-
factor hypothesis in more detail.
To conclude, in this study we could neither confirm the previously reported de novo poly-
merase activity nor detect any other RNA polymerase activity originating from purified 
recombinant EAV nsp9-His, indicating that the characterization of the arterivirus RdRp 
presents a formidable challenge. While the reason(s) underlying the differences to ear-
lier studies remains to be elucidated, the outcome of the present study emphasizes the 
need for selecting proper controls especially when utilizing highly sensitive biochemical 
assays for characterizing enzymes with low activity. Furthermore, it demonstrates that 









































conditions and/or in the presence of interaction partners that may alter substrate prefer-
ences by modifying an enzyme’s conformation. Being aware of this pitfall probably is 
one of the most fundamental prerequisites for the deduction of biological roles from 
biochemical assays.
MATERIAL AND METHODS
Protein expression and purification
C-terminally His-tagged fusion proteins of wild-type and mutant EAV nsp9 were ex-
pressed under the control of a tetracycline promoter from a pASK vector in the E. coli 
BL21 derivative C2523/pCG1 as described (26). As a reference, a previously used pDEST 
construct of nsp9-His6 was expressed in E. coli BL21 (DE3) cells after IPTG induction under 
otherwise identical conditions. Proteins were purified by metal affinity chromatography 
using Co2+ (Talon beads) as described (26) using a buffer containing 20  mM HEPES, 
pH 7.5, 500 mM NaCl, 10% glycerol (v/v), 10 mM imidazole, and 5 mM β-mercaptoethanol 
unless it is explicitly stated otherwise. Where indicated, a second purification step using 
a Superdex 200 10/300 GL gel filtration column with 20 mM HEPES, pH 7.5, 300 mM NaCl, 
1 mM DTT was performed at 4°C using a flow rate of 0.3 ml/min.
Polymerase assays
Three different types of polymerase assays were performed: de  novo, primer exten-
sion, and terminal transferase assays. For de  novo assays samples contained 10  mM 
Tris, pH 8.0, 5 mM KCl, 25 mM NaCl (including 20 mM from the protein storage buffer), 
6 mM MgCl2, 1.5 mM MnCl2, 1.5 mM DTT, 12.5% glycerol (including 10% from the protein 
storage buffer), 0.005% Triton X-100, 1.5 U RiboLock RNase inhibitor (Thermo Scientific), 
0.5 µM single-stranded nucleic acid template, 1.5 mM ATP, if required 0.7 mM GTP and 
0.7 mM UTP, 0.17 µM [α-32P]CTP (Perkin Elmer, 3000 Ci/mmol), and 2 µM nsp9/pASK or 
0.6 µM nsp9/pDEST or 0.05 U T7 RNA polymerase from a commercial source (Life Tech-
nologies). Primer extension and terminal transferase assays were performed in 20 mM 
Tris, pH 8.0, 10 mM KCl, 20 mM NaCl (including 10 mM from the protein storage buffer), 
6 mM MgCl2, 1 mM DTT, 10% glycerol (including 5% from the protein storage buffer), 
0.01% Triton X-100, 0.5  U RiboLock RNase inhibitor, 1  µM partially double-stranded 
(primer extension) or single-stranded (terminal transferase) nucleic acid, 50  µM ATP, 
0.17 µM [α-32P]ATP (Perkin Elmer, 3000 Ci/mmol), and 1 µM nsp9/pASK or 0.3 µM nsp9/
pDEST or 0.025  U T7 RNA polymerase (Life Technologies). Sequences of used nucleic 













































Nucleic acids were annealed with complementary primers by heating to 95°C for 2 min, 
then keeping them at 52°C for 30 min, and finally letting them cool to room temperature 
in 30 min.
In all three assays, samples were incubated for 1  h at 30°C before the reaction was 
stopped by addition of an equal volume of formamide gel loading buffer (95% for-
mamide, 18 mM EDTA, 0.025% SDS, xylene cyanol, bromophenol blue) and 2 min dena-
turing at 95°C. Products were separated by gel electrophoresis in 20% polyacrylamide 
gels (19:1) containing 7 M urea. Gels were run in 0.5x TBE and subsequently exposed 
to phosphorimager screens overnight. Screens were scanned on a Typhoon variable 
mode scanner (GE Healthcare), and band intensities were analyzed with ImageQuant TL 
software (GE Healthcare).
Reverse genetics of EAV
Alanine-encoding mutations of codons specifying conserved nsp9 residues were gener-
ated using the QuikChange protocol and were introduced into full-length cDNA clone 
pEAV211 (39) using appropriate shuttle vectors and restriction enzymes. The presence 
of the mutations was confirmed by sequencing. pEAV211 plasmid DNA was in vitro tran-
scribed and full-length RNA was transfected into BHK-21 cells as described previously 
(40). Transfected cells were monitored until 72  h post transfection (p.t.) by immuno-
fluorescence microscopy using antibodies directed against the nsp3 and N proteins as 
described (41). To monitor the production of viral progeny, supernatants were harvested 
at 48 h p.t. and plaque assays were performed as described (40). To verify the presence 
of the introduced mutations or reversions in viable mutants, fresh BHK-21 cells were 




















































infected with supernatants harvested at 72  h p.t., RNA was isolated with TriPure after 
18 h, and the nsp9-coding region was amplified by RT-PCR and sequenced.
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RNA viruses encode an RNA-dependent RNA polymerase (RdRp) that catalyzes the 
synthesis of their RNA(s). In the case of positive-stranded RNA viruses belonging to the 
order Nidovirales, the RdRp resides in a replicase subunit that is unusually large. Bioin-
formatics analysis of this nidoviral nonstructural protein has now revealed a signature 
domain (genetic marker) that is N-terminally adjacent to the RdRp and has no apparent 
homologs elsewhere. Based on its conservation profile, this domain is proposed to have 
nucleotidylation activity. Using recombinant nonstructural protein 9 of the arterivirus 
equine arteritis virus (EAV), we have demonstrated the manganese-dependent covalent 
binding of guanosine and uridine phosphates to a basic residue in the newly identified 
domain, most likely an invariant lysine residue. Substitution of this lysine with alanine 
severely diminished binding. Furthermore, this mutation crippled EAV and prevented the 
replication of severe acute respiratory syndrome coronavirus (SARS-CoV) in cell culture, 
indicating that this domain, named nidovirus RdRp-associated nucleotidyltransferase 
(NiRAN), is essential for nidoviruses. Potential functions supported by NiRAN include 














































Positive-stranded (+) RNA viruses of the order Nidovirales can infect either vertebrate 
(families Arteriviridae and Coronaviridae) or invertebrate hosts (Mesoniviridae and 
Roniviridae) (1;2). Examples of nidoviruses with high economical and societal impact are 
the arterivirus porcine reproductive and respiratory syndrome virus (PRRSV) (3) and the 
zoonotic coronaviruses (CoVs) causing severe acute respiratory syndrome (SARS) and 
Middle East respiratory syndrome (MERS) in humans (4;5). Besides the need to control 
these life-threatening diseases, studies of nidoviruses are motivated by the quest to 
understand the molecular biology and evolution of the largest RNA genomes known 
to-date. Although nidoviruses constitute a monophyletic group, their genome size dif-
ferences are striking, with genomes ranging from 13-16 kb for arteriviruses to 25-34 kb 
for roniviruses and coronaviruses. Some major transitions must therefore have occurred 
during their evolution, which have been postulated to be reflected in the intermediate 
genome size (20-21 kb) of the mesoniviruses. Genome expansion may have proceeded 
in a highly ordered but lineage-specific manner that was constrained or promoted by 
genome organization, host, and mutation, and was likely facilitated by the acquisition of 
enzymes providing quality control mechanisms for newly synthesized RNAs (6).
Nidoviruses are characterized by their distinct polycistronic genome organization, 
the conservation of key replicative enzymes, and a common genome expression and 
replication strategy (2). Their distinctive transcription mechanism, which provided the 
basis for the name nidoviruses, involves the synthesis of subgenome-length negative-
stranded RNAs that serve as templates for the production of a set of subgenomic (sg) 
mRNAs, which are 3’ co-terminal with the viral genome and may vary considerably in 
number between nidoviruses (7). In most but not all nidoviruses, sg mRNAs and the 
genome also share a common 5’ leader sequence. It derives from a unique mechanism 
of discontinuous negative-strand RNA synthesis that is used to equip the subgenome-
length negative-stranded RNAs with the complement of the genomic leader sequence 
(Figure  1A). The synthesis of sg mRNAs (transcription) and genome RNA (replication) 
is performed by a poorly characterized replication-transcription complex (RTC) that is 
comprised of multiple protein subunits and is associated with virus-induced cytoplasmic 
membrane structures (reviewed in (8)). The viral subunits of this complex are encoded 
in two large open reading frames (ORFs), ORF1a and ORF1b, that are translated from 
the nidoviral genome. Translation starts from a single initiation codon at the 5’ end of 
ORF1a and proceeds to either the ORF1a or the ORF1b termination codon. In the latter 
case, which applies to an estimated 20-40% of the ribosomes, a programmed ribosomal 
frameshift occurs in the short ORF1a/ORF1b overlap region. The two polyproteins (pp) 









































processed by multiple internal proteases, one of which (the 3C-like (3CLpro) or main (Mpro) 
protease) is responsible for the large majority of cleavages. Downstream of ORF1b, nido-
virus genomes contain multiple smaller ORFs, known as the 3’ ORFs, which are expressed 
from the sg mRNAs described above. The ORF1a-ORF1b-3’ ORFs array is flanked by 5‘- and 








































Figure 1. Genome organization and ORF1b-encoded enzymes and domains of nidoviruses. (A) Genome 
organization of Equine arteritis virus (EAV) including replicase open reading frames (ORFs) 1a and 1b, and 3’ 
ORFs encoding structural proteins. Genomes of other nidoviruses employ similar organizations while they 
may vary in respect to size of different regions and number of 3’ ORFs. RFS, ribosomal frameshift site. (B) 
ORF1b size and domain comparison between the four nidovirus families shown for EAV (Arteriviridae), Nam 
Dinh virus (Mesoniviridae), Gill-associated virus (Roniviridae), and Severe acute respiratory syndrome coro-
navirus (Coronaviridae). NiRAN, nidovirus RdRp-associated nucleotidyltransferase; RdRp, RNA-dependent 
RNA polymerase; ZBD, zinc-binding domain; Hel1, helicase superfamily 1 core domain; NendoU, nidovirus 
uridylate-specific endoribonuclease; ExoN, exoribonuclease; N-MT, N7-methyltransferase; O-MT, 2’-O-
methyltransferase; AsD, arterivirus-specific domain; RsD, ronivirus-specific domain. Depicted is a simplified 
domain organization since most enzymes are multidomain proteins. Note that viruses of the Coronaviridae 
family that do not belong to the subfamily of Coronavirinae encode a truncated version of N-MT. Triangles, 
established cleavage sites by 3CLpro in two virus families; ORF1b-encoded proteins of other viruses may be 













































During evolution, most conserved proteins of nidoviruses have accepted substitutions 
at a higher frequency per residue than those of organisms of the Tree of Life. In line with 
the principal function of each region, genome conservation increases from 3’ ORFs to 
ORF1a to ORF1b (6). Accordingly, the 3’ ORF region encodes virion proteins and, option-
ally, accessory proteins that are predominantly group- or family-specific and mediate 
virus-host interactions. ORF1a encodes a variable number of proteins that include co-
factors of the RNA-dependent RNA polymerase (RdRp) and 2’-O-methyltransferase, three 
hydrophobic proteins mediating the association of the RTC with membranes, and the 
viral proteases (7;9;10). The latter include the 3CLpro, which is the only ORF1a-encoded 
enzyme conserved in all nidoviruses. In contrast, ORF1b is highly conserved and encodes 
different RNA-processing enzymes that critically control viral RNA synthesis (Figure 1B). 
These invariantly include the RdRp and a superfamily 1 helicase domain (HEL1), which 
is fused with a multinuclear zinc-binding domain (ZBD). Both enzymes are expressed 
as part of two different cleavage products residing next to each other in pp1ab (7). The 
RdRp is believed to mediate the synthesis of all viral RNA molecules, while over the 
years the unwinding activity of the helicase was implicated in the control of replication, 
transcription, translation, virion biogenesis, and, most recently, post-transcriptional 
RNA quality control (reviewed in (11)). Among the lineage-specific proteins encoded in 
ORF1b are four enzymes. A 3’-5’ exoribonuclease (ExoN, in Coronaviridae, Mesoniviridae, 
and Roniviridae) and an N7-methyltransferase (N-MT, in the Coronavirinae subfamily, 
Mesoniviridae, and Roniviridae) constitute adjacent domains in the same pp1b cleavage 
product. They were implicated in RNA proofreading (12-14) and in 5‘ end cap formation 
(15;16), respectively. Downstream of this subunit, nidoviruses encode an uridylate-
specific endoribonuclease of unknown function (NendoU, in Arteriviridae and Corona-
viridae) (17;18) and/or a 2’-O-methyltransferase (O-MT, in Coronaviridae, Mesoniviridae, 
and Roniviridae), which was implicated in 5‘ end cap modification and immune evasion 
(15;19-21). All six ORF1b-encoded enzymes have distantly related viral and/or cellular 
homologs. Additionally, Roniviridae and Arteriviridae encode family-specific domains of 
unknown origin and function, RsD and AsD, respectively. RsD is located between the 
subunits containing the RdRp and ZBD-HEL1 domains (22), respectively, while AsD is the 
most C-terminal subunit of the arteriviral pp1ab (23).
The protein subunit containing the RdRp domain is known as nonstructural protein 
(nsp) 9 in the Arteriviridae and nsp12 in the Coronaviridae (7). Its major ORF1b-encoded 
part (~95% of its full size in all nidoviruses excluding mammalian toroviruses) varies 
in size from ~700 to ~900 amino acid residues and is N-terminally extended by a por-
tion encoded in ORF1a, which can be as few as five residues long. The borders of the 
corresponding RdRp-containing proteins of the Mesoniviridae and Roniviridae have not 









































analyses ((2;22) and also see below) these proteins are unlikely to be smaller than those 
of arteriviruses. The RdRp-containing replicase subunit of nidoviruses thus seems to be 
larger than the characterized RdRps of other RNA viruses, which commonly comprise 
less than 500 amino acid residues (24;25).
RdRps are known to adopt variations of an α/β fold that is often described as a cupped 
right hand, with the palm domain being most conserved and accommodating structural 
elements of the active site while the less conserved fingers and thumb play an assisting 
role (reviewed in (26;27)). Since the fingers vary in size between known RdRps, nidovi-
ruses – of all or some lineages – might have evolved unusually large fingers that could 
account for most of the observed size difference. Alternatively, another domain, either 
upstream or inside of the RdRp domain, might have been acquired.
Prior bioinformatics analyses mapped conserved sequences (motifs), which are known 
to be predominantly associated with the palm domain, to the C-terminal one-third of the 
nidovirus RdRp-containing protein. Accordingly, the C-terminal two-thirds of SARS-CoV 
nsp12 were sufficient to generate three-dimensional RdRp models using as a template 
the RdRp structures of either rabbit hemorrhagic disease virus or a combination of those 
of hepatitis C virus, poliovirus, rabbit hemorrhagic disease virus, reovirus, phage Φ6, and 
human immunodeficiency virus1 (28;29).
With one notable exception (N-MT) (16), all ORF1b-encoded enzymes were initially 
identified by comparative genomic analysis involving viral and cellular proteins (23;30). 
These assignments were fully corroborated by the subsequent biochemical character-
ization of these enzymes (17;18;21;31-36). Furthermore, the (in)tolerance to replace-
ment of active site residues as tested in reverse genetics studies of coronaviruses and 
arteriviruses in general correlated well with the observed enzyme conservation at the 
scale of nidovirus diversity. Accordingly, the replacement of conserved residues of the 
nidovirus-wide conserved RdRp, ZBD, and HEL1 were lethal for the viruses tested (37-39) 
while viruses were crippled upon inactivation of ExoN, NendoU, or O-MT enzymes (40-
42), which are conserved in only some of the nidovirus families (22). This correlation is 
noteworthy since it coherently links the results of the experimental characterization of 
a few nidoviruses in cell culture systems to evolutionary patterns that were shaped by 
natural selection in many hosts over an extremely large time frame. The fact that this 
correlation is evident for nidoviruses overall, rather than for separate families, indicates 
that nidovirus-wide comparative genomics provides sensible models to the functional 
characterization of the most conserved replicative proteins in experimental settings in 













































In the present study, we aimed to elucidate the domain organization, origin, and func-
tion of the RdRp-containing proteins of nidoviruses by integrating bioinformatics, 
biochemistry, and reverse genetics in a manner that was validated in many prior studies. 
Our extensive bioinformatics analysis revealed a novel domain, encoded upstream of 
the RdRp domain but within the same (predicted) polyprotein cleavage product, which 
is conserved in all nidoviruses and has no apparent viral or cellular homologs, making it 
a second genetic marker for the order Nidovirales. Based on a conservation pattern in-
volving lysine, arginine, glutamate, and aspartate residues, this domain was proposed to 
have nucleotidylation activity. Subsequently, using recombinant nsp9 of the prototypic 
arterivirus equine arteritis virus (EAV), the covalent binding of guanosine and uridine 
phosphates was demonstrated, which was found to be extremely sensitive to replace-
ment of conserved residues. The replication of both EAV and SARS-CoV was found to be 
severely affected by substitution of these conserved residues. Amongst those was also an 
invariant lysine residue that presumably binds the nucleoside phosphate. Accordingly, 
the domain was named nidovirus RdRp-associated nucleotidyltransferase (NiRAN). We 
discuss the potential functions in nidovirus replication in which this essential NiRAN 
activity may be involved, which include RNA ligation, protein-primed RNA synthesis, and 
the guanylyltransferase function that is necessary for mRNA capping.
RESULTS
Delineation of a novel, unique domain that is conserved immediately upstream 
of the RdRp in polyproteins of all nidoviruses
To shed light on the cause of the large size of nidoviral RdRp-containing proteins, we 
have conducted several bioinformatics analyses of their sequences (see Materials and 
Methods for technical details). We have produced family-wide multiple sequence align-
ments (MSAs) of nsp12 of coronaviruses, nsp9 of arteriviruses, and their counterparts of 
mesoniviruses and roniviruses, whose borders have been tentatively mapped through 
limited similarity with known 3CLpro cleavage sites of these viruses (43;44) (Figure S1). 
For simplicity, we will refer to the proteins of mesoni- and roniviruses as nsp12t, with “t” 
standing for tentative. The final subsets include 35, 10, 6, and 2 sequences representing 
all established and putative taxa of corona-, arteri- , mesoni-, and roniviruses, respec-
tively. To scan different databases, MSAs were split into the N-terminal and C-terminal 
parts, which were converted into Hidden Markov Model (HMM) profiles to conduct 
profile-sequence (HMMER 3.1) and profile-profile (HH suite 2.0.15) comparisons and 










































In comparisons with the Protein Data Bank (PDB) (www.rcsb.org, (45)) using Gen-
THREADER, RdRps of different viruses dominated the hit list for the best sampled nidovi-
ruses, corona- and arteriviruses, and they were consistently present among the top hits 
for the two other families (Table S2). Typically the similarity between a nidovirus query 
and a target encompassed the entire target and was limited to the C-terminal part of 
the query, with the N-terminal ~250 and 350 amino acid residues remaining unmatched 
in arteriviruses and other nidoviruses, respectively (Figures 2A and S2). Likewise, the C-
terminal part of nsp9/nsp12/nsp12t matched the RdRp profiles of different virus families 
in PFAM (46) and an in-house database although this analysis was complicated by the 
presence of nidovirus sequences in the top-hit PFAM profile (see below). Based on these 
results we concluded that nsp9, nsp12, and nsp12t contain N-terminal domains that are 
not part of canonical RdRps.
Inspection of the intra-family sequence conservation for MSAs of nsp9, nsp12, and 
nsp12t using a two-dimensional plot (Figure S2) revealed the association of character-
istic RdRp motifs with some of the most prominent conservation peaks, located in the 
C-terminal half of nsp9 and nsp12. For nsp12t (Figure S2), similar conclusions could be 
drawn although the conservation profiles of these viruses, especially roniviruses, were 
of lesser resolution due to the overall higher similarity that was the result of the limited 
virus sampling and divergence. Importantly, also the N-terminal half of nsp9 and nsp12 
included a few above-average conservation peaks although the overall conservation 
was evidently highest around the established RdRp motifs (Figures  2A and S2). We 
concluded from this analysis that the N-terminal parts of at least nsp9 and nsp12 share 
characteristic conserved motifs (the domain is hereafter referred to as NiRAN, see below).
To investigate the relation of the NiRAN domains of the four different families, the 
HHalign program from the HH-suite software package was used to conduct pair-wise 
profile-profile comparisons, which were visualized in dot-plot format (Figure  S3). This 
analysis revealed strong support (~98% confidence and E= 7.7e-09–1.7e-08) for the 
similarity between NiRANs of coronavirus nsp12 and mesonivirus nsp12t, and moder-
ate support (~21-30% confidence and E=0.00091–0.00051) for the similarity between 
the respective domains of mesoni- and roniviruses. Based on this observation, we have 
aligned the NiRAN domain of coronavirus nsp12 and mesonivirus nsp12t using the 
profile mode of ClustalX, with the MSA being slightly adjusted taking into account the 
HHsearch-mediated results. This MSA of two families was superior compared to each 
of the two family-specific MSAs with respect to its similarity to the MSA of roniviruses 
(~54-75% confidence and E=0.00049–0.00011). Consequently, the ronivirus MSA was 








































































































Figure 2: Delineation of the NiRAN domain in RdRp-containing proteins of nidoviruses. (A) Sequence 
variation, domain organization, and secondary structure of the RdRp-containing protein of arteriviruses, 
and location of peptides identified by mass spectrometry after FSBG-labeling of arterivirus nsp9. Shown 
is the similarity density plot obtained for the multiple sequence alignment (MSA) of proteins including 
NiRAN and RdRp domains of arteriviruses. To highlight the regional deviation of conservation from that 
of the MSA average, areas above and below the mean similarity are shaded in black and gray, respectively. 
Uncertainty in respect to the domain boundary between NiRAN and RdRp is indicated by a dashed hori-
zontal line. Sequence motifs of NiRAN and RdRp are labeled. Below the similarity density plot, predicted 
secondary structure elements are presented in gray for α-helices, black for β-strands. Relative positions of 
peptides identified by mass spectrometry after FSBG-labeling of arterivirus nsp9 are shown at the top. (B) 
MSA of the three conserved NiRAN motifs of eight representative nidoviruses and their predicted second-
ary structures. Absolutely conserved residues are highlighted in red boxes. Partially conserved residues 
are indicated in red font. Secondary structure predictions were made with JPred (91) based on arterivirus 
(arteri) or coronavirus (corona) MSAs. Residues mutated in recombinant equine arteritis virus (EAV, Arteri-
viridae) nonstructural protein (nsp) 9 are indicated by filled (conserved) and empty (control) circles. Amino 
acid numbers refer to EAV nsp9. GAV, gill-associated virus (Roniviridae); YHV, yellow head virus (Roniviridae); 
CAVV, Cavally virus (Mesoniviridae); MenoV, Meno virus (Mesoniviridae); SARS-BtCoV, bat severe acute re-
spiratory syndrome coronavirus (Coronaviridae); MERS-CoV, Middle East respiratory syndrome coronavirus 









































the three families, which are hereafter called ExoN-encoding nidoviruses, with reference 
to the feature that distinguishes them as a group compared to arteriviruses (Figure 1B).
In contrast to the above observations, the support for any similarity between the NiRAN 
MSAs of arteriviruses and ExoN-encoding nidoviruses in our HHalign-based analysis was 
considered as weak, particularly with respect to confidence (E=0.03-0.04 and ~1% con-
fidence, when comparing the MSA of arteriviruses versus ExoN-encoding nidoviruses). 
This experience prompted us to compare conserved motifs and predicted secondary 
structures of the domains of these families (Figures S1 and S2). Ten residues were found 
to be invariant in the conserved NiRAN of the ExoN-encoding nidoviruses. They map to 
three motifs designated AN (with a K-x[6-9]-E pattern in ExoN-encoding nidoviruses), BN 
(R-x[8-9]-D) and CN (T-x-DN-x4-G-x[2,4]-DF), respectively (Figure 2A), with motifs BN and 
CN representing the most prominent conservation peaks of this domain in coronaviruses 
(Figure S2). Remarkably, similar conserved motifs are present in the NiRAN of arterivirus-
es (Figure 2A), where BN and CN again occupy the two most prominent peaks (Figure S2). 
The three motifs are similarly positioned relative to the ORF1a/ORF1b frameshift signal 
in all nidoviruses, and they were aligned in the HHalign-based analysis discussed above. 
Specifically, all four invariant residues of motifs AN and BN of ExoN-encoding nidoviruses 
are also conserved in arteriviruses although with slightly smaller distances separating 
the two residues of each pair (Figure  S1). In the most highly conserved motif CN, the 
aspartate-phenylalanine dipeptide and likely glycine (the only deviating arginine at this 
position in the lactate dehydrogenase-elevating virus isolate U15146 may result from 
a sequencing error) are absolutely conserved among all nidoviruses while the other 
invariant residues of ExoN-encoding nidoviruses may be replaced by similar residues in 
arteriviruses. Additionally, there is a good agreement between the predicted secondary 
structure for the domains of arteriviruses and ExoN-encoding nidoviruses, particularly in 
the area encompassing the sequence motifs as well as regions immediately upstream of 
motif AN (named preA motif ) and downstream of motif CN (Figure S1). In ExoN-encoding 
nidoviruses, motifs BN and CN are separated by a variable region of 40-60 amino acid 
residues that does not include absolutely conserved residues, while in arteriviruses mo-
tifs BN and CN are adjacent. Also, we noted that the C-terminal border of the N-terminal 
conserved domain was close to that identified in the GenTHREADER analysis discussed 
above (Figure  S2). Based on these observations, we concluded that nsp9, nsp12, and 
nsp12t contain the NiRAN domain, which is conserved in all nidoviruses.
To gain insight into the origin and function of this domain, MSA-based profiles of this 
domain and its individual motifs of different nidovirus families and the entire order 
were compared with the PFAM, GenBank, Viralis DB, and PDB databases. As a control, 













































3CLpro, RdRp, ZBD, and HEL1. None of the database scans involving the NiRAN retrieved 
a non-nidovirus hit whose E value was better than 0.065 for HMMER and 1.3 for the 
HHsearch program from HH-suite (Figure  3), and none of these hits had sequences 
similar to the motifs of the NiRAN. In contrast, statistically significant hits with virus 
and/or host proteins were identified for the nidoviral control proteins either in both or 
one of the scans; at least some of these hits were true positives in the functional and/
or structural dimension as well. Likewise, in scans of the PDB using GenTHREADER, all 
top hits for the NiRAN of the four virus families had low support (p=0.014 or worse) 
with no match of the conserved motifs. In contrast, top hits for four RdRp queries were 
supported with P values of 0.0003 or better and targeted RdRps of other viruses, at least 
for arteri- and coronavirus queries (Table S2). Based on these results and those involving 
the comparison of arteriviruses and ExoN-containing nidoviruses, we concluded that 
the NiRAN domain could have diverged from its homologs in other organisms beyond 
the level of sequence similarity that can be recognized with the available HMM- and 
PSSM-based tools.
A B
Figure 3: Comparison of nidovirus-wide conserved domains with sequence databases. Shown are his-
tograms depicting E values of the best non-nidovirus hits obtained during HMMER-mediated profile-se-
quence (A) and HHsearch-mediated profile-profile (B) searches of the GenBank and PFAM A databases, 
respectively, using MSA profiles of five nidovirus-wide conserved domains encoded by four nidovirus 
families. The identity of the non-nidovirus top-hit in the respective databases is specified. Stars indicate 
hits whose homologous relationship with the respective query is also supported by the functional and/or 









































EAV nsp9 has Mn2+-dependent nucleotidylation activity with UTP/GTP 
preference
Since we could not identify any homologs of the NiRAN domain whose prior charac-
terization would facilitate the formulation of a hypothesis about its function, we have 
reviewed the available information about nidovirus genome organization and the 
analyses described above. The data were most compatible with the hypothesis that this 
domain is an RNA processing enzyme, in view of i) the abundance of RNA processing 
enzymes in the ORF1b-encoded polyprotein (Figure 1B), ii) the predicted α/β structural 
organization (Figure S1), and iii) the profile of invariant residues, composed of aspartate, 
glutamate, lysine, arginine, and phenylalanine (and possibly glycine) (Figure  2B), the 
first four of which are among the most frequently employed catalytic residues (47). We 
hypothesized that, because the domain is uniquely conserved in nidoviruses, its activity 
might work in concert with that of another, similarly unique RNA processing enzyme. 
At the time of this consideration, the NendoU endoribonuclease of nidoviruses was 
believed to be such an enzyme (17) (assessment revised in 2011, (22)). Consequently, we 
reasoned that a ligase function would be a natural counterpart for the endoribonucle-
ase, as observed in many biological processes, and would fit in the functional coopera-
tion framework outlined in our analysis of the SARS-CoV proteome (30). This hypothesis 
was also compatible with the lack of detectable similarity between the NiRAN and the 
highly diverse nucleotidyltransferase superfamily, to which nucleic acid ligases belong, 
as this superfamily is known to include groups that differ even in the most conserved 
sequence motifs, especially in proteins of viral origin (48;49). Based on mechanistic 
insights obtained with other ligases, it was expected that the conserved lysine is the 
principal catalytic residue of the NiRAN domain.
To detect this putative NTP-dependent RNA ligase activity, we took advantage of the 
universal ligase mechanism, which can be separated into three steps (50). First, an NTP 
molecule, typically ATP, is bound to the enzyme’s binding pocket, and a covalent bond 
is established between the nucleotide’s α-phosphate and the side chain of either lysine 
or histidine, while pyrophosphate is released. Since this protein-NMP is a true, temporar-
ily stable intermediate, it can be readily detected by biochemical methods. In contrast, 
demonstration of the following two steps, NMP transfer to the 5' phosphate of an RNA 
substrate and subsequent ligation of a second RNA molecule under release of the NMP, 
depends on the availability of target RNA sequences whose identification is often not as 
straightforward. Thus, we first assessed our hypothesis by testing the covalent binding of 













































To this end, recombinant EAV nsp9 was purified and incubated with each of the four NTPs, 
which were 32P-labeled at the α-position, and run on denaturing SDS-PAGE gels to discrimi-
nate between covalent and affinity-based nucleotide binding. As can be seen in Figure 4A, 
we could indeed detect a radioactively labeled product with a mobility comparable to 
that of nsp9 in the presence of GTP and UTP. To verify that this labeled band corresponded 
to a protein and did not result from 3’  end labeling of co-purified E.  coli RNA or polyG 
synthesis by the RNA polymerase residing in the C-terminal domain of nsp9, guanylylation 
was followed by the addition of either proteinase K or RNase T1, which cleaves single-
stranded RNA after G residues. As expected, only protease treatment removed the band 
while incubation with RNase T1 had no effect on the product (Figure 4B). The same result 
was obtained after uridylylation using RNase A, which cleaves after pyrimidines in single-
stranded RNA (data not shown). Furthermore, as the use of GTP labeled in the γ-position 
did not result in a radioactive product, we conclude that this phosphate is, in agreement 
with the general nucleotidylation mechanism, released during the reaction (Figure 4B). 
Since these results were compatible with the bioinformatics results described above and 
were corroborated further in experiments described below, the N-terminal domain was 






































































Figure 4. EAV nsp9 has nucleotidylation activity. Purified recombinant EAV nsp9 (78 kDa) was incubated 
with the indicated [32P]NTP in the presence of MnCl2. Reaction products were visualized after denaturing 
SDS-PAGE by Coomassie brilliant blue staining (top panels) and phosphor imaging (bottom panels). Posi-
tions of molecular weight markers are depicted on the left in kDa. (A) Uridylylation and guanylylation activ-
ity as revealed by covalent binding of the respective radioactive nucleotide to nsp9. Note that the protein 
indicated with an asterisk likely is an E. coli -derived impurity reacting with ATP. Relative band intensities 
are shown at the bottom. (B) Guanylylation was distinguished from RNA polymerization by incubating the 
products generated during the nucleotidylation assay with proteinase K (1 mg/ml) or with RNase T1 (0.5 U), 









































Unexpectedly, nsp9 showed a marked substrate specificity for UTP, which resulted in the 
accumulation of 5 times more enzyme-nucleotide complex than observed with GTP. In 
contrast, no covalent binding was observed with ATP or CTP as substrates (Figure 4A). 
The observed substrate preferences are remarkable for two reasons. First, since both 
UTP and GTP are present in significantly lower concentrations under physiological con-
ditions than ATP (51) and are in general not used as primary energy source, it suggests 
that the identity of the base, rather than the energy stored within the phosphodiester 
bonds, may be critical for a subsequent step in the reaction pathway. Obviously, this im-
plies that the involvement of these transitory covalent complexes in reaction pathways 
other than RNA ligation must be considered. Second, the selective utilization of only one 
pyrimidine and one purine substrate raised questions about the nature and number of 
active sites involved, for instance, whether both nucleotides bind to separate binding 
sites or utilize different catalytic residues within the same binding site. Unfortunately, 
there are no crystal structures for any of the nidovirus nsp9/nsp12/nsp12t subunits 
available to date, which might have been used to resolve this matter in docking studies.
Therefore, to address this question indirectly we compared the pH dependence of both 
activities as a signal for structural differences in the immediate environment of the 
catalytic residue. Interestingly, while the relative activities below pH 8.5 were identical 
with both substrates, the relative guanylylation activity was exceedingly higher than 
uridylylation at a pH above 8.5 (Figure 5A). To test whether a difference in the metal ion 







































Figure 5. EAV nsp9 guanylylation has a slightly broader or shifted pH optimum compared to uridylylation 
while the metal ion requirement is identical. (A) The pH optimum in the range from 5.5 to 9.5 was deter-
mined using the buffers listed in Material and Methods. (B) Assessment of the optimal MnCl2 concentration 














































mal manganese concentration for nucleotidylation with both substrates. As is apparent 
from Figure 5B, both activities share the same broad optimum between 6 and 10 mM 
MnCl2. This result made it unlikely that manganese oxidation and a concomitant decrease 
of available Mn2+ ions, as we observed at a pH above 9.0, would selectively favor the 
utilization of one of the two substrates. The observed difference between guanylylation 
and uridylylation with regard to its pH optimum may thus be genuine. For instance, this 
slightly broadened or – more likely – shifted pH optimum of guanylylation may be the 
result of a GTP-induced spatial reorientation of amino acid side chains in the vicinity of 
the catalytic residue and a concomitant alteration of its pKa. Alternatively, it may also be 
explained by the two substrates using different binding sites. These possibilities were 
partially addressed in the experiments described in the subsequent sections.
FSBG labeling of nsp9 suggests the presence of a nucleotide binding site in the 
NiRAN domain
To verify that the newly discovered nucleotidylation activity is associated with the NiRAN 
domain, we first sought to establish the presence of the expected nucleotide binding 
site. To this end, we replaced the substrate in the nucleotidylation assay with the reac-
tive guanosine analog 5’-(4-fluorosulfonylbenzoyl)guanosine (FSBG) (Figure  S4A) (52). 
Depending on the exact shape of the nucleotide binding pocket this compound may 
be suitable for binding and reacting with any nucleophile within the pocket, leaving 
behind a stable sulfonylbenzoyl tag that can be readily detected by mass spectrometry. 
In this way, residues that are lining the binding site can be identified. However, because 
the points of attack of FSBG (sulfonyl group sulfur) and GTP (α-phosphorus) are spatially 
separated (~4Å, Figures S4A and B), these residues are not necessarily of biological rel-
evance to nucleotidylation but rather mark the environment of the nucleotidylation.
After analysis of the nucleotidylation reaction mixture by mass spectrometry, seven 
modified peptides representing five distinct nsp9 regions could be assigned: three in 
(the vicinity of ) the NiRAN domain and two in the RdRp domain (Figures 2A and S5C). 
In agreement with previously published results (52), only lysine and tyrosine residues 
were found to be modified, as these are thought to provide the chemically most stable 
bonds. Selectivity of the modification was evident in the fact that only seven lysine and 
tyrosine residues served as nucleophile for the reaction. Furthermore, all these peptides 
were identified in independent experiments using FSBG concentrations ranging from 
25 µM to 2 mM. Within this range a concentration of 100 µM was sufficient to detect 
all seven peptides. Together this strongly suggests that the reaction with FSBG only 
occurred after binding to a specific site(s) and did not originate from random collisions. 









































α-helix or loop not far upstream and downstream of the AR and ER motifs, respectively, 
which are involved in NTP binding in other better characterized RdRps. The five modified 
residues in the EAV NiRAN domain are poorly conserved in related arteriviruses and are 
located in the vicinity of one of the three major motifs in either a predicted loop region 
(1 residue) or a b-strand (4 residues). These findings are compatible with the expected 
properties of the FSBG modification that may label any nucleophile within a 4 Å distance 
from the NTP-binding site(s). We therefore conclude that the peptides identified in this 
experiment reflect the presence of a nucleotide binding site(s) within the RdRp required 
for RNA synthesis and a second binding site that is located in the NiRAN domain, which 
could serve for nucleotidylation.
Conserved residues of the NiRAN domain but not of the RdRp domain are 
required for nucleotidylation activity
In a next step, the importance of conserved NiRAN residues for the guanylylation and 
uridylylation activities was examined by characterization of alanine substitution mutants 
of several residues, including five invariant residues, in recombinant EAV nsp9. Notably, 
none of these mutations significantly reduced expression or stability (data not shown), 
indicating that they are most likely compatible with the protein’s structure. Subsequent 
characterization demonstrated that all conserved NiRAN residues that were probed are 
important for nucleotidylation activity, as their replacement with alanine led, with the 
exception of S129A, to a drop to below 10% of wild-type protein activity. In contrast, ala-
nine substitution of a non-conserved N-terminal residue (K106A) as well as a conserved 
residue in the RdRp domain (D445A of motif AR), which is known to be essential for the 
polymerase activity in other RNA viruses (27), had only a mild effect, preserving at least 
75% of the activity (Figure 6). Thus, we concluded that the identified sequence motifs in 
the EAV nsp9 NiRAN domain are functionally connected to the nucleotidylation activity. 
In addition, as the level of remaining activity (again with exception of the S129A mutant) 
did not depend on the substrate used, both guanylylation and uridylylation are likely 
catalyzed by the same active site.
In contrast to these results, the mutation at position S129, the only targeted residue 
that is fully conserved in arteriviruses but may be replaced by threonine in other nido-
viruses, exhibited a slightly different effect on guanylylation and uridylylation. Mutant 
S129A displayed an intermediate activity when using GTP but was almost as deficient 
as mutants of the nidovirus-wide conserved residues when UTP was used as substrate 
(Figure 6). This finding may indicate that S129 is specifically involved in the hydrogen 
bond network between protein and UTP. Alternatively, as the covalent binding of the 













































ciple be suitable to play this role. Although to our knowledge nucleic acid ligases typi-
cally employ lysine and rarely histidine as catalytic residues (50;53), we cannot exclude 
that uridylylation occurs via this S129 while guanylylation utilizes another amino acid.
Nucleotidylation occurs via the formation of a phosphoamide bond
In order to identify which type of amino acid is the catalytic residue involved in nucleo-
tidylation, the chemical stability of the bond formed between enzyme and nucleotide 
was probed. To this end, the nucleotidylation product was subjected to either a higher 
or a lower pH for 4 min, while the protein was heat denatured. The loss of the radioac-
tive label under acidic or alkaline conditions is an indicator for the type of bond that 
is formed (Figure  7A) (54). As evident from Figure  7B, the bond between guanosine 
phosphate and nsp9 was acid-labile but stable under alkaline conditions, which was 
indicative of a phosphoamide bond originating either from a lysine or histidine. This 
result was also confirmed for uridylylation (data not shown), excluding a direct role for 
S129 in the attachment of the uridine phosphate. Since there is no conserved histidine 
present in the NiRAN domain, K94 is the most likely candidate within this domain to 











































Figure 6. Alanine substitution of conserved NiRAN residues dramatically decreased the nucleotidylation 
activity of nsp9. In contrast, mutation of the non-conserved K106 in the NiRAN domain or the conserved 
D445 in the RdRp domain had only a mild effect on activity. Error bars represent the standard deviation of 









































Guanosine and uridine phosphates may be attached via different phosphate 
groups
So far we have demonstrated that guanylylation and uridylylation are essentially equally 
sensitive to replacement of NiRAN residues, share the same metal ion requirements, and 
that both rely on the formation of a phosphoamide bond. We therefore concluded that 
there is only one active site responsible for nucleotidylation, which allows utilization of 
both substrates. Interestingly, if this is true, discrimination of GTP and UTP against ATP 
and CTP would be solely based on the presence of an oxygen at C6 of GTP and C4 of 
UTP. However, given the pronounced size difference between UTP and GTP, the position 
of both substrates within the binding site is unlikely to be equivalent. In principle, two 
binding scenarios are possible. First, ribose and phosphates of both nucleotides could 
occupy the same position within the binding site, for example by forming hydrogen 
bonds via the ribose’s 2’ and 3’ hydroxyl groups and charge interactions between the 
protein and the phosphates. Yet, due to the size difference of the bases (pyrimidine 
vs. purine), any additional interactions between protein and bases would involve dif-
ferent hydrogen bond networks, potentially involving water molecules in the case of 
the smaller UTP. Alternatively, due to stacking interactions between an aromatic residue 
of the protein and the bases, uracil and the pyrimidine ring of guanine might occupy 
equivalent positions. As this would inevitably lead to the relative misplacement of the 
A B 
Bond type Low pH High pH 
Phosphoamide 
Arg Instable  Instable  
Lys, His Instable  Stable  
Phosphoester 
Thr, Ser Stable  Instable  
Tyr Stable  Stable 
Phosphothioester 
Cys Stable  Stable  
Phosphoanhydride 
Asp, Glu Instable  Instable  
Figure 7. A phosphoamide bond is formed between nsp9 and the guanosine phosphate. (A) Chemical 
stability of different phosphoamino acid bonds. Adapted from (54). (B) The protein was labeled with [α-32P]
GTP and subsequently incubated at pH 8.5 (control) or under acidic or alkaline conditions. Reaction prod-
ucts were visualized after denaturing SDS-PAGE by Coomassie brilliant blue staining (top panel) and phos-













































ribose and phosphates of UTP compared to GTP, the catalytic residue may compensate 
for the size difference by re-adjusting and attacking the β- instead of the α-phosphate 
of UTP.
To explore this possibility, nsp9 was nucleotidylated as before and non-bound label was 
removed by extensive washing until no residual radioactivity was detected in the wash 
buffer. The nucleotide-protein bond was subsequently broken by lowering of the pH 
and the released nucleotide was analyzed by thin layer chromatography. While nsp9 
incubated with GTP clearly released significantly more of the expected GMP in an acidic 
environment than under alkaline conditions, the results after uridylylation were not 


















































Figure 8. GMP is released from labeled EAV nsp9 under acidic conditions. (A) nsp9 was labeled with [α-32P]
GTP or [α-32P]UTP and was incubated at pH 8.5 (control) or under acidic or alkaline conditions after removal 
of non-incorporated nucleotides. Resulting products were separated with PEI-cellulose TLC. Solid lines rep-
resent the position where samples have been spotted (bottom) and the running front (top). Dashed lines 
represent the respective mobilities of the indicated nucleotides. (B) [α-32P]GTP was incubated under the 










































treatment, the intensity did not match that of GMP and a second product was present 
in higher quantities (Figure 8A). This may indicate that UMP is either further hydrolyzed 
under these conditions or that in fact a UMP-protein adduct is only the minor product 
during uridylylation. Therefore, it remains unclear whether the binding of UTP indeed 
forces an attack of the β-phosphate. To exclude that the observed GMP release is caused 
by the treatment with HCl, control samples lacking nsp9 were also investigated. As 
expected this did not result in a product with equivalent mobility to GMP (Figure 8B).
NiRAN nucleotidylation is essential for EAV and SARS-CoV replication in cell 
culture
To establish the importance of the NiRAN domain for nidoviral replication, reverse ge-
netics was used to engineer both EAV and SARS-CoV mutants in which conserved NiRAN 
residues were substituted with alanine. Following transfection of in vitro-transcribed full-
Table 1: Reverse genetics analysis of EAV nsp9 and SARS-CoV nsp12 mutants.
motif mutant mutation
virus titers
(PFU/ml at 16-18 h p.t.)
nsp9/nsp12 
sequence of P1 
virusa
EAV - wt - 1·107, 2·108 n.d.
AN K94A AAA GCA <20, <20 Reversion
Non-conserved K106A AAA GCA 3·105, 2·106 GCA
BN R124A CGU GCU <20, <20 Reversion
BN S129A UCG GCG 1·104, 5·103 Reversion
BN D132A GAU GCU 3·104, 6·103 Reversion
CN D165A GAU GCU 3·103, 1·104 Reversion
CN F166A UUU GCU <20, <20 n.a.
AR D445A GAC GCC <20, 1·104 Reversion
SARS-CoV - wt - 4·106, 3·105 n.d.
AN K73A AAG GCC <20, <20 n.a.
Non-conserved K103A AAG GCA <20, <20 GCA
BN R116A CGU GCU <20, <20 n.a.
BN T123A ACA GCU 1·105, 4·105 GCU
BN D126A GAU GCG <20, <20 n.a.
CN D218A GAU GCU <20, <20 n.a.
CN F219A UUC GCG 2·104, 8·102 GCG
AR D618A GAU GCG <20, <20 n.a.
aVirus-containing supernatants were collected at 72 h p.t. and subsequently used for re-infection of fresh 
BHK-21 (EAV) or Vero-E6 (SARS-CoV) cells. Total RNA was isolated after appearance of CPE, and nsp9/nsp12 
coding regions were sequenced. All results were confirmed in a second independent experiment. n.d., not 













































length RNA into permissive cells, viral protein expression and progeny production were 
monitored (Table 1). As expected for such conserved residues, most alanine substitutions 
were either lethal for the virus or resulted in a severely crippled virus that reverted, thus 
confirming the essential role of the nucleotidylation activity during the viral replication 
cycle. Similarly, also replacement of a conserved aspartate in motif A of the downstream 
RdRp domain, which is known to be required for the activity of polymerases in other 
(+) RNA viruses (27), was tolerated in neither EAV nor SARS-CoV. Notable exceptions to 
this general pattern, in addition to the replacements of non-conserved lysine residues 
included as controls, were the T123A and F219A mutations in SARS-CoV nsp12. These 
mutations were stably maintained although they produced a mixed plaque phenotype 
comprising wild-type-sized and smaller plaques, with F219A also demonstrating a 
markedly lower progeny titer (at least 2 logs) than the wild-type control (Figure 9). The 
reason for this differential behavior of these two SARS-CoV mutants in comparison to 
those of EAV is unclear at the moment.
wild-type K103A
F219AT123A
Figure 9: Plaque phenotypes of viable SARS-CoV NiRAN mutants. Virus-containing supernatants obtained 
72 h post transfection were used to infect BHK-21 cells. After 72 h cells were fixed with 4% formaldehyde 










































NiRAN is the first enzymatic genetic marker of the order Nidovirales
The NiRAN domain described in this study is the fourth ORF1b-encoded enzyme 
involved in RNA-dependent processes identified in arteriviruses and the seventh in 
coronaviruses. Its existence was not predicted by prior nidovirus research, which attests 
to our poor understanding of the molecular machinery that governs nidovirus replica-
tion. As in most prior studies of nidoviral replicative proteins, this identification was 
initiated by comparative genomics analysis, whose results made it clear why this par-
ticular enzyme, now called the NiRAN domain, was not identified earlier. Unlike all other 
nidovirus enzymes, NiRAN was found to have no appreciable sequence similarity with 
proteins outside the order Nidovirales. The analysis suggested the extreme divergence 
of nidovirus NiRAN domains from their prototypes, since even the similarity between 
the arteriviral NiRAN and that of other nidoviruses was found to be marginal. Five out 
of the seven amino acid residues that are evolutionary invariant in the NiRAN domain 
belong to the most frequently occurring residues in proteins, which likely complicated 
the recognition of NiRAN conservation by even the most powerful HMM-based tools.
Besides technical challenges in the identification of NiRAN, this domain also stands out 
for its properties that are indicative of an unknown but critical role in nidovirus replica-
tion (see below). NiRAN is the only ORF1b-encoded domain that is located upstream of 
the RdRp and resides within the same nonstructural protein. This implies that NiRAN may 
influence the folding of the downstream RdRp domain. It would be reasonable to expect 
that these domains cross-talk to couple the reactions and processes they catalyze. Thus, 
NiRAN is a prime candidate to be a regulator and/or co-factor of the RdRp, a property 
that should be taken into account in future experiments aiming at the characterization 
of the RdRp or reconstitution of RTC activity in vitro.
The exclusive conservation of NiRAN in nidoviruses makes it a genetic marker of this 
order, only the second after the previously identified ZBD and the first with enzymatic 
activity. It may not be a coincidence that each of these markers is associated with a key 
enzyme in (+) RNA virus replication, RdRp and HEL1, respectively. The modulating role of 
the ZBD for HEL1 and its involvement in all major processes of the nidovirus replicative 
cycle have been documented (reviewed in (11)). Similar studies could be performed to 
probe the function(s) of NiRAN. This emerging parallel between NiRAN-RdRp and ZBD-
HEL1 highlights the fruitful cooperation between nidovirus-wide comparative genomics 













































Possible functions of conserved NiRAN residues
We here demonstrated that NiRAN is essential for EAV and SARS-CoV replication in cell 
culture by testing mutants in which conserved residues had been replaced. The mutated 
viruses were either crippled (and in most cases reverted to wt) or dead, depending on 
the targeted residue and the virus studied. Importantly the magnitude of the observed 
effect paralleled that caused by the replacement of an RdRp active site residue of the 
respective virus, which can be expected to put the greatest possible constraints on viral 
replication with the RdRp being the central enzyme involved in this process. This similar-
ity between the two enzymes is most notable because of the much higher divergence of 
the NiRAN sequence compared to the RdRp. These results also show that the significance 
of NiRAN for virus replication must be different from that of NendoU, the only other 
ORF1b-encoded enzyme that has been probed extensively by mutagenesis in reverse 
genetics in both corona- and arteriviruses (17;41;55). Two of those studies revealed that 
EAV and mouse hepatitis virus (MHV) NendoU mutants with replacements in the active 
site were stable and in the latter case even displayed similar plaque phenotypes as the 
wild-type virus while being only slightly delayed in growth (41;55).
In our biochemical assays we detected a second enzymatic activity that is associated 
with the nidovirus RdRp subunit (31;33;56). This new activity, which was categorized as 
nucleotidylation, is associated with the N-terminal domain of EAV nsp9, as demonstrated 
by mass spectrometry analysis (Figures  2A and S4) and the importance of conserved 
NiRAN residues for this activity (Figure 6). Nucleotidylation was most pronounced with 
UTP as substrate but was also observed with GTP (Figure 4A). Despite their size differ-
ence, both substrates appeared to be utilized by the same NiRAN binding site since 
uridylylation as well as guanylylation depended on the same conserved residues. To 
our knowledge such dual specificity has never been reported for a protein of an RNA 
virus and (likely) a host. Our results strongly suggested the nucleotidylated residue to 
be either a lysine or a histidine (Figure 7). Since NiRAN lacks a conserved histidine, K94 
in EAV nsp9 is the most likely target for nucleotidylation. Alternatively, reminiscent of 
the protein kinase mechanism, the conserved NiRAN residues might merely constitute a 
nucleotide binding site that presents the nucleotide to a catalytic residue located in the 
C-terminal RdRp domain.
Next to K94 and/or R124, which may mediate NTP binding via interactions with the 
negatively charged phosphates, a third conserved residue which may contribute to NTP 
binding is F166 in EAV. Since phenylalanine would most likely interact with the nucleo-
tide substrate by base stacking, its contribution in terms of binding energy would be one 









































the phosphates (57). Based solely on these considerations, F166 could be expected to 
be of “lesser” importance than the basic residues. However, this was apparently not the 
case since the replacement of the aromatic residue with alanine was lethal for EAV while 
substitution of either of the basic residues led to a low level of replication that eventu-
ally facilitated reversion (Table 1). When analyzing these results, a consideration must be 
made about the feasibility of reversion for different engineered substitutions, which all 
require two nucleotide point mutations to revert back to wild-type. As simultaneous re-
version of both nucleotides during a single round of replication should be an extremely 
rare event, the dead phenotype of the F166A mutant may hint at a lower tolerance of 
single-nucleotide partial revertants (F166V or F166S) in comparison to those originating 
from K94A (K94T or K94E) and R124A (R124P or R124G). Alternatively, the observed dead 
F166A phenotype may be explained by a vital interaction between NiRAN and RdRp 
or other proteins involving F166. In contrast to EAV, the homologous residue in SARS-
CoV nsp12, F219, appeared to be less essential since its replacement merely reduced 
progeny titers and altered the plaque phenotype, while the nucleotide changes were 
maintained. At present, the exact reason for this difference between EAV and SARS-CoV 
is unclear, but it suggests that the role and/or regulation of this conserved phenylalanine 
may have evolved in these distantly related nidoviruses, whose NiRAN domains are of 
strikingly different sizes; such evolution has parallels in other enzymes (58).
Since neither binding of phosphates nor base stacking would enable the enzyme to 
discriminate between the four bases, it is likely that some of the conserved residues are 
involved in the formation of a hydrogen bond network that is specific for GTP or UTP. We 
already speculated on the participation of nsp9 S129 in such a network, as substitution 
of this serine was the only mutation that had a differential effect on guanylylation and 
uridylylation (Figure 6). Finally, in agreement with observations for other nucleotidylate-
forming enzymes (59-61), also nsp9 nucleotidylation is metal-dependent (Figure  4B), 
potentially due to an important role for metal ions in coordination of the triphosphate 
or charge neutralization of the pyrophosphate leaving group. We thus propose that at 
least one of the three acidic conserved residues (E100, D132, and D165 in EAV nsp9) is 
directly involved in the binding of the essential manganese ion(s).
Possible roles of nucleotidylation in the context of viral replication
The identification of the nucleotidylation activity raises the question which role it may 
play in the nidovirus replicative cycle. Given that the roles of other replicative enzymes of 
nidoviruses are far from firmly established, considerable challenges may be expected in 
the characterization of the NiRAN domain, starting from the identification of the ultimate 













































employ covalent binding of NMPs to catalyze different reactions, which are dominated 
by those that generate essential metabolites in an energy-dependent manner. These 
host metabolites are utilized by RNA viruses, whose relatively small genomes can thus 
be used to encode NMP-binding enzymes for other, virus-specific purposes. Therefore, 
in the discussion that follows we will consider the pros and cons of the involvement of 
NiRAN’s nucleotidylation activity in three previously described functions that are not 
involved in metabolism: nucleic acid ligation, mRNA capping, and protein-primed RNA 
synthesis.
Ligase function
We initially considered NiRAN to be a non-canonical ATP-dependent RNA ligase. It was 
reasoned that in the context of nidovirus replication such an activity would be the 
functional complement of the NendoU endoribonuclease (6). Moreover, at that time 
both enzymes were considered to have been conserved across all taxa during evolu-
tion of the nidovirus lineage. Prompted by nidovirus comparative genomics, it recently 
became clear that NendoU is conserved only in nidoviruses infecting vertebrate hosts. 
Consequently, our original hypothesis would not explain why this putative ligase would 
be conserved in roni- and mesoniviruses, which do not encode the endoribonuclease. 
Another complication regarding that original hypothesis has emerged from the present 
study, which identified NiRAN as being UTP/GTP-specific. Although the hydrolysis of all 
NTPs results in the release of the same amount of energy, ATP-dependent RNA ligases, 
which dominate the ligase family, are – as their name already suggests – restricted in 
their substrate use. It would therefore be surprising, if nidoviruses encoded a ligase that 
strongly discriminates against ATP. To our knowledge the GTP-specific tRNA-splicing 
ligase RtcB is the only currently known example of a protein involved in nucleic acid 
strand joining exhibiting this kind of substrate specificity (53). Also no substrates which 
would require a ligase function were identified in the nidovirus replication, which how-
ever remains poorly characterized.
5’ end cap guanylyltransferase function
Besides RNA ligases, there is another group of enzymes, known as guanylyltransferases 
(GTases), that employ a very similar mechanism of nucleotidylation and may be relevant 
to nidovirus replication. Unlike ligases, the covalent binding of GMP by GTases does not 
occur for energetic reasons. Rather, the bound GMP is used to permanently modify the 5‘ 
end of RNA in a process called RNA capping (reviewed in (62)). Intriguingly, three of the 
four enzyme activities required for this pathway have been identified in coronaviruses 









































of EAV nsp10 in our lab (unpublished) showed that it resembles its coronavirus homolog 
in terms of possessing RNA-triphosphatase activity, which is required prior to GTase 
activity in the conventional capping pathway. In line with these findings, experimental 
evidence supporting the presence of a cap structure on genomic RNA was reported 
for three very distantly related species of the Nidovirales order, namely for MHV (64), 
Equine torovirus (EToV) (65) (both Coronaviridae), and Simian hemorrhagic fever virus 
(SHFV) (Arteriviridae) (66). Thus, the NiRAN domain could be a candidate for catalyzing 
the important GTase reaction in the nidovirus capping pathway. Like ligases, canonical 
cellular GTases share the characteristic Kx(D/N)G motif including the principal catalytic 
lysine, which has no match in NiRAN. Although this deviation is notable, it is not unprec-
edented in established viral GTases. For instance, upstream of its RdRp domain, flavivirus 
NS5 contains the GTase domain, which neither has homology to any other GTase nor 
contains the canonical Kx(D/N)G motif (67). Likewise, the GTase activity of alphavirus 
nsP1 and related proteins is associated with a unique domain (60;68). Thus, NiRAN being 
a cap-synthesizing GTase could be reconciled with our current knowledge about GTase 
structural and sequence diversity.
The same cannot be said about NiRAN’s substrate preference for UTP over GTP, which 
has not been reported for GTases mediating cap formation. To reconcile this property 
with the considered functional model, we would therefore have to assume that either 
NiRAN has another substrate or that uridylylation is an in vitro artifact due to the absence 
of essential interaction partners of NiRAN. For instance, it would be conceivable that 
the association with other proteins modulates the binding site allowing discrimination 
against UTP.
Protein-priming function
If UTP binding by NiRAN faithfully reflects a genuine property of the enzyme, a plausible 
explanation for the nucleotidylation activity of nsp9 may be its involvement in protein-
primed RNA synthesis. This mechanism is used by many viruses including a large group of 
picornavirus-like viruses, which notably have evolutionary affinity to nidoviruses (69;70). 
In these viruses a nucleotide is covalently attached to a protein commonly known as 
VPg (viral protein genome-linked), which may then be extended to a dinucleotide. This 
dinucleotide is subsequently base-paired to the 3’ end of the viral RNA where it serves 
as the primer for synthesis of the complementary RNA strand (71). Interestingly, the 
first nucleotide of the EAV genome is a G while the 3’ end is equipped with a poly(A) 
tail. Thus, the dual specificity of nsp9 for GTP and UTP would be compatible with the 














































However, there are also observations that distinguish nidoviruses from viruses that 
use a VPg. First, to our knowledge, all currently described nucleotide-VPg bonds are 
realized via the hydroxyl group of either a tyrosine or a serine/threonine (72-76) while 
NiRAN is most likely to use the invariant lysine residue (Figure 7). Second, at least for 
coronaviruses, the VPg-based mechanism would compete with the already proposed 
primase-based mechanism (77) for the initiation of RNA synthesis. The latter mechanism 
is yet to be fully established since it assigns primase activity to a protein complex that 
may merely be a processivity co-factor for the nsp12 RdRp according to a recent study 
(78). Finally, as mentioned before, nidovirus mRNAs were concluded to be capped at 
their 5’ end, a modification that is not observed in known VPg-utilizing viruses. To use 
both capping and VPg, it would thus be necessary for nidoviruses to actively or passively 
remove the attached protein in order to allow mRNA capping to commence. Such a 
reaction sequence would also imply a variation of the capping pathway as the RNA 5’ 
end would not be di- or triphosphorylated after removal of the VPg, a requirement for 
entering any of the known viral capping pathways (62).
In view of the considerations outlined for each of the three possible scenarios employ-
ing nucleotidylation activity, it is evident that presently none of these can be fully 
reconciled with the evolutionary, structural, and functional characteristics of NiRAN 
described in this study. This may reflect yet-to-be revealed specifics of the nidovirus RTC 
and its unparalleled complexity. On the other hand, the unique NiRAN is now part of 
this complexity and its properties must be taken into account in future experiments 
involving RdRp-encoding and other replicative proteins, as well as in theoretical models 
describing the molecular biology of nidoviruses.
MATERIAL AND METHODS
Virus genomes
Genomes of nidoviruses were retrieved from GenBank (79) and RefSeq (80) using 
Homology-Annotation hYbrid retrieval of GENetic Sequences (HAYGENS) tool http://
veb.lumc.nl/HAYGENS. Genomes of all viruses were used to produce sequence align-
ments (see below), which were purged to retain only subsets of viruses representing 
the known diversity of each nidovirus family for downstream bioinformatics analyses. 
For the Arteriviridae and Coronaviridae families, one representative was drawn randomly 
from each evolutionary compact cluster corresponding to known and tentative species 
that were defined with the help of DEmARC1.3 (81). Twenty nine viruses of the family 









































ary distance was below and above 0.075, respectively. One representative was chosen 
randomly from each of the six groups. For the Roniviridae family, two viruses, each 
prototyping a species, were used. To retrieve information about genomes, the SNAD 
program (82) was used.
Multiple sequence alignments
MSAs of five nidovirus-wide conserved protein domains: 3C-like protease (3CLpro), 
RNA-dependent RNA polymerase (RdRp), RdRp-associated nucleotidyltransferase (Ni-
RAN), superfamily 1 helicase (HEL1) and zinc-binding domain fused with HEL1 (ZBD) 
were obtained for four nidovirus families using the Viralis platform (83) and assisted by 
HMMER 3.1 (84), Muscle 3.8.31 (85), and ClustalW 2.012 (86) programs. Family-specific 
MSAs of the NiRAN domain were combined in a step-wise manner using the HH-suite 
2.0.15 software (87;88) and the profile mode of ClustalW with subsequent manual 
refinement to produce MSAs that included two, three, and four families, respectively, 
namely: Coronavirinae, Torovirinae, and Mesoniviridae (named CoToMe), Coronaviridae, 
Mesoniviridae, and Roniviridae (CoToMeRo), Coronaviridae, Mesoniviridae, Roniviridae, 
and Arteriviridae (CoToMeRoAr). To reveal all local similarities between two MSAs, their 
profiles were compared in a dot-plot fashion using a routine in HH-suite 2.0.15, whose 
results were visualized. Distribution of similarity density in MSAs was plotted using R 
package Bio3D (89) under the conservation assessment method “similarity”, substitution 
matrix Blosum62 (90) and a sliding window of 11 MSA columns. Peaks of similarity were 
attributed to the known RdRp motifs G, F, A, B, C, D, E (69), or named and assigned to the 
newly recognized motifs of NiRAN, preA, A, B, and C. To facilitate distinguishing between 
the RdRp and NiRAN motifs, suffix R and N were added to motif labels of the RdRp and 
NiRAN domain, respectively. Based on family-specific MSAs of NiRAN and RdRp, the 
secondary structure of these domains was predicted using software Jpred 3 (91) and 
PSIPRED (92). In both cases, the sequence with the least gaps was selected from the 
sequences forming the MSA. The prediction was made only for columns of the MSA in 
which the selected sequence does not contain gaps. The MSAs were converted into the 
final figure using ESPript (93).
Homology detection
The obtained MSAs were converted into HMM profiles or PSSMs and used as queries 
to search for homologs in three different types of databases composed of: individual 
sequences (nr database, including GenBank CDS translations, RefSeq proteins, Swis-
sProt, PIR and PRF (94)), profiles (PFAM A (46)), and protein 3D structures (PDB (45)). 













































threshold -10. To search for homologs among profiles, HH-suite 2.0.15 software (87;88) 
was used. To search for homologs among protein 3D structures pGenTHREADER 8.9 
software (95-97) was used.
Protein Expression and Purification
Nucleotides 5256 to 7333 of the EAV Bucyrus strain were cloned into a pASK3 (IBA) 
vector essentially as described (38) to yield a construct that expresses nsp9 that is N-
terminally fused to ubiquitin and tagged with hexahistidine at its C-terminus. Mutations 
were introduced according to the QuikChange protocol and verified by sequencing. 
Plasmids were transformed into E.  coli C2523/pCG1, which constitutively express the 
Ubp1 protease to remove the ubiquitin tag during expression and thereby generate the 
native nsp9 N-terminus. Cells were cultured in Luria Broth in the presence of ampicillin 
(100 µg/ml) and chloramphenicol (34 µg/ml) at 37°C until an OD600 >0.7. At this point 
protein expression was induced by the addition of anhydrotetracycline to a final con-
centration of 200 ng/ml, and incubation was continued at 20°C overnight. Cell pellets 
were harvested by centrifugation and stored at -20°C until further use.
Proteins were batch purified by immobilized metal ion affinity chromatography using 
Co2+ Talon beads. In short, cell pellets were resuspended in lysis buffer (20 mM HEPES, 
pH 7.5, 10% glycerol (v/v), 10 mM imidazole, 5 mM β-mercaptoethanol) supplemented 
with 500 mM NaCl. Lysis was achieved by a 30-min incubation with 0.1 mg/ml lysozyme 
and five subsequent cycles of 10-s sonication to shear genomic DNA. Cellular debris 
was removed by centrifugation at 20,000g for 20  min. The cleared supernatant was 
recovered, and equilibrated Talon-beads were added. After 1 h of binding under agita-
tion, beads were washed four times for 15 min with a 25-times bigger volume of lysis 
buffer containing first 500  mM, than 250  mM, and finally twice 100  mM NaCl. In the 
end, proteins were eluted twice with lysis buffer containing 100 mM NaCl and 150 mM 
imidazole. Both fractions were pooled and dialyzed twice for 6 h or longer against an 
at least 100-fold bigger volume of 20  mM HEPES, pH  7.5, 50% glycerol (v/v), 100  mM 
NaCl, 2 mM DTT. All steps of the purification were performed at 4°C or on ice. All mutant 
proteins were expressed and purified in parallel with the wild-type protein used as refer-
ence in nucleotidylation assays. Protein concentrations were measured by absorbance 
at 280 nm using a calculated extinction coefficient of 93,170 M-1cm-1 and a molecular 
mass of 77,885  Da  for wild-type nsp9. Typical protein yields were 5  mg/l culture and 
nucleotidylation activity was observed for at least 4  months if stored at -20°C at a 
concentration below 15  µM. Finally, the absence of the N-terminal ubiquitin tag was 










































Nucleotidylation assays were performed in a total volume of 10  µl containing, unless 
specified otherwise, 50  mM Tris, pH  8.5, 6  mM MnCl2, 5  mM DTT, up to 2.5  µM nsp9, 
and 0.17  µM [α-32P]NTP (Perkin Elmer, 3000  Ci/mmol). Furthermore, 12.5% glycerol 
(v/v), 25  mM NaCl, 5  mM HEPES, pH 7.5, and 0.5  mM DTT were carried over from the 
protein storage buffer. In preliminary experiments magnesium (1-20 mM) did not sup-
port nucleotidylation activity and was consequently not pursued further. Samples were 
incubated for 30 min at 30°C. Reactions were stopped by addition of 5 µl gel loading 
buffer (62.5 mM Tris, pH 6.8, 100 mM DTT, 2.5% SDS, 10% glycerol, 0.005% bromophe-
nol blue) and denaturing of the proteins by heating at 95°C for 5 min. 12% SDS-PAGE 
gels were run, stained with Coomassie G-250, and destained overnight. After drying, 
phosphorimager screens were exposed to gels for 5 h and scanned on a Typhoon vari-
able mode scanner (GE healthcare), after which band intensities were analyzed with 
ImageQuant TL software (GE healthcare). The buffers used to find the pH optimum of 
the nucleotidylation reaction were MES (pH 5.5 – 6.5), MOPS (pH 7.0), Tris (pH 7.5 – 8.5), 
and CHES (pH 9.0 – 9.5) (20 mM).
To assess the chemical nature of the nucleotide-protein bond, the pH was temporarily 
shifted after product formation. To this end, 1  µl HCl or NaOH (both 1  M) was added 
before incubation at 95°C for 4 min. Afterwards the original pH was restored by addi-
tion of the complementary base or acid, and samples were separated and analyzed as 
described.
FSBG Labeling and Mass Spectrometry
Reaction mixtures were the same as described for the nucleotidylation assay with 
two modifications. Radioactive nucleotides were replaced by the reactive GTP analog 
5’-(4-fluorosulfonylbenzoyl)guanosine (FSBG) (52) (up to 2  mM) (see supplementary 
Materials and Methods for the synthesis protocol), and samples were incubated for 1 h 
at 30°C to increase the ratio between labeled and unlabeled protein. Subsequently, the 
protein (20  µg) was reduced by addition of 5  mM DTT and denatured in 1% SDS for 
10 min at 70°C. Next, the samples were alkylated by addition of 15 mM iodoacetamide 
and incubation for 20 min at RT. Next, the protein was applied to a centrifugal filter (Mil-
lipore Microcon, MWCO 30 kDa) and washed three times with NH4HCO3 (25 mM) before 
a protease digestion was performed with 2 µg trypsin in 100 µl NH4HCO3 overnight at 
RT. Recovered peptides were treated with 50 mM NaOH for 25 min, desalted using Oasis 
spin columns (Waters), and finally analyzed by on-line nano-liquid chromatography tan-













































spectra were searched against the Uniprot database, using mascot version 2.2.04, with a 
precursor accuracy of 2 ppm, and product ion accuracy of 0.5 Da. Carbamidomethyl was 
set as a fixed modification, and oxidation, N-acetylation (protein N-terminus), and FSBG 
were set as variable modifications.
Label Release
For analysis of the released nucleotides, 350  pmol of nsp9 were nucleotidylated with 
[α-32P]NTPs as described above for 1  h at 30°C. After the reaction free NTPs were re-
moved by buffer exchange and extensive washing with the help of a centrifugal filter 
(Millipore ultrafree-0.5, MWCO 10 kDa). Protein was precipitated with a 5-times greater 
volume of acetone overnight at -20°C. The resulting pellet was resuspended in 20 mM 
Tris, pH 8.5, 100 mM NaCl. Equal amounts of the solutions were incubated at 95°C for 
4 min after addition of HCl or NaOH (1 M). Samples were adjusted to their original pH 
and spotted onto polyethylenimine cellulose thin layer chromatography plates, which 
were developed in 80% acetic acid (1 M), 20% ethanol (v/v), 0.5 M LiCl. Plates were dried 
and phosphorimaging was performed as described above. Non-radioactive nucleotide 
standards were run on each plate and visualized by UV-shadowing to allow the identifi-
cation of the radioactive products.
Reverse Genetics of EAV
Alanine-coding mutations for conserved and control residues were introduced into 
full-length cDNA clone pEAV211 (98) using appropriate shuttle vectors and restriction 
enzymes. The presence of the mutations was confirmed by sequencing. pEAV plasmid 
DNA was in vitro transcribed with the mMessage-mMachine T7 kit (Ambion), and the 
synthesized RNA was transfected into BHK-21 cells after LiCl precipitation as described 
previously (99). Virus replication was monitored by immunofluorescence microscopy 
until 72 h post transfection (p.t.) using antibodies directed against nsp3 and N protein 
as described (100) and by plaque assays (99) using transfected cell culture supernatants, 
to monitor the production of viral progeny.
Sequence analysis of the nsp9-coding region was performed to either verify the pres-
ence of the introduced mutations or to monitor the presence of (second site) reversions. 
For this purpose, fresh BHK-21 cells were infected with virus-containing cell culture 
supernatants and total RNA was extracted with Tripure Isolation Reagent (Roche Ap-
plied Science) after appearance of cytopathic effect (CPE) (typically at 18 h post infec-
tion (p.i.)). EAV-specific primers were used to reverse transcribe RNA and PCR amplify 









































sequenced after gel purification and sequences compared to those of the respective 
RNA used for transfection.
Reverse Genetics of SARS-CoV
Mutations in the SARS-CoV nsp12-coding region were engineered in prSCV, a pBelo-
Bac11 derivative containing a full-length cDNA copy of the SARS-CoV Frankfurt-1 se-
quence (101) by using “en passant recombineering” as described in Tischer et al. (102). 
The (mutated) BAC DNA was linearized with NotI, extracted with phenol-chloroform, 
and transcribed with T7 RNA Polymerase (mMessage-mMachine T7 kit; Ambion) using 
an input of 2 μg of BAC DNA per 20-μL reaction. Viral RNA transcripts were precipitated 
with LiCl according to the manufacturer’s protocol. Subsequently, 6 μg of RNA were 
electroporated into 5 × 106 BHK-Tet-SARS-N cells, which expressed the SARS-CoV N 
protein following 4 h induction with 2 µM doxycycline as described previously (78). 
Electroporated BHK-Tet-SARS-N cells were seeded in a 1:1 ratio with Vero-E6 cells. Viral 
protein expression and the production of viral progeny was followed until 72 h p.t. by 
immunofluorescence microscopy using antibodies directed against nsp4 and N protein 
and by plaque assays of cell culture supernatants, respectively (both methods were 
described previously in Subissi et al. (78)). All work with live SARS-CoV was performed in-
side biosafety cabinets in a biosafety level 3 facility at Leiden University Medical Center.
For sequence analysis of viral progeny, fresh Vero-E6 cells were infected with harvests 
from viable mutants taken at 72 h p.t., and SARS-CoV RNA was isolated 18 h p.i. using 
TriPure Isolation Reagent (Roche Applied Science) as described in the manufacturer’s 
instructions. Random hexamers were used to prime the RT reaction, which was followed 
by amplification of the nsp12-coding region (nt 13398-16166) by using SARS-CoV-spe-
cific primers. RT-PCR products were sequenced to verify the presence of the introduced 
mutations.
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Supplementary Material and Methods
Synthesis of 5’-(4-fluorosulfonylbenzoyl)guanosine (FSBG)
Guanosine monohydrate (875 mg, 2.90 mmol) was co-evaporated twice with anhydrous 
DMF and subsequently dissolved in DMPU with gentle warming. The clear solution was 
cooled in an ice bath, and 4-(fluorosulfonyl)benzoyl chloride (812 mg, 3.65 mmol) was 
added. After 15 minutes the mixture was warmed to room temperature and stirred 
for another 4 hours. Petroleum ether 40/60 (50 ml) was added and a white precipitate 
formed. The organic layer was decanted and the residue triturated twice with a 1/1 
mixture of ethyl acetate/diethyl ether (2 x 50 ml). The residue was re-crystallized from 
MeOH/water and further purified by C18-RP-HPLC (Phenomenex Gemini C18, pore size 
110Å, particle size 5 µm, 150 x 21.2 mm, gradient 20 – 50% Acetonitrile in 0.1 % aque-














































Table S1: GenBank accession number, name, and acronym of each virus genome used for the bioinformat-
ics analyses.
Acession 
number Virus name Acronym Species
AF227196 Gill-associated virus GAV Gill-associated virus
EU487200 Yellow head virus YHV to be established
HM746600 Cavally virus CAVV Alphamesonivirus 1
NC_023986 Casuarina virus CASV to be established
AB753015.2 Dak Nong virus DKNV to be established
JQ957872 Hana virus HanaV to be established
JQ957874 Nse virus NseV to be established
JQ957873 Meno virus MenoV to be established
DQ412042 Bat SARS coronavirus Rf1 SARS-Rf1-BtCoV Severe acute respiratory 
syndrome-related coronavirus
JN874560 Rabbit coronavirus HKU14 RbCoV_HKU14 Betacoronavirus 1
AF201929 Murine hepatitis virus strain 2 MHV-2 Murine coronavirus
AY884001 Human coronavirus HKU1 HCoV_HKU1 Human coronavirus HKU1
KC545383 Betacoronavirus Erinaceus/VMC/
DEU/2012
EriCoV to be established
DQ648794 Bat coronavirus (BtCoV/133/2005) BtCoV/133/2005 Tylonycteris bat coronavirus 
HKU4
EF065509 Bat coronavirus HKU5-1 BtCoV_HKU5 Pipistrellus bat coronavirus HKU5
JX869059.2 MERS coronavirus EMC/2012 HCoV-EMC/2012 to be established
HM211101 Bat coronavirus HKU9-10-2 BtCoV_HKU9 Rousettus bat coronavirus HKU9
KF430219 Bat coronavirus CDPHE15/USA/2006 BtCoV_CDPHE15 to be established
AY567487 Human coronavirus NL63 HCoV-NL63 Human coronavirus NL63
EU420139 Miniopterus bat coronavirus HKU8 BtCoV_HKU8 Miniopterus bat coronavirus 
HKU8
EF203064 Rhinolophus bat coronavirus HKU2 BtCoV_HKU2 Rhinolophus bat coronavirus 
HKU2
EU420138 Bat coronavirus 1A BtCoV_1A Miniopterus bat coronavirus 1
JQ410000 Alpaca respiratory coronavirus ACoV Human coronavirus 229E
DQ648858 Bat coronavirus (BtCoV/512/2005) BtCoV/512/2005 Scotophilus bat coronavirus 512
KC140102 Porcine epidemic diarrhea virus PEDV Porcine epidemic diarrhea virus
JQ989271 Rousettus bat coronavirus HKU10 BtCoV_HKU10 to be established
HM245925 Mink coronavirus strain WD1127 MCoV to be established
FJ938060 Feline coronavirus UU2 FCoV_UU2 Alphacoronavirus 1
KC008600 Infectious bronchitis virus IBV Avian coronavirus
KF793824 Bottlenose dolphin coronavirus 
HKU22
BdCoV_HKU22 Beluga whale coronavirus SW1
JQ065045 Sparrow coronavirus HKU17 SpCoV_HKU17 to be established




















































































Table S1: GenBank accession number, name, and acronym of each virus genome used for the bioinfor-
matics analyses. (continued)
Acession 
number Virus name Acronym Species
JQ065049 Common-moorhen coronavirus 
HKU21
CMCoV_HKU21 to be established
FJ376619.2 Bulbul coronavirus HKU11-934 BuCoV_HKU11 Bulbul coronavirus HKU11
FJ376621 Thrush coronavirus HKU12-600 ThCoV_HKU12 Thrush coronavirus HKU12
JQ065044 White-eye coronavirus HKU16 WECoV_HKU16 to be established
JQ065047 Night-heron coronavirus HKU19 NHCoV_HKU19 to be established
JQ065048 Wigeon coronavirus HKU20 WiCoV_HKU20 to be established
NC_022787 Porcine torovirus PToV_SH1 Porcine torovirus
AY427798 Breda virus BRV-1 Bovine torovirus
DQ898157 White bream virus WBV White bream virus
GU002364.2 Fathead minnow nidovirus FHMNV to be established
NC_024709 Ball python nidovirus BPNV to be established
JN116253 Possum nidovirus WPDV to be established
AF180391 Simian hemorrhagic fever virus SHFV-LVR Simian hemorrhagic fever virus
JX473847 Simian hemorrhagic fever virus SHFV-krtg1 to be established
JX473848 Simian hemorrhagic fever virus SHFV-krtg2 to be established
HQ845737 Simian hemorrhagic fever virus SHFV-krc1 to be established
JX138233 Porcine reproductive and respiratory 
syndrome virus
PRRSV-2 Porcine reproductive and 
respiratory syndrome virus
GU737264.2 Porcine reproductive and respiratory 
syndrome virus
PRRSV-1 Porcine reproductive and 
respiratory syndrome virus



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S1: Core part of the nidovirus-wide NiRAN MSA encompassing conserved motifs. Virus names and 
accession numbers are listed in Table S1. Fully and partially conserved residues are depicted in red boxes or 
red font, respectively. Sequence motifs are indicated by stars. Secondary structure predictions are shown 
on the top of the MSA. The name of each prediction indicates what software (Jpred 3 (91) or PSIPRED (91)) 
and which family-specific NiRAN MSA (R, Roniviridae; M, Mesoniviridae; C, Coronaviridae; A, Arteriviridae) 
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Figure S2: Sequence variation, domain organization, and secondary structure of NiRAN-RdRp-containing 
proteins of nidovirus families. For each family, the similarity density plot obtained for the MSA of proteins 
including the NiRAN and RdRp domains is shown. To highlight the regional deviation of conservation from 
that of the MSA average, areas above and below the mean similarity are shaded in black and gray, respec-
tively. Sequence motifs of NiRAN and RdRp are labelled. Uncertainty in respect to the domain boundary 
between NiRAN and RdRp is indicated by dashed horizontal lines. Domain boundaries used for all bioinfor-
matics analyses are indicated by dashed vertical lines. Below each similarity density plot predicted second-

























































































































































































































































































































Figure S3: Pairwise MSA-based HMM-HMM comparison of NiRANs of different origins. Each MSA of NiRAN 
was converted to an HMM profile, all possible pairs of obtained HMMs were aligned with the help of HH-
suite 2.0.15 software (87,88). Information about each HMM-HMM comparison is presented in a pseudo-
symmetrical matrix whose row (left) and column (top) label specifies the group of viruses used as query and 
target, respectively. Below each dot-plot the probability of the target being homologous to the query and 
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Figure S4: (A) FSBG and (B) GTP structures indicating the spatial separation of the points of attack in FSBG 
and GTP. Asterisks mark the positions of the nucleophilic attack. (C) Mass spectrometry analysis of FSBG-
linked EAV nsp9 identified seven unique, modified peptides (outlined) located either in vicinity of the Ni-
RAN (dark gray background) or within the C-terminal RdRp domain (light gray background). Residues car-
rying the sulfonylbenzoyl modification are colored in red. Sequence or structural motifs are indicated by 











































Figure S5: NMR analysis of 5’-(4-fluorosulfonylbenzoyl)guanosine. (A) 1H NMR (300 MHz, DMSO-d6) δ 10.70 
(s, 1H), 8.38 – 8.12 (m, 4H), 7.93 (s, 1H), 6.52 (broad s, 2H), 5.75 (d, J = 4.8 Hz, 1H), 5.75 (broad s, 2H), 4.65 
(dd, J = 11.9, 3.6 Hz, 1H), 4.59 – 4.42 (m, 2H), 4.34 (t, J = 5.1 Hz, 1H), 4.25 – 4.12 (m, 1H). (B) 13C NMR (75 MHz, 
DMSO-d6) δ 163.92, 156.63, 153.77, 151.20, 136.22, 135.72, 130.97, 128.98, 104.16, 87.13, 81.06, 72.98, 70.17, 
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Arterivirus nsp12 versus 
the coronavirus nsp16 
2’-O-methyltransferase: comparison 
of the C-terminal cleavage products of 



















































The 3’-terminal domain of the most conserved open reading frame 1b (ORF1b) in three 
of the four families of the order Nidovirales (except the Arteriviridae) encodes a (putative) 
2’-O-methyltransferase (O-MT), known as nonstructural protein (nsp) 16 in coronaviruses 
and implicated in methylation of the 5’ cap structure of nidoviral mRNAs. Like coronavi-
rus transcripts, arterivirus mRNAs are assumed to possess a 5’ cap although no candidate 
methyltransferases (MTases) were identified thus far. To address this knowledge gap, we 
analyzed the uncharacterized nsp12 of arteriviruses, which occupies the ORF1b position 
equivalent to that of coronavirus nsp16. In our in-depth bioinformatics analysis of nsp12, 
the protein was confirmed to be family-specific while having diverged much farther 
than other nidovirus ORF1b-encoded proteins, including those of the Coronaviridae. 
Only one invariant and several partially conserved, predominantly aromatic residues 
were identified in nsp12, which may adopt a structure with alternating α-helices and 
β-strands, an organization also found in known MTases. However, no statistically signifi-
cant similarity was found between nsp12 and the two-fold larger coronavirus nsp16, nor 
could we detect MTase activity in biochemical assays using recombinant equine arteritis 
virus nsp12. Our further analysis established that this subunit is essential for replica-
tion of this prototypic arterivirus. Using reverse genetics, we assessed the impact of 25 
substitutions at 14 positions, yielding virus phenotypes ranging from wild-type-like to 
nonviable. Notably, replacement of the invariant phenylalanine 109 with tyrosine was 
lethal. We conclude that nsp12 plays an essential role during EAV replication, possibly by 














































Arteriviruses (family Arteriviridae) are positive-stranded RNA viruses with genome sizes 
ranging from 13 to 16 kilobases. The family currently comprises a single genus that 
includes four species: Equine arteritis virus (EAV), Simian hemorrhagic fever virus (SHFV), 
Lactate dehydrogenase-elevating virus (LDV), and Porcine reproductive and respiratory 
syndrome virus (PRRSV) (1;2). Among those, the latter is the economically most relevant 
species causing annual losses to the American swine industry alone of about $800 
million (3). Additionally, several recently identified arteriviruses remain to be formally 
classified, but are likely to prototype multiple novel species or even higher order taxa 
(4-7). Arterivirus genomes are polycistronic and contain 10 to 15 (known) open reading 
frames (ORFs). The 5’-proximal ORFs 1a and 1b are expressed as polyproteins (pps) 1a 
and 1ab that are autoproteolytically processed into the nonstructural proteins (nsps) 
required for genome replication and transcription (Figure  1) (8). The remaining ORFs 
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Figure 1: Organization of key replicase domains encoded by nidovirus open reading frames (ORFs) 1a 
and 1b. Proteolytic cleavage products described in the text for the Corona- and Arteriviridae are indicated. 
Matching colors/patterns indicate domain conservation between families. Domains (putatively) involved 
in capping (HEL, N-MT, O-MT, AsD) are depicted in bright colors. nsp, nonstructural protein; TM, transmem-
brane domain; 3CLpro, 3C-like protease; black dot and RFS, ribosomal frameshift site; RdRp, RNA-dependent 
RNA polymerase; HEL, helicase/RNA triphosphatase; ExoN, exoribonuclease; N-MT, N7-methyltransferase; 
NendoU, endoribonuclease; O-MT, 2’-O-methyltransferase; RsD, Ronivirus-specific domain; AsD, arterivirus-
specific domain (nsp12). Genomic organizations are shown for Beluga whale coronavirus SW1 (Corona-
viridae), gill-associated virus (Roniviridae), Nam Dinh virus (Mesoniviridae), and porcine respiratory and 
reproductive syndrome virus, North American genotype (Arteriviridae). Depicted is a simplified domain or-
ganization since most enzymes are multidomain proteins. Note that viruses of the Coronaviridae family that 









































mRNAs (9). Based on overall similarities in terms of genome expression and organization 
as well as synteny and homology of key replicase domains, arteriviruses were united in 
the order Nidovirales with the families Mesoniviridae, Roniviridae, and Coronaviridae, the 
latter including two distantly related subfamilies, Coronavirinae and Torovirinae (10;11). 
In the nidovirus tree, the arteriviruses form a basal lineage next to the one that combines 
the three other families, which have substantially larger genomes (12).
ORF1b is the most conserved part of the nidovirus genome, and all ORF1b-encoded 
proteins characterized thus far are enzymes conserved in two or more nidovirus families. 
The RNA-dependent RNA polymerase and a zinc-binding domain (ZBD) fused with a 
superfamily 1 helicase (HEL1) are conserved in all nidoviruses. In contrast, six other do-
mains are lineage specific. Four of these are conserved in two or three nidovirus families 
only: exoribonuclease (ExoN), N7-methyltransferase (N-MT), nidovirus uridylate-specific 
endoribonuclease (NendoU), and 2’-O-methyltransferase (O-MT). Two other domains 
are yet uncharacterized and unique to either roniviruses (RsD, ronivirus-specific domain) 
or arteriviruses (AsD, arterivirus-specific domain). Since five of the six lineage-specific 
domains occupy a unique position in the genome, the pattern of their conservation 
could be explained by loss or acquisition of a single domain during nidovirus evolu-
tion (12). The exception is AsD, which resides in the most C-terminal subunit of the 
arterivirus ORF1b polyprotein (nsp12), the position occupied by the O-MT protein in 
all other nidoviruses (nsp16 in coronaviruses, Figure 1). If these positionally equivalent 
proteins are unrelated, as reported 14 years ago based on the analysis of only a few 
genome sequences and prior to the identification of the O-MT (13), their emergence 
would require the consideration of complex evolutionary hypotheses. Thus, the relation 
of AsD with the O-MT and other proteins must be re-evaluated while taking advantage 
of the increased availability of sequences and improved techniques.
Unlike AsD, the coronavirus O-MT has been experimentally characterized (14-17) and 
was found to provide one of the four activities required for the formation of a so-called 
type I cap (cap-1) (mGpppNm) structure at the 5’ end of coronaviral mRNAs (18;19). Two 
other coronavirus enzymes, HEL1 (nsp13) (20;21) and the N-MT (nsp14) (14;22), are also 
known to be involved in capping, whereas the fourth enzyme required (guanylyltrans-
ferase) remains to be identified. In vitro the coronavirus N-MT and O-MT were found to 
cooperate during cap formation. The latter enzyme also requires the ORF1a-encoded 
nsp10 as a co-factor (14). Although arteriviruses were not characterized in detail, the 
SHFV genome was reported to be capped (23), and they do encode a HEL1 (24), which 
could contribute to capping. Thus, the discovery of arteriviral N-MT and/or O-MT activi-













































Based on the above evolutionary and functional considerations, we sought to character-
ize nsp12 of arteriviruses by testing the hypothesis that it may be a methyltransferase. 
We show that, unlike the coronavirus O-MT, nsp12 is poorly conserved among known 
arteriviruses compared to the proteins carrying the endoribonuclease (nsp11) and heli-
case (nsp10) activities, and that it contains only one evolutionary invariant residue. No 
statistically significant similarity was found between arterivirus nsp12 and coronavirus 
nsp16 or other proteins although the two nidovirus proteins may belong to the same 
α/β fold class. Likewise, no MTase activity was detected in carefully controlled assays 
using recombinant EAV nsp12 in the absence or presence of several other nsps that were 
included as potential co-factors. Using reverse genetics, a large set of EAV nsp12 mutants 
was generated and tested for replication, revealing phenotypes ranging from wild-type-
like to replication-deficient, which broadly correlated with the natural variation of the 
probed residues. We conclude that nsp12 plays an essential role in EAV replication and 
discuss possible directions to elucidate its enigmatic function.
RESULTS
Sequence similarities and dissimilarities between arterivirus nsp12 and 
(putative) methyltransferases of the Coronaviridae
We first analyzed the conservation of nsp12 in comparison with that of other proteins 
deriving from the C-terminal portion of pp1ab of arteriviruses and the Coronavirinae 
and Torovirinae. Starting at the ZBD, the region analyzed included the three proteins 
implicated in 5’ cap formation in coronaviruses. We found that nsp12 is conserved in 
all established and provisional arterivirus species, including the most distantly related 
wobbly possum disease virus (WPDV). Inspection of the arterivirus conservation profile 
showed that the entire nsp12 sequence exhibits similarity values that are below average 
for this pp1ab region (0.320 on a -0,1-1 scale; Figure 2A). Only the C-terminal domain 
of nsp10 and to some extent the ZBD were similarly divergent while the similarity of 
the nsp10 helicase core and particularly nsp11 were above average. This remarkably 
low conservation distinguishes arterivirus nsp12 also from all proteins in this region 
of the Coronavirinae (average conservation 0.491) and Torovirinae (0.270), including 
nsp16 (Figures 2B and C). Accordingly, arterivirus nsp12 contains the smallest number 
of conserved residues among the analyzed proteins, with only a single phenylalanine 
(F109 in EAV) being evolutionarily invariant (Figure 3). Other notable conserved nsp12 
residues (out of 18 in total) are an asparagine, a serine/threonine and six aromatic 
residues. We also noted the presence of four conserved cysteines in a pattern typical for 












































Figure 2: Similarity density plots of the C-terminal region of polyprotein 1ab of different nidovirus (sub)
families. Values above and below average similarities are indicated in black and gray, respectively. nsp, 
nonstructural protein; ZBD, zinc-binding domain; Hel1, helicase core domain; ExoN, exoribonuclease; NMT, 
N7-methyltransferase (t, truncated); NendoU, endoribonuclease; OMT, 2’-O-methyltransferase. For the sake 
of simplicity, we have applied the nsp nomenclature of the Coronavirinae subfamily also to the orthologous 













































stitute a phylogenetically compact cluster. Patristic pair-wise distances (PPDs) of nsp12 
compared to those of ZBD, HEL1, and NendoU were consistently larger while PPDs of 
(putative) O-MTs were comparable on average with those of five other domains in the 
Coronavirinae and Torovirinae (Figure S1). These results showed that, in comparison to 
the coronavirus O-MT, nsp12 must have evolved under unusually relaxed constraints or 
1 10 20 30 40 50









Figure 3: Multiple sequence alignment and secondary structure predictions of representative arterivirus 
nsp12 sequences. Partially and fully conserved amino acids are highlighted in colored boxes. Colors rep-
resent residues with similar biophysical properties; yellow, aromatic; black, hydrophobic; blue, (putatively) 
zinc-binding; green, other. Secondary structures (barrel, α-helix; arrow, β-strand) were predicted with JPred 
(50) (gray) or PsiPred (51) (red) based on the multiple sequence alignment. Residue numbers are indicated 
for nsp12 of the EAV-Bucyrus isolate (pEAV030) (57), the parental strain of pEAV211 used for the reverse 
genetics experiments. Replaced residues are indicated below the alignment; black stars, positions where 
stop codons were introduced; empty circles, control residues; filled circles, conserved residues. A puta-
tive zinc-finger in simian arterivirus nsp12 sequences is indicated by a dashed line. EAV, equine arteritis 
virus (GenBank accession number AY349167); SHFV, simian hemorrhagic fever virus (AF180391, JX473847, 
JX473848, HQ845737, HQ845738); PRRSV, porcine reproductive and respiratory syndrome virus (JX138233, 










































in a changing molecular environment. Secondary structure predictions using JPred and 
PsiPred consistently indicated the alternation of α-helices and β-strands in arterivirus 
nsp12 (Figure 3). Interestingly, also the coronavirus MTases belong to the α/β structural 
class and contain conserved aromatic residues (15;17). Nevertheless, HH-suite profile-
profile comparison did not reveal sequence similarity above the background between 
nsp12 and the O-MT of corona- or toroviruses, E=0.41 and 0.53, respectively (Figure S2). 
Furthermore, these proteins are also of different sizes: 119-178 aa (arterivirus nsp12) 
versus 263-312 aa (coronavirus nsp16), with the arterivirus proteins being also smaller 
than MTases of other origins. The above HH-based negative result contrasted with the 
strong similarity signal observed in (control) comparisons between arteriviruses and 
corona- or toroviruses for HEL1 and NendoU (E=3.5e-17 or better), or in the control 
comparison between corona- and torovirus nsp16, E=2.3e-32 (Figure S2). No statistically 
significant similarity was observed between nsp12 and other proteins in an HMM-based 
scan of the PFAM-A database (top hit: PF12581, E=1.0). We thus concluded that nsp12 
has diverged beyond recognition from its homologs and differs considerably from the 
O-MT of large nidoviruses. Nevertheless, the obtained results did not rule out the pos-
sibility that it could be a deviant MTase, and we therefore set out to test this hypothesis 
experimentally by biochemical and molecular virological methods.
Purification of recombinant EAV nsp12 and several ORF1a-encoded proteins
We engineered vectors encoding recombinant EAV nsp12 derivatives carrying either 
an N-terminal or a C-terminal hexahistidine tag and expressed them in E. coli. Only 
the N-terminally tagged protein was successfully expressed and purified by metal 
affinity chromatography using Co2+ (Talon) beads (Figure  4A). The protein appeared 
to be reasonably stable at all conditions tested, including a pH range from 6.0 to 7.5 
and protein concentrations of up to 500 µM. Yet upon storage the protein increasingly 
formed dimers and higher order multimers, even in the presence of 1 mM DTT. In gel 
filtration experiments with fresh protein these oligomers were not evident. Instead a 
single peak was observed (not shown) that corresponded well to the expected size of an 
nsp12 monomer (calculated weight 13 kDa vs. predicted weight based on Stokes radius 
16 kDa).
In addition to nsp12, we also expressed five small mature proteins and cleavage in-
termediates from the nsp7 region of pp1a (nsp6-7, nsp6-7-8, nsp7α, nsp7β, and nsp7 
(i.e., nsp7α-7β)) (25;26) (Figure 4B). In coronaviruses, the corresponding part of ORF1a 
encodes nsp10, an essential co-factor for the O-MT (14). Consequently, we added these 













































Recombinant nsp12 does not display in vitro MTase activity using a variety of 
substrates
Using purified arterivirus proteins, we proceeded to test for MTase activity in the presence 
of different methyl acceptors by employing an in vitro assay similar to that previously 
established for SARS-CoV nsp14 and nsp16 (14). In agreement with published results 
(14;22;27), both SARS-CoV MTases (kindly provided by Dr. Etienne Decroly, Marseille), 
which were used as positive controls, transferred the radioactive methyl group from the 
universal methyl donor S-adenosylmethionine to non-methylated or N7-methylated cap 
analogs (Figure 5). Likewise, also vaccinia virus capping enzyme, obtained from a com-
mercial source and known to harbor N-MT activity, demonstrated the expected activity. 
Based on these activities and the results of two negative control reactions (assays using 
BSA and no acceptor, respectively), we defined an incorporation threshold of 1000 cpm 
to distinguish the enzyme activity in this assay. According to this definition, EAV nsp12 
did not display activity with any of the methyl acceptors in the absence or presence 
of any of the potential ORF1a-encoded co-factors described above (nsp6-7, nsp6-7-8, 















































Figure 4: SDS-PAGE analysis of purified EAV nonstructural proteins. (A) The progression 
of metal-ion chromatography of EAV nsp12-containing (MW 13 kDa) E. coli lysates was 
monitored by Coomassie brilliant blue staining. Insoluble and soluble: proteins retained 
in pellet or supernatant, respectively, after cell lysis and ultracentrifugation; after bind-
ing: proteins in supernatant after removal of Talon beads. (B) Elution fractions of EAV 
ORF1a proteins and intermediates (MWnsp6-7 29 kDa, MWnsp6-7-8 34 kDa, MWnsp7 26 
kDa, MWnsp7α 15 kDa, MWnsp7ß 13 kDa). Products marked with an asterisk are remain-

















































































































































































































































+ EAV nsp12 + EAV nsp12
+ EAV nsp12+ EAV nsp12
Figure 5: Methyltransferase (MTase) activity assays using recombinant EAV nsp12 in the presence and ab-
sence of possible co-factors. Recombinant EAV nsp12 (1 µM) and equimolar amounts of the indicated pos-
sible co-factors were incubated for 30 (light gray), 60 (dark gray), or 180 min (black) with S-[methyl-3H]-ade-
nosylmethionine and the indicated methyl acceptor. Proteins with known MTase activity served as positive 
controls. v.v.c.e., vaccinia virus capping enzyme (0.1 U/µl, N-MT); SARS nsp14 (75 nM, N-MT); SARS nsp10/
nsp16 (2 µM complex, O-MT); SARS, SARS coronavirus; BSA served as negative control; error bars indicate 
the standard deviation of the mean of two independent experiments. The background variation evident 
for several of the protein combinations using GTP, GpppG, GpppAC4, or mGpppA most likely represents an 













































The tolerance of EAV replication to nsp12 mutagenesis correlates with the 
natural variation of probed residues
To establish the general importance of nsp12 for EAV replication, we used reverse genet-
ics to assess whether EAV tolerates replacements at conserved positions, including the 
single absolutely (F109) and ten partially (F26, N35, S45, Y49, S56, Y64, Y70, F82, C84, 
and F107) conserved residues (Figure 3). We also tested replacements of three poorly 
conserved residues (S25, S30, and Y32) that served as controls. Furthermore, we also 
abolished nsp12 expression by replacing its codons 6 to 8 with three consecutive trans-
lation termination codons (STOP mutant). The engineered cDNA clones were used for in 
vitro transcription, yielding full-length RNA that was subsequently electroporated into 
BHK-21 cells. The effects of the replacements were first assessed on the level of viral pro-
tein expression by immunofluorescence microscopy utilizing antibodies against nsp3 
and the structural nucleocapsid (N) protein. Furthermore, we monitored the production 
of virus progeny by harvesting transfected cell culture supernatants and performing 
plaque assays (Table 1).
For the STOP mutant neither protein expression nor progeny production was observed, 
indicating that nsp12 performs an indispensable function during virus replication. 
Alternatively, the truncation of nps12 may have affected virus viability indirectly, e.g. 
by impairing proteolytic cleavage of the nsp11/nsp12 junction, which might be detri-
mental to the activity of the nsp11 endoribonuclease. This concern was addressed by 
replacing individual nsp12 residues.
The 14 residues probed by making 25 mutants could be classified into four groups based 
on the impact of their replacement. The first group included residues F107 and F109, 
with the four mutants carrying alanine or (more conservative) tyrosine substitutions at 
these positions not producing any virus progeny. Interestingly, in contrast to both ala-
nine mutants and F109Y, which also did not produce viral proteins, immunofluorescence 
signal for nsp3 and N protein was detected for F107Y at 24 h and 48 h post transfection 
(p.t.), with a stronger signal being observed at the earlier time point. Collectively, these 
results show that F107 or F109 are most strongly constrained in EAV and indicate a vital 
role of these residues in virus viability.
The second group comprised residues F26, N35, and C84, which appeared to be only 
slightly less important than the aforementioned F107 and F109, based on the pheno-
type of five mutants. Alanine substitutions at position F26 and N35 were either lethal 
(F26A) or severely detrimental (N35A), whereas tyrosine or aspartate substitutions of 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































tion, which allowed early reversion of these mutants. Similarly, also the C84Y mutant 
reverted, which is notable given the presence of a tyrosine at this position in most other 
arteriviruses.
In contrast to the above results, EAV tolerated replacements by another aromatic residue 
at four other partially conserved aromatic residues, Y49, Y64, Y70, and F82, which form 
group 3. These virus mutants were stable and yielded progeny titers up to 1 log below 
that of the wild-type control. Interestingly, although the titer of Y49F was not very dif-
ferent from that of the parental virus, this mutant exhibited a small-plaque phenotype 
(Figure 6). In contrast alanine substitutions at these positions were again lethal.
The replacement – more or less conservative – of all residues mentioned thus far had a 
moderate to severe impact on virus replication. In contrast, the fourth group included 
five residues whose replacement did neither affect viral protein production nor progeny 
titers. As expected this group included the three poorly conserved control residues (S25, 
S30, and Y32). Nevertheless, S30A exhibited a small-plaque phenotype (Figure 6). Un-
expectedly, we also repeatedly observed the pseudo-reversion of Y32A to Y32V, which 
required only a single nucleotide change. Although valine is not among the naturally oc-
curring amino acid residues at this position (Figure 3), a hydrophobic residue is observed 
in several arteriviruses other than EAV. Besides substitutions of these control residues, 
EAV also tolerated the substitution of S56 with alanine or threonine. Given the strict 
conservation of serine and threonine, this lack of impact was the expected outcome for 
S56T, but was rather surprising for S56A. Finally, S45A was stable and indistinguishable 
from the parental virus, while S45T reverted. Together with the sequence variation at 
this position, which is limited to the small amino acids glycine, alanine, and serine, this 
wt S25A S30A Y32V S45A
Y49F S56A Y64F Y70F F82YS56T
Y32F
Figure 6: Plaque phenotypes of viable EAV nsp12 mutants. Virus-containing supernatants obtained 48 h 
post transfection were serially diluted and used to infect BHK-21 cells. After 72 h cells were fixed with 4% 













































probably indicates a certain degree of steric hindrance by any residue larger than serine. 
Overall the observed mutant phenotypes were compatible with the natural variation 
observed at the respective positions, with the possible exception of the C84Y mutant. 
These correlations support the multiple sequence alignment of the highly variable 
nsp12 and suggest that EAV replication in BHK-21 is a faithful model system for probing 
nsp12 function by mutagenesis.
Both mutants displaying a small-plaque phenotype (S30A and Y49F), as well as the 
unexpected Y32V pseudo-revertant, were further investigated in terms of growth kinet-
ics and accumulation of intracellular viral RNA (not shown). Compared to the wild-type 
control, S30A and Y49F demonstrated a slight delay in replication early during infection 
(8 h post infection (p.i.)) but eventually reached comparable titers by 24 h p.i.. In line 
with this finding, the amounts of genomic and sg mRNA at 8 h p.i. were reduced for 
both mutants. Whether this was due to a decreased synthesis or lower stability of their 
RNAs remains to be investigated. In contrast, the stable Y32V mutant was essentially 
indistinguishable from the wild-type control both in growth kinetics and amounts of 
RNA produced.
DISCUSSION
The most conserved ORF1b of nidoviruses encodes only two proteins that have not 
been studied before in any virus. Our study aimed to address this knowledge gap for 
one of these proteins, arterivirus nsp12. It established (i) the exceptional divergence of 
nsp12, (ii) the lack of strong bioinformatics and biochemical support for nsp12 being an 
MTase, and (iii) the fact that nsp12 is essential for arterivirus replication.
So far, none of the four enzymatic activities required for conventional cap-1 synthesis, 
or any of the known alternative capping strategies, was uncovered for arteriviruses 
although arteriviral mRNAs are presumed to be capped. In the conserved relative ar-
rangement of replicative enzymes within nidovirus polyproteins 1a and 1ab, the unique 
arterivirus nsp12 is encoded in a genome position equivalent to that of the coronavirus 
O-MT, which is conserved also in invertebrate nidoviruses (Figure  1). We thus asked 
whether this so far uncharacterized subunit may represent an MTase, potentially capable 
to perform both methylation reactions as, for example, the flavivirus NS5 MTase domain 
is (28). Upon our bioinformatics analysis of nsp12 sequences, we found that this subunit, 
similar to the N-MT residing in coronavirus nsp14, is enriched with (partially) conserved 









































(Figure 3). Nevertheless, no statistically significant similarity was found between nsp12 
and other MTases of viral or cellular origin.
When we subsequently sought to verify our hypothesis using an in vitro MTase assay, we 
could not detect any activity for recombinant EAV nsp12, whereas our positive controls 
clearly confirmed the functionality of the assay. To explain this lack of activity, we argued 
that, as for coronavirus nsp16, a second EAV protein may be required to form a func-
tional MTase complex. By analogy with the coronavirus nsp10 co-factor, we tested the 
possibility that this second protein might be encoded just upstream of the ORF1a/1b 
ribosomal frameshift site. We thus expressed and purified nsp7α and nsp7β, as well as 
three polyprotein cleavage intermediates containing these two proteins, and included 
them in our assays (Figure 5). However, also in these extended assays we could not de-
tect any MTase activity. This could have multiple reasons. First, the proteins tested here 
may not be the correct co-factors or may be unable to properly associate with nsp12 
under the conditions employed. Second, more than one co-factor may be needed to 
spur nsp12’s MTase activity, or different RNA substrates containing specific sequences 
may be required. Finally, our results are compatible with a scenario in which nsp12, 
which is smaller than other viral MTases, does not possess MTase activity, in which case 
other hypotheses about its function should be considered (see below).
To explore nsp12’s relevance for arterivirus replication, we engineered one truncation 
and 25 point mutations of EAV nsp12 and launched the corresponding mutant genomes 
in BHK-21 cells. Reflecting the conservation of several aromatic residues in arteriviruses, 
substitution with alanine was tolerated in none of the cases, whereas more conservative 
substitutions maintaining the residue’s aromatic nature were tolerated in most of the 
partially conserved positions (Table 1). The only exception was F107Y, which interesting-
ly showed a certain level of protein expression but did not produce infectious progeny. 
Since two arteriviruses distantly related to EAV, LDV and PRRSV genotype 1, naturally 
encode a tyrosine at this position (Figure 3), this result suggests an epistatic interaction 
between residue 107 and other unknown residue(s). EAV also did not tolerate a block of 
nsp12 expression (STOP mutant) or the replacement of its single absolutely conserved 
nsp12 residue, F109, with alanine or tyrosine. This phenotype could be explained by a 
trans-dominant negative effect of the nsp12 substitutions on an interaction partner of 
nsp12, if this partner is essential for EAV replication. This explanation is also compat-
ible with the nonviable phenotype of several other mutants and suggests a particularly 














































The fact that EAV does not tolerate substitution of its single invariant nsp12 residue 
stands in remarkable contrast to phenotypes described for mutants of the invariant 
residues of the NendoU or O-MT of nidoviruses (29-32), which are both more strongly 
conserved than nsp12. In these studies alanine substitutions of absolutely conserved 
putative active site residues resulted in lower virus progeny titers and in part in small-
plaque phenotypes in cell culture but did not entirely abolish virus replication.
In conclusion, our combined results may be most compatible with the notion that nsp12 
is not an MTase and possibly not even an enzyme but rather a co-factor of an essential 
component of the arterivirus replicase. In this context, a future in-depth analysis of the 
nsp12 interaction network could be most informative. If nsp12 is not an MTase, this ac-
tivity must be provided by another protein, but it is unlikely to be one of the three other 
ORF1b proteins, which are known to possess different enzymatic domains. This implies 
that arteriviruses may be (very) different from other nidoviruses with respect to either 
the nature of the 5’ end of their mRNAs and/or the mechanism generating it. We note 
that the presence of a 5’-terminal cap-1 structure was reported for the SHFV genome 
(23), but that monophosphates were claimed to present at the 5’ end of LDV mRNAs 
(33), calling for additional studies to resolve the apparent conflict. Finally, the possibility 
of cap-snatching, the strategy employed by some families of negative-stranded RNA 
viruses (34-36), may be explored for arteriviruses. This mechanism might accommodate 
the nsp11 NendoU as endoribonuclease and nsp12 as a cap-binding protein, which 




Genomes of members of the Arteriviridae and Coronaviridae families were retrieved 
from GenBank (37) and RefSeq (38) using the Homology-Annotation hYbrid retrieval of 
GENetic Sequences (Haygens) tool http://veb.lumc.nl/HAYGENS. Codon-based multiple 
sequence alignments (MSAs) of virus genomes were produced using the Viralis platform 
(39) and assisted by the HMMER 3.1 (40), Muscle 3.8.31 (41), and ClustalW 2.012 (42) 
programs. Only one virus per established or tentative species, which were defined 
with the help of DEmARC1.3 (43), was retained for bioinformatics analyses. To retrieve 
information about genomes, the SNAD program (44) was used. To reveal the full extent 
of similarity between pairs of alignments, they were converted into HMM profiles, which 









































(45;46). Distribution of similarity density in alignments was plotted using R package 
Bio3D (47) under the conservation assessment method “similarity”, substitution matrix 
Blosum62 (48), and a sliding window of 11 alignment columns. To search for homologs 
among profiles in the PFAM A database (49), the HH-suite 2.0.15 software (45;46) was 
used. Secondary structure of proteins was predicted by applying JPred 3 (50) and PsiPred 
(51) to MSAs, with the prediction being applied to the top sequence in the MSA. The 
MSAs were converted into figures  using ESPript (52). Reconstruction of phylogenetic 
trees was performed using PhyML 3.0, with the WAG amino acid substitution matrix, 
allowing substitution rate heterogeneity among sites (4 categories), and 1000 iterations 
of non-parametric bootstrapping (53). Pairwise patristic distances (PPDs) between 
viruses were calculated from protein trees using R package “ape” (54). Linear regression 
was calculated using R package “stats” (55).
Reverse genetics of EAV
Mutations specifying alanine and conservative replacements of (partially) conserved 
and control residues in nsp12 were generated using the QuikChange protocol. In all 
cases translationally silent marker mutations were introduced to allow discrimination 
between (partial) reversion of mutants after transfection and (possible) contamination 
with wild-type virus. Mutated gene fragments were introduced into full-length cDNA 
clone pEAV211 (56), a pEAV030 derivative (57), using appropriate shuttle vectors and 
restriction enzymes. The presence of the mutations was confirmed by sequencing. 
pEAV211 DNA was in vitro transcribed and RNA was purified by LiCl precipitation. RNA 
was transfected into BHK-21 cells as described previously (58). Transfected cells were 
monitored by immunofluorescence microscopy until 68 h post transfection (p.t.), using 
antibodies directed against EAV nsp3 and N protein as described (59). To monitor the 
production of viral progeny, plaque assays were performed with supernatants collected 
at 14 and 48 h p.t. or during the first 24 hours p.i. to determine growth kinetics, as de-
scribed (58). To verify the presence of the introduced mutations or reversions in viable 
mutants, fresh BHK-21 cells were infected with supernatants harvested at time points 
at which transfected cells were positive in immunofluorescence microscopy. RNA was 
isolated after 18 h or when cytopathic effect was detected. Finally, the nsp12-coding 
region was amplified by RT-PCR using random hexameric primers in the RT step and 
EAV-specific primers for the PCR. PCR fragments were purified and sequenced.
Protein expression and purification
N-terminal and C-terminal His-tag fusion proteins of wild-type nsp12 were expressed 













































grown in Luria Broth with 100 µg/ml ampicillin at 37°C until OD600 reached 0.7. Expres-
sion was induced after addition of 0.5 mM IPTG and cells were grown for further 4 h at 
37°C.
EAV ORF1a-encoded proteins were expressed with N-terminal ubiquitin and C-terminal 
His tags from pASK vectors (60). Plasmids were transformed into E. coli C2523 contain-
ing the pCG1 plasmid, which leads to constitutive expression of the ubiquitin-specific 
protease UBP1. Cells were grown in Luria Broth with 100 µg/ml ampicillin and 34 µg/ml 
chloramphenicol at 37°C until OD600 reached 0.7. Expression was induced after addition 
of 200  ng/ml anhydrotetracycline and cells were grown for another 18  h at 20°C. All 
pellets were harvested by centrifugation and stored at -20°C until further use.
Proteins were batch purified by metal affinity chromatography using Co2+ (Talon beads). 
All steps were performed at 4°C or on ice. Cells were resuspended in nsp12 resuspen-
sion buffer (20 mM HEPES, pH 7.5, 5 mM β-mercaptoethanol) or co-factor resuspension 
buffer (20  mM HEPES, pH  7.5, 10% glycerol (v/v), 5  mM β-mercaptoethanol) contain-
ing 500 mM NaCl and Roche complete EDTA-free protease inhibitor cocktail. Lysis was 
achieved by 30 min incubation with lysozyme (0.1 mg/ml). Genomic DNA was sheared 
during four sonication cycles of 10 s with intermittent cooling. Cell debris was removed 
by centrifugation at 20.000 g for 20 min. Cleared supernatants were incubated with an 
appropriate amount of Talon beads for 1  h under slow rolling. Beads were collected 
and washed four times for 15 min with a 20-fold volume of the respective resuspen-
sion buffer supplemented with 10 mM imidazole and first 500 mM, then 250 mM, and 
finally twice 100 mM NaCl. Proteins were eluted with the respective resuspension buf-
fer containing 300 mM imidazole and 100 mM NaCl. Elution fractions were examined 
by SDS-PAGE, pooled, and dialyzed against 20 mM HEPES, pH 7.5, 100 mM NaCl, 25% 
glycerol, 1 mM DTT. All proteins were stored at -20°C. Typical yields were 1-2 mg/l culture 
for all proteins. Protein concentrations were calculated based on theoretical extinction 
coefficients and absorption at 280 nm.
Gel filtration of nsp12 was performed on a Superdex 75 10/300 GL gel filtration column 
with 10 mM Na-phosphate buffer, pH 6.0, 100 mM NaCl, 1 mM DTT at 4°C and a flow rate 
of 0.5 ml/min.
Methyltransferase assay
Methyltransferase assays were performed essentially as described previously (14). Pro-
teins at the indicated final concentrations were incubated at 30°C for 30, 60, or 180 min 









































10 µM S-adenosylmethionine, 2 µM capping substrate, and 1×103 Bq/µl S-[methyl-3H]-
adenosylmethionine. Additionally 7.5  mM NaCl were carried over from the protein 
storage buffer. Vaccinia virus capping enzyme (New England Biolabs) was incubated in 
the buffer supplied by the vendor. To stop the reaction a 10-fold volume of ice-cold 
S-adenosylhomocysteine (100  µM) was added. Samples were spotted on DEAE filter-
mats (Perkin Elmer), which were subsequently washed twice with 10 mM ammonium 
formate, pH 8.0, then twice with water, and finally with ethanol. Filtermats were cut, and 
radioactivity was measured by scintillation counting.
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Figure S1. Relative scale of divergence of nsp12 of the Arteriviridae and (putative) nsp16 of the Corona-
virinae and Torovirinae. Shown are three (sub)family-specific two-dimensional scatter plots that compare 
PPDs of the most C-terminal protein (nsp12 or nsp16-OMT, x-axis) versus PPDs of other proteins/domains of 
ORF1b starting from the ZBD (detailed in inset, y-axis). PPDs were calculated from PhyML trees for separate 
proteins. Dashed lines, linear regressions fit in respective (color matching) dot distributions with R2 and 


















































































































Figure S2. Analysis of co-conservation of C-terminal parts of ORF1b of the Arteriviridae, Coronavirinae, and 
Torovirinae. Shown are three pair-wise MSA-based HMM-HMM plots comparing parts of ORF1b starting 
from the ZBD of three origins. The position of proteins and some domains are indicated. Each MSA was 
converted to an HMM profile, three possible pairs of obtained HMMs were aligned with the help of HH-suite 
2.0.15 software (45,46). The presence of similarity above the threshold of 0.3 is recorded with a dot. Diago-
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Development of an anti-coronavirus 










































In contrast to all other chapters of this thesis, this chapter does not present scientific 
data on single nidovirus proteins that may serve as drug targets and ultimately may 
lead to the discovery of antiviral compounds. Instead it gives a rough overview of some 
of the economic and legal questions that need to be addressed before a pharmaceuti-
cal company would engage in the development of such a compound. This project was 
realized as part of the Marie Curie Initial Training Network EUVIRNA, which aimed to 
provide multidisciplinary training at the interface between academia and industry. 
Under guidance of a mentor from one of the industrial partners of the consortium, 
Janssen Infectious Diseases, the presented information was gathered from internet re-
search, telephone conference calls, and face-to-face meetings with experts with diverse 
backgrounds working in different relevant fields, such as regulatory affairs, global public 
health, strategic marketing, and market access. Although the duration of this project 
was too short for a more detailed analysis, it still was an interesting experience writing 
it, and it is hoped that it at least provides some food for thought that is otherwise rarely 
obtained in a purely academic setting.
SUMMARY
In the past ten years the emergence of two new zoonotic coronaviruses (SARS-CoV and 
MERS-CoV) has prompted concerns about the possibility of a serious human pandemic 
caused by such a previously unknown virus from an animal source. In response to this 
threat, several academic groups started to design or search for inhibitors of coronavirus 
replication. However, to date none of the identified molecules has been further devel-
oped. This essay summarizes and discusses the reasons for this slow development. From 
an industrial perspective, questions relating to regulatory requirements, drug proper-
ties, and economic incentives are addressed. Due to market considerations, the only 
potentially profitable purpose of an anti-coronavirus drug appeared to be its inclusion 
in (mostly public) stockpiles as a countermeasure in case of an outbreak of a newly 
emerging coronavirus. Since the actual target virus will thus not be available during 
the development phase, a broad-spectrum inhibitor would need to be discovered to in-
crease the chances that the drug will be effective against such a virus. Similarly, this lack 
of a target definition during clinical testing would require a substantial deviation from 
the standard approval process. Nevertheless, special FDA (United States Food and Drug 
Administration) regulations are in place to allow approval for the intended use. Although 
early countermeasures may mitigate the impact of an outbreak on public health and 













































pandemic and on which scale they would do so. Given this major uncertainty, it seems 
unlikely that a private company will invest in the development of an anti-coronavirus 
drug. Yet, the establishment of a public-private partnership with a clear public commit-
ment to support research and development, coupled to a guarantee to purchase certain 
quantities of the product, may compensate for this risk. However, where coronaviruses 
are concerned the sense of urgency required to realize such a commitment is currently 
not evident.
1. INTRODUCTION
In late 2002, the sudden appearance of severe acute respiratory syndrome coronavirus 
(SARS-CoV) and the first pandemic of the 21st century that it caused exemplified the 
potential threat newly emerging viruses may pose to public health, society, and the 
global economy. To confine the spread of such viruses, it would be desirable to have 
potent antiviral drugs for treatment and prophylaxis available when the first cases are 
recognized. However, meeting this goal would require the arrangement of national or 
global drug stockpiles and therefore the prior approval to use such a drug before any 
information on the actual pandemic agent is available.
To exemplify the spectrum of considerations a company needs to take into account 
before engaging in such an endeavor, this essay will explore the potential development 
and use of drugs directed against coronaviruses. Although this assumption cannot be 
supported by sufficient scientific data at this time, it shall be assumed that it is, at least in 
principle, possible to design a broad-spectrum antiviral drug effective against all or the 
majority of currently known mammalian coronaviruses. However, I would like to point 
out that a detailed scientific evaluation of this undertaking is beyond the scope of this 
essay, which will be mainly focused on economic facets of developing a potential new 
drug. The central question will be:
would it, from an economic point of view, be reasonable to invest in the dis-
covery and/or development of an anti-coronavirus compound, even though 
there is neither a guarantee that a coronavirus will cause an outbreak in the 
near future nor the certainty that the developed drug will actually be active 









































To reach a conclusion on this question, aspects as regulatory requirements, market and 
drug properties, as well as competing products will be discussed below1.
2. BACKGROUND INFORMATION ON CORONAVIRUSES
Coronaviruses are a family of RNA viruses with a single-stranded genome of positive 
polarity, i.e., their genomes serve immediately as mRNAs for protein production. Their 
name originates from the characteristic crown-like appearance of their surface projec-
tions under the electron microscope. Coronaviruses typically replicate in the respiratory 
or enteric tract of humans and a wide range of animal hosts and cause clinical symptoms 
accordingly (see Table 1). Notably, infection with one of the four human coronaviruses 
(HCoVs) is the second leading cause of the common cold, exceeded only by rhinovirus 
infections. Besides these widespread HCoVs with a seroprevalence in adults of up to 
80% (1), which were in part originally described in the mid-1960s, two zoonotic2 coro-
naviruses have jumped to humans more recently, SARS-CoV and MERS-CoV (Middle East 
respiratory syndrome coronavirus). In contrast to the “established” HCoVs, both zoonotic 
agents are associated with severe respiratory disease and a high case fatality rate. For 
SARS 8,439 cases leading to 812 deaths were reported between November 2002 and July 
2003 (2). For the ongoing MERS outbreak, the number of cases since April 2012 currently 
approaches 1,000, of which 35-40% had a fatal outcome, often in patients with underly-
ing medical conditions (3). Reasons for the limited spread of these viruses appear to lie in 
their late onset of transmission in comparison to the onset of symptoms and a relatively 
poor transmissibility among humans. Nevertheless, direct spread upon close contact, 
for instance between family members or in healthcare facilities, has been reported for 
both viruses (4;5). In comparison, a highly contagious virus, like influenza virus, was 
estimated to be responsible for 43-88 million infections, including 8,700-18,000 deaths, 
during the 2009 influenza A(H1N1) pandemic in the United States alone (6). Obviously, 
if a novel coronavirus would surface that would be transmitted with similar efficiency 
as the established HCoVs appear to be while sharing the high pathogenicity with the 
zoonotic coronaviruses, the impact on society and economy could be devastating.
1 The discussed information is, for the most part, derived from regulations and prepared-
ness plans issued by the United States (U.S.) federal government. This is due to the consid-
eration that the U.S. are one of the most likely and most relevant partners for stockpiling 













































r 73. NEW DRUG APPROVAL
Obtaining approval to use a new drug and subsequently bringing it to market typically 
requires more than ten years of pre-clinical development and clinical research. Obvi-
ously, this time frame precludes the development of a drug as part of the direct response 
to an outbreak of a novel infectious disease and calls for an alternative route towards 
approval in those situations. The most promising of these alternative routes permitted 
by FDA (United States Food and Drug Administration) regulations is the approval of a 
broad-spectrum antiviral drug before a pandemic, followed by an extension of the ap-
proved indication to include the newly emerged pathogen. However, when employing 
this quicker approach special criteria and prerequisites have to be met, which are out-
lined below. Furthermore, although these approval and emergency processes are based 








α HCov-229E Human + ?
HCoV-NL63 Human +
PEDV Pig +
TGEV Pig + + +
CCoV Dog +
FECoV Cat +
FIPV Cat + + + + +
RbCoV Rabbit + +
β HCoV-OC43 Human + ? ?
HCoV-HKU1 Human +
SARS-CoV Human + + +
MERS-CoV Human + + +
PHEV Pig + + +
BCoV Cow + +
ECoV Horse + +
γ IBV Chicken + + +
TCoV Turkey + +
δ SDCV Pig +
HCoV, human coronavirus; PEDV, porcine epidemic diarrhea virus, TGEV, transmissible gastroenteritis virus; 
CCoV, canine coronavirus; FECoV, feline enteric coronavirus; FIPV, feline infectious peritonitis virus; RbCoV, 
rabbit coronavirus; SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East re-
spiratory syndrome coronavirus; PHEV, porcine hemagglutinating encephalomyelitis virus; BCoV, bovine 
coronavirus; ECoV, equine coronavirus; IBV, infectious bronchitis virus; TCoV, turkey coronavirus; SDCV, 









































on U.S. law, equivalent arrangements likely exist under European Union and national 
regulations as well, enabling a similar approval strategy in all high-income countries.
As the etiological agent of the postulated future coronavirus pandemic is probably 
unknown, it first needs to be decided which related viruses will be the basis for the pre-
clinical screening process. Inclusion criteria could be our knowledge-base for those par-
ticular agents, the biosafety level required to handle them, the availability of cell culture 
and animal infection models, and preferably also an animal model reproducing disease. 
Furthermore, to increase the likelihood of the drug being efficacious against any new 
coronavirus, the viruses tested should ideally represent all genera of the coronavirus 
family but at least alpha- (e.g., HCoV-229E) and beta-coronaviruses (e.g., HCoV-OC43), 
which include the majority of currently known coronaviruses with a mammalian host.
After obtaining the investigational new drug-status (IND status) and demonstrating 
safety in a clinical phase  I study, efficacy needs to be shown either in patients with a 
confirmed coronavirus infection or in challenge studies where healthy volunteers are 
exposed to the virus within a closed, monitored setting. For the former option MERS 
patients may represent a small but suitable target group, should the virus continue to 
circulate in the Middle East. Alternatively, any of the four HCoVs may be considered for 
use in clinical trials. However, due to the mildness of symptoms of most HCoV infections, 
which typically do not prompt any clinical testing or differentiation against, for example, 
rhinoviruses, technical problems will likely arise during the recruitment process of 
patients. Therefore, challenge studies with HCoVs may be the only feasible option for 
phase II trials in which also the dose for treatment or suitability for prophylaxis can be 
established. Finally, HCoV patients already hospitalized with other illnesses affecting the 
immune system or respiratory tract could be a target group to complete the require-
ments for approval in phase  III trials by demonstrating the immediate benefit of an 
anti-coronavirus drug.
If an outbreak occurs that is caused by a new coronavirus, the above drug will not be 
automatically approved for treatment of this new disease since its indication will at that 
time be limited to treatment of those CoVs evaluated in phase III trials. However, it is pos-
sible to amend the original approval with additional indications as soon as they become 
apparent. Typically such a so-called prior approval supplement needs to be supported 
by new efficacy studies in animals as well as phase II and III trials (7). Yet, since the virus 
itself and the disease it causes will not be well defined during the early stages of an out-
break, any studies involving human subjects would be considered unethical. Therefore, 
it is likely that the extension will have to be granted based on the two animal rule (8), 













































be tested for effectiveness in humans but are expected to be beneficial for patients. 
This alternative drug approval track requires a demonstration of efficacy in at least two 
animal models that are assumed to respond similar to humans. Once this data is deemed 
satisfactory, dispensing could start quickly given the fact that safety of the compound 
has already been demonstrated and a novel treatment is provided which will likely have 
an impact on survival. Ideally, data generated from treated patients should be collected 
and analyzed in real time to serve as uncontrolled clinical study and to enable a better 
determination of the doses needed for treatment but also for prophylaxis.
Depending on the dynamics of the outbreak it may still be necessary to act faster than 
this approval process would allow. For these cases, it has to be possible to bypass the 
strict FDA requirements for a limited amount of time during emergency situations. Thus, 
it is generally always possible for each physician to prescribe any drug for any indication 
on a per patient basis. Therefore, it can be expected, especially in the absence of any 
other known treatments for life-threatening coronavirus infections, that the antiviral 
drug, even if it were only approved for treatment of HCoVs (or MERS-CoV), would be 
used for this new indication by informed physicians. However, as pharmaceutical 
companies themselves are forbidden to advertise the off-label use of their drugs, WHO 
(World Health Organization) or national bodies would need to promote this application. 
For this purpose a special emergency act is in place allowing the FDA commissioner to 
temporarily permit and promote the use of drugs for an unapproved indication if they 
are intended to treat or prevent life-threatening diseases and no approved alternative 
exists (9).
In conclusion, although U.S. federal regulations for approval of new medical products are 
stringent to ensure efficacy but foremost consumer safety, there is still room to respond 
quickly to newly emerging public health threats. Nevertheless, the time from initial 
discovery of an active compound to approval will never be short enough to prevent a 
pandemic if the development is only started once first cases appear. Thus, preparation 
and planning ahead, even for apparently unlikely events that may have a huge impact 
on the global population and economy, is essential.
4. MARKET CONSIDERATIONS
In the absence of preparedness plans to combat a potential coronavirus pandemic, the 











































Whenever and wherever an outbreak of a contagious agent occurs, the primary goal has 
to be to prevent further spread and to contain the disease within a certain area. Since 
modern modes of transportation have made this increasingly difficult to achieve, rapid 
initiation and enforcement of countermeasures, as social distancing, travel restrictions, 
and pharmaceutical intervention, are all the more important. Although these measures 
usually are applied in combination, a recent study using pandemic influenza as model 
indicated that, in the absence of a vaccine, the curative and prophylactic use of antivirals 
has a bigger impact on the progression of an outbreak than any of the other counter-
measures. In short, the authors concluded that under all pandemic severity categories an 
intervention strategy including antivirals leads to the biggest reduction of costs, both in 
terms of loss of life and economic loss, compared to a scenario without any intervention 
(10). Furthermore, antivirals are, next to a vaccine, the only measure providing protec-
tion for healthcare workers and other employees in essential services. Unfortunately, 
there is currently no drug specifically against any coronavirus on the market that would 
at least offer the prospect of treatment in case of a coronavirus pandemic. This again 
emphasizes the need for the development of an anti-coronavirus drug before a major 
outbreak occurs.
4.2 Purpose of the antiviral drug treatment
The anti-coronavirus drug is intended to be used as an outbreak control measure 
complementary to non-pharmaceutical interventions. Accordingly, the drug will be 
used both curatively as well as prophylactically (if allowed by the infection kinetics), 
with the latter presumably being of greater importance in respect to sales volumes. To 
serve this purpose, the drug will need to be included in public and private stockpiles. 
Additionally, the development of a diagnostic test may be a valuable complementary 
tool to support the drug’s use.
Although human coronaviruses are estimated to cause 10 to 15 percent of common 
cold cases (11), this field is not expected to be a significant market considering the mild 
nature and short duration of symptoms and the consequential lack of clinical testing. 
However, there could be a small market for treatment of HCoV infections in patients with 
certain co-morbidities.
Besides humans many animals are hosts to one or multiple coronaviruses, suggesting 
the possibility of veterinary applications. However, vaccines are on the market against 













































(porcine transmissible gastroenteritis virus) (13), and IBV (avian infectious bronchitis 
virus) (14). Due to this limitation, usage of an antiviral in an animal health setting is not 
expected to provide a significant market and will not be considered further.
4.3 Customers and market size
Currently none of the three major healthcare authorities CDC (United States Centers 
for Disease Control and Prevention), ECDC (European Center for Disease Prevention and 
Control), or WHO have developed a specific response plan for the event of a severe coro-
navirus pandemic. Thus, any of the following considerations are based on recommenda-
tions for an influenza pandemic made by the U.S. Department of Health and Human 
Services (15). Since both influenza and coronaviruses cause respiratory symptoms and 
appear to be transmitted via respiratory droplets and contaminated surfaces (16;17), 
these considerations likely also apply in scope and size for a potential coronavirus pan-
demic.
In order to bridge the gap between the beginning of an influenza outbreak and the start 
of antiviral drug or vaccine production, the preparedness plan recommends the buildup 
of public stockpiles with amounts of antivirals that will suffice to treat about 25 percent 
of the U.S. population (80 million people). If we apply the same percentage to the EU, 
125 million regimens would need to be available. However, since EU member states do 
not necessarily follow the same policy, the actual coverage of each individual state may 
deviate considerably. For instance, a survey made by the ECDC in 2006 counted national 
stockpiles of influenza antivirals sufficient for treatment of 5 to 50 percent of the coun-
tries’ respective populations and listed many nations intending to increase this level 
further (18). If we assume a similar coverage for the event of a coronavirus pandemic, the 
total demand in high-income countries with about 1.1 billion inhabitants may add up to 
150-250 million regimens. Additionally, it may be considered to increase a coronavirus 
stockpile further as it is unlikely that a vaccine will be available as fast as one against 
influenza virus (typically six months). However, given the fact that the anti-coronavirus 
and anti-influenza virus drug stockpiles would compete for the same budget and in-
frastructure, it seems to be more realistic to expect a significant downward deviation 
from the set targets. In contrast to drugs against influenza, which re-occurs seasonally, 
a coronavirus drug would be restricted to those stockpiles, resulting in a limited regular 
turnover during non-outbreak phases, primarily due to shelf life limitations. On the 
other hand, if a pandemic would occur, demand could increase dramatically. However, 
the extent to which a company could profit from this situation would depend on its 









































potential, production capacity would have to match the hypothetical future demand 
and not the regular turnover, thus causing additional costs.
Next to treatment, the recommendations include expansion of the U.S. national stock-
pile to provide multiple drug regimens for outbreak prophylaxis for people working in 
healthcare and emergency services, as well as for people with compromised immunity 
but not for the general public as undifferentiated mass prophylaxis is unfeasible. Addi-
tionally, people living in group settings, for instance nursing homes, should be provided 
with single regimen post-exposure prophylaxis if an outbreak occurs at their facility. Ide-
ally, an anti-coronavirus drug should also be suitable for prophylactic use. The number 
of additionally required regimens is, however, hard to predict as it depends, for instance, 
on the specific estimates on the progression of a local outbreak, drug efficacy, and the 
efficiency of human-to-human transmission of the newly emerging virus. Alternatively, 
the development of SARS symptoms in relation to the viral titer gives rise to the assump-
tion that early intervention may be as suitable in containing an outbreak as infection 
prevention. In this particular case, patients started to spread the disease only from 
day seven after onset of symptoms and peak viral loads were reached three days later, 
leaving a window of several days to intervene with antivirals in order to suppress the 
infection (19). Nevertheless, as it cannot be predicted whether these dynamics will be 
shared by the new pandemic coronavirus, it seems likely that a stockpile would at least 
to a certain extent allow for prophylactic drug use.
To complement public stockpiles, employers are encouraged to ensure private stocks to 
offer protection to workers who are critical to maintain operations in businesses essen-
tial to the community, as for example, power grid or money and food supply. Moreover, 
employers may consider to arrange additional stocks for employees overseas, who may 
not have access to any publicly supplied drugs, or, if concerns regarding the availability 
and timely dispensing of public stockpiles exist, for the early treatment of employees 
falling ill. Additionally, an employer has to consider which dispensing model should be 
used. The options are: triggered dispensing from a central pharmacy when an outbreak 
starts and pre-pandemic dispensing to the actual consumer. The most fundamental 
difference, as it relates to market size, lies in the applicable expiration date of the drug. 
If the drug is to be stored in a licensed pharmacy, the FDA-approved expiration date 
applies, for example seven years for the anti-influenza drug tamiflu (20), while the same 
is limited to six to twelve months once the drug has been distributed to the consumer. 
Obviously, the latter would considerably increase the turnover of the antiviral within 
private stockpiles. To conclude, depending on the number of employers following these 













































pensing, private stockpiles could represent a significant market segment next to public 
stockpiles.
4.4 Expected customer advantage
The experience of the SARS pandemic has reminded us that these kinds of events do 
not only cost lives but also have a huge impact on economy. Although this pandemic 
was relatively small with less than 9,000 cases including about 800 deaths and was con-
tained within half a year, its costs to the global economy were estimated at about $30 
billion. In comparison, the costs of a global influenza pandemic, which may more closely 
resemble a future pandemic with a more contagious coronavirus, may well exceed $500 
billion (21). These estimates, including costs for healthcare and countermeasures, loss 
of productivity due to prophylactic absenteeism, illness or death, loss of productivity 
due to supply chain effects, decreased demand for products and services, and decrease 
of tourism and travel, make clear how important the rapid elimination of a contagious 
disease is. An antiviral can help in this process and considerably shorten the duration of 
an outbreak and can thereby reduce the costs of the disease for individual companies 
and society.
4.5 Target product profile
As the drug is, on the one hand, intended to provide protection for people coming into 
contact with patients and, on the other hand, intended to enable treatment of these 
patients, two different subpopulations with quite different requirements need to be 
considered. According to the perceived relative importance of these two subgroups, 
drug requirements arising from prophylactic use will be given priority and shall be ad-
dressed first.
Besides the disruption of the chain of infection, continuation of essential community 
services is the main goal of the prophylactic administration of the drug. Therefore, the 
antiviral cannot cause side effects that interfere with the provision of such services. Ad-
ditionally, the absence of noteworthy side effects will increase the general compliance 
to take the antiviral. For the same purpose, the drug should be easy to take, preferen-
tially as an oral, single daily dose. Next to side effects also cytotoxicity, especially for 
the liver, has to be low over the duration of intake. However, the length of this period 
is hard to predict and would essentially depend on the severity of the local outbreak 
and the number of days the virus is transmitted by patients but may fall in a window 
of several weeks up to a few months. Furthermore, since the recipients of prophylactic 









































to suppress the development of symptoms and spread of the disease. Thus, the dose for 
effective prophylaxis could potentially be lower than the one for intervention. This fact 
in turn may help to reduce side effects during the indicated period.
In contrast, more severe side effects would be expected for the higher dose of the antivi-
ral used for treatment of patients, but this would also be more acceptable for this group. 
However, to relieve the strain on the healthcare infrastructure, which has seen average 
admission periods exceeding 25 days for SARS (21), it would be desirable to be able to 
release mild cases to their homes. Therefore, side effects requiring permanent medi-
cal attention should not occur. Another necessity, particular for one group of patients, 
became apparent from our experiences with MERS CoV infection, which causes the most 
severe symptoms, often eventually leading to the death of the patient, in patients with 
medical preconditions (22). Consequently, the antiviral has to be compatible with other 
drugs frequently used to treat common preconditions.
Finally, the last drug requirement that should be met is arising from the intention to 
stockpile rather than from the targeted user group. As it is unpredictable when the 
antiviral will be needed, the necessity for drug turnover due to shelf life expiration as 
well as the costs for long term storage and distribution should be taken into account. 
For instance, although cooled warehouses exist for certain parts of the U.S. emergency 
stockpile, cheaper storage and transport at ambient temperature is surely preferred and 
may be a factor in the decision for or against stockpiling a certain drug. Thus, long-term 
stability at ambient temperature is another desirable drug property.
4.6 Competing products
4.6.1 Vaccine
Efforts have been initiated to develop vaccines against SARS and MERS coronaviruses 
(23;24), which may, if approved, provide cross-protection against other coronaviruses 
and could potentially be distributed with little response time. However, given the high 
antigenic diversity of coronaviruses, such a case of effective cross-protection may be the 
exception rather than the rule (1).
In contrast, an effective vaccine specifically tailored against the novel pandemic agent 
will most likely not be available within the first year of a pandemic since multiple difficul-
ties in the vaccine’s development could arise. First, natural infections with HCoVs seem 
to fail to induce long-lasting immunity as test subjects could not only be re-infected 













































symptoms. If this observation represents a general feature of the human immune re-
sponse towards coronaviruses, strategies that will overcome this shortcoming need to 
be developed. Additionally, vaccination against feline enteric coronavirus (FECoV) has 
been associated with antibody-dependent enhancement of disease. Next to these two 
antibody-related complications, additional challenges will likely arise from the genetic 
properties of coronaviruses. Foremost their ability to mutate quickly and to recombine 
presents a problem. For instance, a case of recombination between a live attenuated IBV 
vaccine strain and a field strain was reported, which had caused a local outbreak and 
raised some safety concerns. Furthermore, recombination likely increases the range of 
antigenic variants against which a vaccine would need to provide protection (1). Also, as 
the primary target of a vaccine will be the spike (S) surface protein, mutations affecting 
the efficacy of a vaccine may arise more readily than those providing resistance against 
an antiviral, which may target a more conserved enzyme.
To conclude, although a potent and safe vaccine is as an outbreak control measure surely 
superior to an antiviral drug, the probability that a vaccine actually can be developed in a 
timely fashion when an outbreak occurs is low. With this said, it also has to be made clear 
that eventually a vaccine will be approved if the virus stays in circulation long enough to 
warrant the efforts to overcome the described complications. As soon as this happens, 
the market share of the putative, novel antiviral will gradually decrease. Nevertheless, in 
view of the intended use of this drug as part of an emergency stockpile, a coronavirus 
vaccine does not represent a source of competition during the initial outbreak situation.
4.6.2 Antiviral drug candidates
Over the past decade, several academic groups screened for and identified compounds 
active against SARS-CoV. These compounds included inhibitors of viral fusion and entry, 
as well as of essential viral enzymes as proteases, RNA-dependent RNA polymerase, and 
helicase. Furthermore, siRNAs targeting the expression of structural or accessory pro-
teins were evaluated. Next to these virus-oriented strategies, also compounds targeting 
host factors, which may be essential for virus replication but temporarily dispensable for 
the human host, were explored (25). Currently, efforts are made to test the efficacy of 
some of these drug candidates against MERS-CoV, which may lead to the identification 
of compounds with a broader activity against coronaviruses (26).
Although it is encouraging that inhibitory compounds have been found in in vitro assays 
and animal models, none of these compounds have been brought to clinical phase  I 









































patent holders. However, licenses may have been or may be acquired in the future by 
any competitor.
4.6.3 Repurposed drugs
In the absence of an approved drug, different strategies of treatment were followed 
in response to the SARS pandemic. These included administration of interferon, cor-
ticosteroids, ribavirin, and the HIV protease inhibitors Lopinavir/ritonavir. As the case 
numbers of SARS have been generally low, no sufficient evidence supporting or refuting 
the efficacy of any of these treatments could be gathered from patient data. Therefore, 
none of these experimental interventions are currently recommended as treatment for 
MERS (27). However, these or other rededicated approved drugs may compete with or 
at least may define the minimal efficacy required for a new anti-coronavirus drug if their 
efficacies are better characterized.
5. CONCLUSION
Bringing a new drug to the market requires on average an investment of $1.2 billion (28). 
To ensure the return of this significant investment, any factors influencing the future 
marketability need to be carefully assessed and opportunities weighed against risks. 
For this analysis of the potential of an antiviral drug against coronaviruses, a scenario 
of an imminent pandemic caused by an at present unknown coronavirus was assumed. 
Implicitly this scenario acknowledges the fact that currently circulating coronaviruses 
either do not pose a threat to public health due to the mild clinical symptoms they cause 
(HCoVs) or are associated with low case numbers (MERS-CoV). Therefore, pre-pandemic 
stockpiling is, from a current perspective, the only purpose providing a sufficient market 
need and size to generate profit. However, this intended use also poses some inherent 
risks for development and marketing. First, as a broad-spectrum antiviral is required, it 
can be expected that the discovery and development process will be longer and more 
difficult, and thus more expensive, than for drugs with more restricted therapeutic use. 
Additionally, any efforts to demonstrate the value of the antiviral will be hampered by 
the fact that the pathogen that ultimately may become the trigger for dispensing of 
the stockpile is not present at the time of the purchase decision. Thus, in a competitive 
environment where other drugs are developed for which a market need and health 
benefit can clearly be proven, a coronavirus antiviral may not be considered to have 
a positive cost-benefit ratio to make it a reasonable choice for stockpiling, especially 
under continuing austerity measures. Therefore, an essential question would be how the 













































on the one hand, be expected that the number and intensity of virus outbreaks but also 
the frequency of emergence events of zoonotic viruses will increase in the future due 
to increased mobility and population density in urban areas, as well as the expansion of 
settlements into previously not inhabited areas. On the other hand, it will remain unpre-
dictable to which family a newly emerging virus will belong. How these two arguments 
are weighed and may affect the decision to stockpile will likely differ from country to 
country, also depending on their individual financial situation as well as their willingness 
to take risks. Given their previous commitment to prepare for the event of future out-
breaks caused by different biological agents and the recent classification of SARS-CoV 
as a Select Agent (29), recognizing a potential public health threat, the United States 
are one of the most likely customers for an anti-coronavirus drug. This assumption is 
additionally supported by their recent purchase of 2 million doses of a smallpox antiviral 
for inclusion into the national stockpile (30). Although the volume of this purchase was 
far smaller (because 300 million doses of the cheaper, complementary vaccine are stock-
piled) than would be expected for an anti-coronavirus drug, the purchase of this antiviral 
demonstrates a mode of public-private partnership that could also be applicable for a 
coronavirus antiviral. In essence the smallpox antiviral was developed by order of the 
U.S. federal government, which granted a total of $100 million in research grants and 
contracts through several governmental agencies and agreed to purchase 2 million to 
14 million courses for a minimum of $433 million and up to $2.8 billion (31;32). In the 
absence of regular retail sales and the presence of high uncertainty in respect to sales 
volumes, seeking such partnerships to mitigate financial risks may be the only feasible 
option to realize such projects. To conclude, if such a public commitment for the devel-
opment of a coronavirus drug is not evident, the inherently high risk of this project will 
likely preclude any private initiative, even though market need and size would warrant 
an investment.
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ONE GOAL, MANY SOLUTIONS: MECHANISTIC ALTERNATIVES FOR 
ARTERIVIRUS RNA SYNTHESIS AND CAPPING
A few words on nidovirus diversity and genome architecture
The order Nidovirales with its families Arteriviridae, Coronaviridae (subfamilies Corona-
virinae and Torovirinae), Mesoniviridae, and Roniviridae comprises members that are 
genetically more distant from each other than the most diverged organisms of the Tree 
of Life (1-6). It may thus be asked, what defines a nidovirus and what unites members 
of the order. On the protein level three enzymatic subunits, the chymotrypsin-like main 
protease 3CLpro, the RNA-dependent RNA polymerase (RdRp), and the superfamily (SF) 1 
helicase, are the most conserved (1). However, none of these enzymatic domains can be 
considered nidovirus-specific as they are also common in many other positive-stranded 
(+) RNA viruses. Instead, bioinformatics studies identified the N-terminal domains of the 
proteins including also the RdRp or helicase domains as genetic markers for the order 
(chapter 5 and (5)). On a higher level, nidoviruses share a unique genome organization 
comprising a conserved array of features, encoded in the two 5’ replicase open reading 
frames (ORFs), and multiple 3’ ORFs that are translated from subgenomic (sg) mRNAs. In 
the 5’ to 3’ direction, this array includes the 3CLpro flanked by two transmembrane pro-
teins, a ribosomal frameshift site (RFS), the RdRp, and the helicase. The positioning of the 
helicase subunit downstream of the RdRp is not observed for any other group of (+) RNA 
viruses, and the implications of this organization have remained elusive so far. However, it 
is assumed that the particular arrangement of the array reflects strong constraints due to 
certain essential and universal requirements of the nidovirus replication cycle, which are 
poorly understood (5). Next to these core attributes, additional less conserved domains 
may be integrated into the replicase of specific members or subgroups of the order (see 
Figure 1 of chapter 6, p. 199). These additional domains, as well as a further expansion 
of the size of conserved proteins, were the major contributors to the lineage-specific 
increase in genome length of intermediate (Mesoniviridae) and large (Coronaviridae, 
Roniviridae) nidoviruses compared to that of the smaller arteriviruses (7). The profound 
divergence of nidovirus families on the protein level must have functional implications 
and calls for caution when attempting to generalize our limited biochemical knowledge 
on nidoviruses, which is based on studies of only a few corona- and arteriviruses. In this 
context, the following paragraphs discuss alternative interpretations of the arterivirus 
data presented in this thesis and elsewhere and formulate plausible hypotheses, which 









































Initiation of RNA synthesis
The copying of genetic information with the intent to produce progeny and blueprints 
for protein production is one of the few characteristics viruses and living organisms 
have in common. It is therefore not surprising that the “cupped right-hand” structure 
of canonical polymerases and their mechanisms are heavily conserved, even among 
otherwise genetically distant viruses and organisms (8;9). Nevertheless, some variation 
exists in the mechanisms used to initiate nucleic acid synthesis. In general two types of 
initiation can be distinguished: primer-dependent and primer-independent (also called 
de novo). Polymerases capable of the latter start nucleic acid synthesis by joining two 
NTPs, either independently or in association with a template but not necessarily with its 
3’ end. This dinucleotide then gets elongated in the 5’-3’ direction in a strictly template-
dependent manner. In contrast, primer-dependent polymerases rely on another enzyme 
to generate this starting dinucleotide (9). Which type of initiation a polymerase utilizes 
has been associated with the presence (primer-dependent) or absence (de novo) of the 
conserved so-called G  motif in the enzyme (10). Particularly, this motif was found in 
the putative RdRps of the Arteriviridae and Coronaviridae (11;12), and of the other two 
nidovirus families (Gorbalenya, personal communication). In the RdRp of severe acute 
respiratory syndrome coronavirus (SARS-CoV), designated nsp12, the presence of this 
motif was correlated with primer-dependent RdRp activity (13). These observations 
thus provided a rationale for the earlier described, but still debated, non-processive de 
novo RdRp activity of a smaller coronavirus protein, nsp8, encoded upstream of the RFS 
and lacking canonical polymerase motifs (14-16), which was proposed to generate the 
primers for the nsp12-based RdRp. In contrast to the situation for coronavirus nsp12, 
the G motif was found to be incomplete in the arterivirus equine arteritis virus (EAV) 
RdRp designated nsp9 (12). Additionally, the protein with the proposed “accessory 
RdRp” activity was found to be conserved in corona- and toroviruses, but its presence in 
other nidoviruses is uncertain due to very low sequence similarity in the corresponding 
part of the replicase protein (Gorbalenya, personal communication). It may therefore be 
speculated that, contrary to its coronavirus homolog, the RdRp encoded downstream 
of the RFS in arteriviruses is itself a de novo-initiating polymerase. This hypothesis was 
seemingly confirmed in in vitro assays using recombinant EAV nsp9 (12). Yet, this finding 
could not be extended to activity on natural EAV RNA templates and could furthermore 
not be reproduced in the present study (chapter 4).
Interestingly, EAV nsp9 was shown to possess a second enzymatic activity (chapter 5), 
which may be part of an alternative priming mechanism that is independent of the 
recruitment of a second cognate RdRp acting as a primase. This mechanism, which is 













































protein-linked polynucleotides that are subsequently positioned at the template’s 3’ end 
to allow elongation by the polymerase. The enzyme activity catalyzing this reaction is, 
where known, exerted by the polymerase itself with the help of a substrate protein 
that is typically named VPg (viral protein genome-linked) and ranges in size from 20 to 
more than 200 amino acids (17;18). So far this type of “protein priming” was described 
for double-stranded (ds) DNA viruses of the Hepadnaviridae (19), dsRNA viruses of the 
Birnaviridae (20), and (+)  RNA viruses of the Picornavirales (21-25), Caliciviridae (26), 
Potyviridae (27;28), Permutotetraviridae (29), and Astroviridae (30). Intriguingly, despite 
having genomes of only half the size of those of arteriviruses, the latter share the basic 
genome organization of nidoviruses including the 3CLpro-RFS-RdRp array and expres-
sion of structural proteins from a 3’-coterminal sg  mRNA (Figure  1). It was therefore 
speculated that an early nidovirus ancestor might have resembled the contemporary 
astroviruses (5). Although this genetic similarity is no guarantee that also mechanistic 
details of viral replication correspond, it is tempting to speculate that the mode of initia-
tion of RNA synthesis might only have been altered upon acquisition of a second RdRp 
in the course of the genome expansion of the large (and intermediate) nidoviruses.
In the first step of protein-priming a nucleotide monophosphate is covalently attached 
to the substrate protein under release of pyrophosphate, a reaction classified as nucleo-
tidylation. In most cases this substrate is not part of the polymerase subunit itself, but 
the extent of auto-nucleotidylation may vary in response to reaction conditions, as it 
was described for the RdRp of poliovirus (Picornavirales) (23). Currently, the only known 
notable exceptions to this general trend are proteins of the hepadnavirus hepatitis B 




















Figure 1: Replicase organization of nidoviruses and human astrovirus. Protein domains belonging to the 
conserved functional array of nidoviruses and their counterparts in astrovirus are indicated. Proteins that 
are known or hypothesized to take part in the initiation of RNA synthesis are depicted in purple. TM, trans-
membrane domain; 3CLpro, 3C-like protease; black dot and RFS, ribosomal frameshift site; RdRp, RNA-de-









































Furthermore, for infectious bursa disease virus (Birnaviridae) VP1, which contains the 
RdRp domain, it was shown that auto-nucleotidylation at the site located upstream of 
the RdRp domain does not depend on the conserved polymerase active site (20). In 
contrast, such a dependence was observed for VP1 of infectious pancreatic necrosis 
virus, another distantly related birnavirus (31). That study demonstrated a template-
independent auto-guanylylation activity that modified a serine residue conserved in 
birnaviruses. Interestingly, only the fraction of VP1 molecules that served as primers was 
guanylylated while other, non-modified RdRp molecules served in elongation (32). This 
mechanism may also be conserved in the (+) RNA Permutotetraviridae (29).
In these respects nucleotidylation of EAV nsp9 (chapter 5) may behave quite similar to 
that seen in birnaviruses. However, a rough estimation indicated that only a very small 
fraction (<1%) of nsp9 proteins was labeled with UMP or GMP – not taking into account 
the potential presence of inactive nsp9 molecules, which may be numerous given the 
instability of this recombinant protein. It may thus be questionable if a birnavirus-like 
division between priming and elongating protein fractions can be envisioned for EAV 
nsp9. In addition, we noticed a tendency to transfer this label to other EAV proteins 
but also unrelated polypeptides. Yet, as we were so far unable to identify a protein that 
serves as the preferred acceptor for UMP or GMP, we currently consider this transfer 
activity an artifact of the in vitro assay, maybe due to the general instability of the 
phosphoamide bond that is formed between the nucleotides and nsp9. Neverthe-
less, the low nucleotidylation efficiency and nonspecific transfer may be indicators of 
suboptimal reaction conditions, especially a lack of co-factors that may enhance nsp9 
activity or serve themselves as VPg. Given the numerous replicase subunits and long-
lived cleavage intermediates without an assigned function in arteriviruses (33), it can 
only be speculated which subunits might fulfill such a function. Strikingly, all currently 
known co-factors of RNA-processing enzymes in nidoviruses, specifically coronavirus 
nsp7, 8, and 10 (15;16;34), derive from the region between the transmembrane domain 
downstream of the 3CLpro and the RFS. Could an arterivirus VPg also be derived from that 
region, which comprises nsp6 to nsp8? Interestingly, arterivirus nsp6, a conserved 11 to 
22 amino acid peptide, is known to be part of a number of uncharacterized cleavage 
intermediates that are subject to alternative processing pathways in EAV (33). Next to 
the fully cleaved nsp6, one of these nsp6-containing intermediates may be considered 
as initial nucleotidylation substrate, whose regulated cleavage may be a convenient way 
to reduce affinity for and thus prevent retention of the polymerase at the RNA 5’ end 
once initiation has occurred. Finally, to invoke again the above mentioned similarity to 
astroviruses, it remains to be noted that the VPg of this virus family is indeed located 













































After auto-nucleotidylation of the RdRp-containing protein or its nucleotidylation of the 
VPg, the first nucleotide is extended by one or more additional nucleotides to generate 
a sufficient platform for annealing to the template strand. Thus, if the specificity of the 
nucleotidylation reaction in vitro faithfully reflects that in vivo, it must match the con-
servation of the 5’ ends of genome and/or antigenome. In the case of the EAV Bucyrus 
strain, which was the source of the nsp9 characterized in chapter 5, this sequence is GCU 
for the genome and GGU for the antigenome. Due to the unique replication mecha-
nism of nidoviruses, all sg mRNAs and subgenome-size negative-stranded RNAs would 
contain identical 5’  ends as the genome or antigenome, respectively (5;35). Although 
no evidence for an elongation of the first nucleotide was obtained in our experiments 
(chapter 5), it is noteworthy that for both RNA polarities nucleotidylation using GTP as 
substrate would be consistent with the observed nucleotide sequences. Intriguingly, 
bovine coronavirus was reported to encode a short poly uridine (poly(U)) tract at the an-
tigenome’s 5’ end, which is thought to serve as template for poly(A) tailing of all mRNAs 
(36). The antigenome sequence has not been characterized for any arterivirus, but if it in-
cludes poly(U) at the 5’ end, it could explain the dual specificity of nsp9 nucleotidylation. 
In contrast, neither the presence of this poly(U) tract nor the sequence of the genomic 
5’ end can be easily reconciled with de novo synthesis, which is assumed to generally 
require two purines as start nucleotides based on the biochemical characterization of a 
number of polymerases (9). To accommodate de novo synthesis, arteriviruses would thus 
require additional editing of one or both 5’ ends. In contrast to large nidoviruses, encod-
ing dedicated enzyme domains for this function may represent a significant burden to 
arteriviruses.
Despite these arguments for protein-primed RNA synthesis in EAV, there is one compli-
cation with this hypothesis since the chemical nature of the protein-nucleotide bond in 
the previously characterized VPgs does not match that between nsp9 and GMP/UMP. In 
all viruses with protein-primed replication that were investigated in detail the protein-
nucleotide bond was established with the help of either a tyrosine or serine, in other 
words via a hydroxyl moiety (17;18;20;23). In EAV nsp9 the bond to the GMP/UMP is 
formed via the side chain amino group of a lysine or less likely histidine (chapter  5), 
and thus the situation would be more similar to that observed in nucleotidylating 
enzymes involved in nucleic acid ligation or mRNA capping (both discussed in detail in 
chapter 5) (37-39). This difference could have profound functional implications, because 
phosphoesters are known to be chemically more stable under physiological conditions 
than phosphoamides (40). However, arteriviruses may have evolved to have a labile 
bond between nsp9 and the nucleotide to allow the subsequent nucleotide transfer to 
a genuine VPg. This two-stage mechanism would provide an additional level of control 









































monophosphate. Furthermore, the instability and therefore transient nature of the bond 
would only impact EAV replication if the protein modification at the 5’ end would serve 
functions beyond initiation of RNA synthesis that are required throughout the entire 
lifetime of the RNA, for example nuclease protection or translation initiation. The lat-
ter function is fulfilled by calicivirus VPgs, which substitute for 5’ mRNA nucleotide cap 
structures and bind directly to the translation initiation factor eIF4E (41;42). The fact that 
the putative bond between EAV RNA and a terminal protein might be unstable, may 
thus merely indicate that this virus utilizes a secondary mechanism to modify its mRNAs 
with regular cap structures after the transiently bound VPg has been removed.
mRNA 5’-terminal modifications
Besides protein-priming, nucleotidylation could be implicated in the formation of 
the cap structure of mRNAs. Nidovirus mRNAs are thought to contain a type 1 cap 
structure (cap-1) (mGpppNm) at their 5’  end that enables translation in the absence of 
special RNA secondary structure elements as internal ribosome entry sites (IRESs) or 3’ 
cap-independent translation enhancers (CITEs). However, some experimental evidence 
supporting that assumption has only been obtained for equine torovirus (43), the coro-
navirus mouse hepatitis virus (MHV) (44;45), and the arterivirus simian hemorrhagic fe-
ver virus (46). As the question regarding the 5’ modification was not addressed for either 
roniviruses or mesoniviruses and a contradicting report exists for another arterivirus 
(47), it is far from proven that the presence of a cap-1 is a universal feature of the order. 
Additionally, there is considerable uncertainty about nidoviruses universally encoding a 
set of specific enzymes that were shown to be required to produce the cap-1 structure 
in better characterized (+) RNA viruses (Figure 2). While two of the enzymatic activities 
that are essential for the four-step synthesis of the cap-1 may reside in the nidovirus-
wide conserved N-terminal domain of the RdRp subunit (chapter  5) and the helicase 
subunit (chapter 3), the two methyltransferase domains were so far only identified in 
coronaviruses, roniviruses, and mesoniviruses (6;48-52) but not in arteriviruses (7). Yet, 
methylation of the cap serves, on the one hand, translation initiation (N7-methylation) 
via the recruitment of eIF4E and, on the other hand, immune evasion (2’-O-methylation) 
(53-55). Therefore in theory, at least N7-methylation should be an essential step in the 
transcription of nidoviral mRNAs if it follows mechanisms established for other viruses. In 
chapter 6 we investigated whether the arterivirus-specific protein nsp12 might contain 
methyltransferase activity but were unsuccessful in verifying this hypothesis, potentially 
due to purely technical reasons. Thus, it remains an open question how arteriviruses 
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Figure 2: Conventional mRNA capping mechanism, nidovirus proteins (putatively) involved, and functional 
roles of the cap. RTPase, RNA 5’-triphosphatase; GTase, guanylyltransferase; N-MT, N7-methyltransferase; 









































Besides nsp12 supplying the N7-methyltransferase activity in arteriviruses, several other 
options could be considered. First, the recruitment of cellular enzymes, which are lo-
cated in the nucleus (56), seems to be a possibility potentially through the involvement 
of dedicated viral proteins that shuttle to the nucleus. Another option is snatching a cap 
structure from cellular mRNAs. For this purpose, several groups of negative-stranded 
(-)  RNA viruses that employ this mechanism have evolved specific cap-binding and 
endoribonuclease domains (57-60). Also arteriviruses are known to encode an endori-
bonuclease that is associated with nsp11 (61). However, upon analysis of genomes and 
mRNAs of established cap-snatching viruses of the Orthomyxoviridae, Bunyaviridae, and 
Arenaviridae, it became evident that all of these viruses harbor at least one (arenaviruses) 
and up to 17 (bunyaviruses) nucleotides at their mRNA 5’ ends that are variable and not 
virus-encoded (62;63). Since such host-derived sequences have not been discovered in 
the extensive study of arterivirus 5’ untranslated regions (UTRs) (47;64-66), the utiliza-
tion of an analogous cap-snatching mechanism by arteriviruses seems very unlikely.
Noteworthy, a variant of cap-snatching in which only the terminal mGMP moiety is 
removed from cellular substrates is employed by the dsRNA viruses of the Totiviridae 
(67). Still, if this mechanism, or a variation thereof, is considered for arteriviruses, other 
incompatibilities between its characteristics and our knowledge about arteriviruses be-
come apparent. Particularly, cleavage within the peculiar 5’-5’ linkage of the cap is usu-
ally not catalyzed by ribonucleases that are able to cleave regular 5’-3’ bonds. Although 
the physiological substrate for nsp11 has not been established yet, its demonstrated 
in vitro specificity for pyrimidine-containing single- and double-stranded RNAs makes 
it unlikely that this unusual bond would fall within the enzyme’s substrate range (61). 
Finally, one of the arterivirus proteins may specifically recognize the 5’ end of arterivirus 
mRNAs and facilitate translation initiation without the need for eIF4E involvement and 
hence potentially independent of N7-methylation.
To conclude, the remaining significant gaps in our understanding of arterivirus RNA 
synthesis and 5’ modification(s) currently leave space to formulate a number of parallel 
hypotheses. Given that arteriviruses are even considerably well characterized compared 
to all nidovirus families other than coronaviruses, a significantly bigger effort regarding 
biochemical and structural studies is required to establish universal and lineage-specific 













































THE IMPORTANCE OF HOST HELICASES FOR NIDOVIRUS REPLICATION
In chapters 2 and 3 potential functions of the conserved UPF1-like nidovirus helicase 
have been discussed. Reflecting the enzyme’s versatile nature, those include roles during 
replication, transcription, RNA modification and processing, as well as virion biogenesis, 
which place this protein at the very center of the nidoviral replication cycle. Despite 
these prominent roles in nidoviruses and other (+) RNA viruses with a genome larger 
than 7 kilobases, helicases are not encoded by retroviruses or (-) RNA viruses, which are, 
for the most part, considerably larger than 7 kilobases (68). This may be explained by 
significant differences in their respective replication cycles compared to (+) RNA viruses, 
which, on the one hand, may have rendered those viruses helicase-independent or, on 
the other hand, may have enabled them to recruit cellular helicases. A case in point is 
the retrovirus human immunodeficiency virus, whose proteins or RNA elements interact 
with at least seven host RNA helicases – MOV10 (Upf1-like, SF1), DDX1, DDX3, DDX24 (all 
DEAD-box family, SF2), DHX9, DHX30 (both DEAH-box family, SF2), and RH116 (DExH-
box family, SF2) – to promote, amongst others, transcription initiation, translation, and 
virion infectivity (reviewed in (69)). Furthermore, recently DDX21 was implicated in the 
temporal regulation of influenza A virus gene expression (70).
Interestingly, utilization of host helicases for specific functions during their replication 
cycle is not exclusively a feature of viruses that do not encode their own helicase. For 
example, also the helicase-encoding bovine viral diarrhea virus (BVDV), hepatitis C virus 
(both Flaviviridae), and foot-and-mouth disease virus (FMDV, Picornaviridae) were found 
to depend on DHX9 for genome replication. While the exact role of this protein in BVDV 
infection remains unknown (71), the latter two viruses likely require this host factor for 
circularization of viral RNAs, as the protein was shown to bind to the 5’ and 3’ UTRs of the 
viral genome (72;73). Furthermore, in FMDV the same protein co-immunoprecipitated 
with the viral SF3 helicase 2C and nonstructural protein 3A (72). Together these results 
may indicate that cellular helicases are not only required to exert their enzymatic 
activities but may also serve as scaffolds for the assembly of multimeric protein-RNA 
complexes via their accessory domains.
Although the number of RNA viruses with proven dependence on host cell helicases 
is currently small, it can be expected that more and more of these host factors will 
be identified due to the rising popularity of large-scale siRNA, yeast two-hybrid, and 
proteomics screens. For example, these approaches recently led to the discovery of an 
interaction between DDX1 and two coronavirus proteins, nsp14 and the nucleocapsid 
protein N (74-76). The results of two independent studies addressing these interactions 









































Moreover, in recent years a number of RNA helicases other than the well characterized 
RIG-I and MDA5 have been implicated in cellular antiviral defense mechanisms (77). 
Curiously, these again include DDX1 and Upf1. Thus, the recruitment of or structural 
similarity to these cellular helicases possibly serve a dual role in the nidovirus replica-
tion cycle. This section is therefore concluded with a short summary on the defense 
mechanisms mediated by these two proteins.
The cellular helicase DDX1 and nidovirus transcription regulation
As discussed in detail in chapter 3, the nidovirus helicase is one of the few proteins that 
has been directly implicated in the mechanism of discontinuous negative-strand syn-
thesis that produces the subgenome-length templates for sg mRNA synthesis (78;79). 
Surprisingly, two studies now also linked the cellular helicase DDX1 to (sg)  mRNA 
synthesis. Originally this host factor, which seems to be involved in 3’ mRNA processing 
and tRNA splicing in the nucleus of uninfected cells (80;81), was identified in a large-
scale yeast two-hybrid screen as an interaction partner of nsp14 of the coronaviruses 
infectious bronchitis virus (IBV) (76). Further directed investigation by the same group 
extended this interaction also to SARS-CoV nsp14 and mapped the interaction surface 
to the N-terminal exoribonuclease domain of this protein. In line with this finding, upon 
IBV infection of Vero cells the mostly nuclear localization of DDX1 was altered into a 
cytoplasmic punctuate pattern, similar to that observed for coronavirus replicase pro-
teins. Given this apparent recruitment to replication-transcription complexes, it was not 
surprising that stable or transient knock-down of DDX1 led to a tenfold decrease of virus 
peak titers. Interestingly, when examining the levels of N and S protein expression – pro-
duced from the shortest and longest sg mRNAs, respectively, in IBV – the amount of S 
protein appeared to be significantly reduced upon DDX1 knock-down while the amount 
of N protein was not affected. This finding correlated with the preferential decrease of 
the transcription level of longer mRNAs (subgenomic and genomic) compared to shorter 
ones, which was also observed. Since this effect had the same relative magnitude for 
RNAs of both polarities, it was speculated that DDX1 might be involved in the regulation 
of the relative abundance of individual negative-stranded RNAs (76). Notwithstanding 
the fact that this hypothesis was devised to explain the features of coronavirus repli-
cation, this host factor may thus act on a different level or by a different mechanism 
than the endogenous nidoviral helicase, whose mutation may impair the synthesis of 
all sg mRNAs uniformly and selectively relative to genomic RNA production in EAV (79). 
Whether or not this regulatory mechanism actually involves the proven interaction with 
IBV nsp14 was not established. However, it was noted that continued passaging of IBV 
in DDX1 knock-down cells did neither induce mutations in nsp14 nor had any impact 













































DDX1. Based on these results, it seems more likely that the nsp14-DDX1 interaction plays 
a different, as yet unidentified, role in the coronavirus replication cycle (76).
A few years after this study, the same host helicase was identified as interaction partner 
of the IBV and MHV N proteins both in the absence and presence of cellular RNA (74;75). 
As for IBV earlier, also the MHV study demonstrated the selective reduction of longer 
RNA species upon DDX1 knock-down. Additionally, subsequent ectopic over-expression 
of knock-down resistant, functional DDX1 but not of a helicase active site mutant led to a 
reversal of this effect, establishing its dependence on helicase activity. In contrast to the 
study detailed above, it was furthermore demonstrated that abolishing the interaction 
between N and DDX1 by preventing phosphorylation of N at serine 197 had the same 
impact on RNA abundance as DDX1 knock-down. It was thus concluded that complex 
formation between these two proteins may promote read-through at transcription 
regulatory sequences during discontinuous negative-stranded RNA synthesis (75). How-
ever, this would imply that abolishing complex formation should not only specifically 
diminish the quantity of longer RNA species but at the same time also increase that of 
shorter RNAs if no other limiting factor plays a role. Neither of the two studies reported 
such an outcome (75;76). Instead total RNA amounts were reduced while that of short 
sg mRNAs remained largely constant. The most obvious alternative explanation for this 
pattern would therefore be a direct stimulation of RdRp processivity by the N:DDX1 
complex. This, however, is unlikely to be true as the synthesis of genomic RNA, which 
is more than three times as long as the longest sg  mRNA, was affected to the same 
extent as that of this latter sg mRNA. Next to a direct involvement in RNA synthesis, the 
reported data would also be consistent with a role for the N:DDX1 complex in a selective 
stabilization of certain negative-stranded  RNAs before mRNA synthesis commences. 
In order to elucidate the exact role of DDX1, a deeper understanding of the nidovirus 
replication mechanism and potential downstream regulatory pathways influencing the 
stability of the negative-stranded subgenome-length RNAs would be required. Yet, this 
appears to become an ever more daunting task with every additional protein, viral or 
cellular, that is implicated in the nidovirus replication cycle.
Cellular helicases and antiviral defense
In the course of evolution eukaryotic cells have developed an intricate defense system 
to counteract infections by bacterial, eukaryotic, and viral pathogens. A central role in 
one arm of this system, the innate immune system, is played by conserved pattern-
recognition receptors that recognize a certain signature molecule of defined groups of 
pathogens. In the case of RNA viruses this recognition largely depends on the sensing 









































somal Toll-like receptors 3, 7, and 8, as well as cytosolic NOD-like and RIG-I-like receptors. 
The latter group is comprised of the three DExH-box SF2 RNA helicases RIG-I, MDA5, and 
LGP2, of which MDA5 was shown to sense MHV RNA (82). Once these receptors bind 
their ligand, a complex cascade of downstream effectors is activated, eventually leading 
to the transcription of genes involved in inflammatory response and cross-talk with the 
adaptive immune system. Most notably is the production of type I interferons, which in 
turn indirectly regulate protein synthesis, cell growth, and apoptosis (reviewed in (83)).
As would be expected, during an extensive period of co-evolution with their hosts, vi-
ruses have developed a variety of means to avoid, inhibit, or redirect essential factors of 
the innate immune system. For instance, nidoviruses, as all other characterized (+) RNA 
viruses infecting eukaryotes, are known to induce extensive membrane modifications 
inside the host cell (84). Since these are thought to be the site of viral RNA synthesis, 
they may serve to hide viral nucleic acids, in particular the highly immunogenic double-
stranded replication intermediates, from cytosolic sensors. Additional avoidance 
strategies that could be employed by at least a subset of nidoviruses are the disguising 
of viral RNAs by attaching the typical eukaryotic double-methylated cap structure to 
mRNA 5’ ends or the degradation of an excess of viral RNAs by either of the two viral 
ribonucleases (85). Furthermore, the nsp1α, nsp1β, and nsp4 proteases of the arterivirus 
porcine reproductive and respiratory syndrome virus (PRRSV), as well as the PLP2 prote-
ase domains of EAV and PRRSV nsp2 have been implicated in the inhibition of immune 
signaling although interestingly not in all cases through their proteolytic activity (86). 
Also coronavirus nsp1 and nsp3 appear to be engaged in immune suppression (87-89). 
It remains to be seen whether similar strategies have also evolved in the other nidovirus 
(sub)families. Yet, these examples show that a significant number of proteins may be 
dedicated to counteract the host’s defense mechanisms and to shape a more beneficial 
environment for virus replication. Thus, given the extensive divergence between indi-
vidual members of the order, it is currently difficult to estimate how large the repertoire 
of nidovirus evasion strategies really is.
DEAD/H-box helicases and RNA detection
Interestingly, a number of SF2 RNA helicases besides RIG-1 and MDA-5 were identified 
as additional players in virus sensing and immune signaling in recent years (77). One 
of those is the above mentioned DDX1, which was shown to bind to poly(I:C) RNA and 
may recognize any RNA species. Binding of DDX1 to a substrate promotes the complex 
formation with two other helicases, DDX21 and DHX36. Both of these helicases can sub-
sequently interact with the innate immunity signaling protein TRIF and thereby induce 













































on influenza virus and reovirus, in which interferon production was reduced once any 
of the three helicases was knocked-down (90). Additionally, DDX1 is able to directly 
bind to the RelA subunit of the pro-inflammatory transcription factor NF-kB, thereby 
stimulating transcription activation by this factor (91). Intriguingly, next to DDX1, also 
DDX21 and DHX36 were identified as putative interaction partners of the IBV N protein 
by co-immunoprecipitation (74). The latter interaction was also found for PRRSV (92).
Further RNA helicases that are involved in immunity and that were identified as binding 
partners of N in IBV and PRRSV are DDX3 and DHX9 (74;77;92). The former, which also 
serves in translation regulation especially of mRNAs with complex 5’ UTRs (93), acts as 
a sensor for dsRNA. However, unlike signaling by the DDX1 complex, the pathway for 
this helicase is identical to that of RIG-I and involves the downstream effector MAVS 
(94). Similarly, also the transcriptional regulator DHX9 was shown to interact with MAVS 
upon encountering dsRNA (95). It was therefore speculated that both DDX3 and DHX9 
may be of particular importance early in infection when the RIG-I concentration is still 
low. Whether any of these cellular helicases actually plays a role in nidovirus sensing, 
immune evasion, or replication remains to be seen. Nevertheless, it is an interesting 
possibility that the interaction of these host proteins with N might interfere with their 
immune signaling responsibilities.
Upf1 and NMD-mediated defense
In eukaryotic cells the relative abundance of mRNAs is heavily regulated. One of the 
involved mechanisms, which controls the quantities of up to 10% of all transcribed 
mRNAs, is termed nonsense-mediated decay (NMD). Besides this function, the same 
mechanism also controls ribosome release from, as well as translation repression 
and  –  ultimately  –  decay of aberrant transcripts with, for example, premature stop 
codons that may arise due to wrong or incomplete splicing and nonsense or frameshift 
mutations. Although NMD has been studied extensively in different species, neither 
its RNA or protein triggers nor the exact sequence of events involved in this process 
are well understood. Notwithstanding this uncertainty, the SF1 helicase Upf1 and the 
poly(A) binding protein (PABP)  –  or more precisely the competition between these 
proteins  –  appear to be of special importance. During translation of wild-type host 
mRNAs, PABP is bound sufficiently close to the terminating ribosome to establish an 
interaction with the termination factor eRF3, which in turn stimulates termination 
and triggers ribosomal release. Conversely, if the distance between eRF3 and PABP is 
artificially elongated by, for instance, the introduction of an upstream stop codon or 
the presence of a second downstream ORF, termination becomes less efficient. In this 









































larger protein complex, which marks this mRNA for decay (reviewed in (96;97)). While 
cellular mRNAs have evolved to contain the correct spacing  –  on average 700 to 800 
nucleotides in humans  –  between stop codon and poly(A) tail (98), some viral RNAs 
comprising multiple ORFs and elongated 3’ UTRs may be particularly vulnerable to this 
quality control mechanism. This assumption was recently confirmed with the help of the 
(+) RNA viruses potato virus X (Alphaflexiviridae) and Semliki Forest virus (SFV) (Togaviri-
dae) (99;100), which both utilize 3’ co-terminal sg mRNAs. For the plant virus a mutation 
within the Upf1-gene was shown to lead to an increase in the amount of sg mRNAs with 
long 3’ UTRs compared to the wild-type situation. At the same time, the abundance of 
the shortest sg mRNA comprising only a very short 3’ UTR was unaffected (99). Similarly, 
knock-down of Upf1 extended the half-life of the SFV genomic RNA in HeLa cells from 
63 min to 89 min. Consequently, viral titers increased by threefold. This effect could be 
reversed by ectopic expression of a knock-down resistant functional Upf1 but not an 
helicase active site mutant. Surprisingly, shortening of the ~4000 nucleotide 3’ UTR of 
the SFV genomic RNA to 62 nucleotides did not abolish Upf1-mediated decay, a find-
ing which stands in sharp contrast to the observations for the plant virus (100). Even 
more puzzling is the proven independence of the antiviral mechanism from 5’ cap but 
especially 3’ poly(A) tail (99). These observations essentially argue for a non-canonical 
NMD mechanism being involved during antiviral defense. Since two (-)  RNA viruses, 
respiratory syncytial virus (Paramyxoviridae) and Uukuniemi virus (Bunyaviridae) that 
strictly encode monocistronic mRNAs, were not affected by Upf1 knock-down (100), the 
polycistronic nature of mRNAs appears to be the common denominator of this pathway 
at the moment. Future research may reveal whether different RNA features emerge as 
triggering factors.
As already speculated for cellular NMD, specific RNA sequences or secondary structures 
might have evolved to recruit NMD antagonists or inhibit NMD in other ways (96). Given 
this context, if this defense mechanism actually plays a role for at least a subset of viruses, 
it would be expected that these viruses employ certain mechanisms to counteract Upf1-
mediated decay (101). In view of this assumption, it is intriguing that all nidoviruses 
encode a helicase that structurally resembles Upf1 (chapters 2 and 3). Although a direct 
role of this viral protein in RNA quality control might be a preferable explanation for its 
fixation in the ancestral nidovirus genome, one could envision a secondary function 
of the nidovirus helicase in counteracting cellular defenses. However, due to its pre-
sumed multiple roles during viral replication, confirming this immune evasion strategy 
will not be an easy task. In addition, Upf1 is known to be a central player in a number 
of pathways that involve the manipulation of nucleic acids and each employ different 
protein complexes (96;97). Further research in this area should therefore initially focus 
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(+) positive-stranded, i.e., of mRNA polarity
3’ CITE 3’ cap-independent translation enhancer
AsD Arterivirus-specific domain
ATP adenosine triphosphate
BCoV bovine coronavirus (Coronaviridae)
BHK baby hamster kidney
bp base pair
BSA bovine serum albumin
BVDV bovine viral diarrhea virus (Flaviviridae)
cap-0 type-0 cap structure, mGpppN
cap-1 type-1 cap structure, mGpppNm
CDC United States Centers for Disease Control and Prevention
cDNA complementary DNA
CHES N-cyclohexyl-2-aminoethanesulfonic acid
CHIKV chikungunya virus (Alphaviridae)
CM convoluted membrane
CPE cytopathic effect






E nidovirus envelop protein
E. coli Escherichia coli
EAV equine arteritis virus (Arteriviridae)
ECDC European Center for Disease Prevention and Control
EDTA ethylenediaminetetraacetic acid
ER endoplasmic reticulum
ExoN nidovirus 3’-5’ exoribonuclease domain
FDA United States Food and Drug Administration
FECoV feline enteric coronavirus (Coronaviridae)














































HCoV human coronavirus (Coronaviridae)
HCoV-229E human coronavirus 229E (Coronaviridae)
HCV hepatitis C virus (Flaviviridae)
HEL1 nidovirus helicase domain
HEPES hydroxyethyl piperazineethanesulfonic acid
HEV hepatitis E virus (Hepeviridae)
HMM Hidden Markov Model
IBV infectious bronchitis virus (Coronaviridae)
IC50 inhibitory concentration
ICTV International Committee on Taxonomy of Viruses
IFA immunofluorescence assay
IND investigational new drug





LDV lactate dehydrogenase-elevating virus (Arteriviridae)
M nidovirus membrane protein
MAD multiple-wavelength anomalous diffraction
MBP maltose-binding protein
Mbp Megabase pair
MERS-CoV Middle East respiratory syndrome coronavirus (Coronaviridae)
MES 2-(N-morpholino)ethanesulfonic acid
MHV mouse hepatitis virus (Coronaviridae)
MOPS 3-(N-morpholino)propanesulfonic acid
mRNA messenger RNA
MSA multiple sequence alignment
MTase methyltransferase
MWCO molecular weight cut-off
N nidovirus nucleocapsid protein
n.a. not applicable
n.d. not done
NendoU nidovirus uridylate-specific endoribonuclease domain


























































PABP poly(A) binding protein
PAGE polyacrylamide gel electrophoresis
pC poly-cytidine
PCR polymerase chain reaction






PRRSV porcine reproductive and respiratory syndrome virus (Arteriviridae)
PSSM position-specific scoring matrix
pU poly-uridine
RdRp RNA-dependent RNA polymerase
RF replicative form








RT-PCR reverse transcription polymerase chain reaction
SARS-CoV severe acute respiratory syndrome coronavirus (Coronaviridae)
SDS sodium dodecyl sulfate
SF helicase superfamily
SFV Semliki Forest virus (Togaviridae)
sg subgenomic








































270 List of abbreviations
TBE tris-borate-EDTA buffer
TEV tobacco etch virus (Potyviridae)
TGEV transmissible gastroenteritis virus (Coronaviridae)
TLR Toll-like receptor
TM transmembrane domain







VPg viral protein genome-linked
WHO World Health Organization


















































The order Nidovirales comprises a monophyletic group of viruses with positive-stranded 
RNA genomes that are classified in the families Arteriviridae, Coronaviridae, Mesoniviridae, 
and Roniviridae. They share a conserved genome organization and a characteristic set 
of key replicative proteins. Although, in principle, this suggests a conserved replication 
mechanism, it is currently unclear how far exactly the resemblance extends on a more 
detailed level. This is foremost due to our poor understanding of the role of most viral 
proteins in the replication cycle. In addition, most of the knowledge that was obtained 
predominantly derives from studies of only few coronaviruses, the nidovirus subgroup 
with the largest known genome and therefore presumably employing the most complex 
replication strategy. In contrast, thus far only limited attention was given to the RNA rep-
licating and processing enzymes of arteriviruses, and none at all to those of mesoni- and 
roniviruses, whose genome sizes are (much) smaller than those of coronaviruses. Given 
this disparity, it may be premature to assume that within this divergent group of viruses 
essential steps of the viral replication cycle, like for example RNA synthesis and mRNA 
5’ end modification, strictly follow the same mechanistic pathways.
The work described in this thesis addresses some poorly or uncharacterized (domains 
of ) nonstructural proteins (nsps) that are likely involved in one or multiple steps of 
RNA replication and/or transcription of the prototypic arterivirus equine arteritis virus 
(EAV). After a short introduction on the nidovirus replication cycle and our knowledge 
of the molecular details of the unusual transcription and mRNA processing mechanism 
(chapter 1), chapter 2 presents the crystal structure of the enzymatically active EAV 
helicase nsp10, which was obtained and analyzed in close collaboration with Chinese 
colleagues. Interestingly, a strong resemblance between this viral protein and the con-
served cellular helicase Upf1, in particular with respect to their N-terminal zinc-binding 
domains, became obvious. Since this cellular helicase has been implicated in a number 
of eukaryotic post-transcriptional quality control mechanisms, a role for nsp10 and its 
nidovirus homologs in genome expansion is proposed. This and other potential func-
tions of the nidovirus helicase in RNA replication, transcription, and translation, as well 
as virion biogenesis are further discussed in chapter 3, which presents a review of our 
current knowledge about nidovirus helicases. Special emphasis is placed on gaps that 
still remain, facts that cannot be easily reconciled with our current understanding of the 
nidovirus replication mechanisms, and questions that need to be addressed in future.
Chapters 4 and 5 focus on one of the central arterivirus replication proteins, nsp9, which 
harbors the RNA-dependent RNA polymerase (RdRp) domain. Chapter 4 describes a care-









































including a previously claimed primer-independent RdRp activity. Despite considerable 
efforts, involving experiments with different preparations of nsp9 and assays performed 
in the presence of putative polymerase co-factors, no in vitro activity was observed that 
could be clearly attributed to this protein. Moreover, circumstantial evidence suggested 
that the previously reported activity may have been caused by a contamination of the 
recombinant nsp9 preparation with the T7 RNA polymerase used to drive its expression 
in E. coli. In arteriviruses, the RdRp domain is located in the C-terminal two-thirds of nsp9. 
In chapter 5, it is now described for the first time that the RdRp domain is flanked at its 
N-terminus by another domain that is conserved in all nidoviruses. However, unlike the 
situation for the RdRp domain, no homologs of this domain have been found in other 
RNA viruses. This domain is thus proposed to be a second marker for the Nidovirales 
order, besides the N-terminal zinc-binding domain of the helicase subunit. Residues that 
are part of three conserved sequence motifs were without exception associated with 
a newly discovered nucleotidylation activity of recombinant nsp9. It is thus proposed 
that this activity could play a role in the modification of the 5’ end of viral RNAs through 
either RNA ligation, protein priming of RNA synthesis, or guanylyl transfer during mRNA 
capping. Further research is required to definitely tie nsp9 to one of these pathways. 
Nevertheless, alanine substitution of any of these conserved residues was either lethal 
to EAV and severe acute respiratory syndrome coronavirus (SARS-CoV) or severely 
crippled these viruses, eventually resulting in reversion of the mutation. These results 
thus demonstrate the essential nature of this domain for virus replication, whatever its 
exact function will turn out to be.
Two methyltransferase activities, commonly required for capping of mRNAs, were 
previously identified in two ORF1b-encoded coronavirus proteins, nsp14 and nsp16. 
While the former has no counterpart among the arterivirus nonstructural proteins, the 
latter and the arterivirus C-terminal subunit nsp12 occupy equivalent positions in the 
ORF1b-encoded part of the replicase although the two proteins share no detectable 
sequence similarity. It is thus a long standing question, how arteriviruses may catalyze 
the 5’ end modification of mRNAs, and we therefore performed a first characterization of 
the entirely uncharacterized EAV nsp12 subunit (chapter 6). Based on the genomic posi-
tion of its coding sequence, sequence alignment, and secondary structure prediction, it 
is hypothesized that nsp12 might represent a unique arterivirus methyltransferase that 
has diverged from its homologs beyond sharing appreciated similarity. To test this hy-
pothesis, recombinant nsp12 was expressed in and purified from E. coli and tested alone 
and in combination with potential co-factors for N7- and 2’-O-methyltransferase activ-
ity. Although positive controls represented by the SARS-CoV methyltransferases (nsp14 
and the nsp10:nsp16 complex) demonstrated the functionality of the assay, no activity 















































mutants was generated and characterized with respect to their plaque phenotype and 
progeny titer, as well as their protein expression. These reverse genetics experiments 
revealed a number of phenotypes ranging from wild-type-like via non-spreading to 
replication-incompetent, which indicated that nsp12 is essential for viral replication.
The above chapters describing biochemical properties of selected proteins may ulti-
mately contribute to the identification of drug targets to combat nidovirus infections. In 
chapter 7 the prerequisites under which the marketing of such an antiviral drug would 
be economically viable are analyzed. This project was realized under guidance of several 
specialists of one of the industrial partners, Janssen Infectious Diseases, of the EUVIRNA 
consortium, the Marie Curie Initial Training Network to which my research project be-
longed. This study concludes that, at the moment, none of the circulating nidoviruses 
constitutes a sufficiently sized market to warrant the considerable investments required 
for drug development. The situation may be different if a new highly-pathogenic virus 
would emerge, as exemplified in 2002 by SARS-CoV or 2012 by MERS-CoV. In view of 
such threats, pre-pandemic drug stockpiling could be considered. However, also under 
those circumstances, it seems likely that the inherent financial risk would preclude an in-
dependent private initiative, even though market parameters and approval procedures 
appear to be favorable.
Finally, chapter 8 connects some of the main findings described in this thesis with 
previously described data. In particular, potential differences between small and large 
nidoviruses on the level of the molecular mechanisms of RNA synthesis initiation and 
mRNA capping are highlighted. To this end, alternative mechanisms are considered that 
would be consistent with the data on arteriviruses presented in this thesis and else-
where. Furthermore, potential roles of cellular helicases in nidovirus replication and the 



















































De orde Nidovirales omvat een monofyletische groep van virussen met positiefstrengige 
RNA genomen, die geclassificeerd zijn in de families Arteriviridae, Coronaviridae, Meso-
niviridae en Roniviridae. Deze groepen delen een geconserveerde genoomorganisatie 
en een karakteristieke set van cruciale replicatie-eiwitten. Alhoewel dit, in principe, een 
geconserveerd replicatiemechanisme suggereert, is het op dit moment onduidelijk in 
hoeverre deze gelijkenis op een gedetailleerder niveau stand houdt. Dit komt voorna-
melijk door ons beperkte begrip van de rol van het gros van de virale eiwitten in de 
replicatiecyclus. Bovendien, het grootste deel van de beschikbare kennis is afkomstig 
van studies van slechts enkele coronavirussen, de nidovirus subgroep met het langste 
bekende RNA genoom die daarom vermoedelijk gebruik maakt van de meest complexe 
replicatiestrategie. In tegenstelling hiermee is tot nu toe slechts beperkt aandacht be-
steed aan de RNA-replicerende en -modificerende enzymen van arterivirussen en geen 
enkele aandacht aan die van de mesoni- en ronivirussen, die (veel) kleinere genomen 
hebben dan coronavirussen. Gegeven deze ongelijkheid, kan het voorbarig zijn om aan 
te nemen dat de essentiële stappen van de virale replicatiecyclus, zoals bijvoorbeeld 
RNA synthese en modificatie van het 5’ uiteinde van mRNA’s, in deze uiteenlopende 
groep van verwante virussen strikt dezelfde mechanistische routes volgen.
Het werk beschreven in dit proefschrift betreft enkele slecht of niet gekarakteriseerde 
(domeinen van) niet-structurele proteïnen (nsp) die waarschijnlijk betrokken zijn bij één 
of meerdere stappen tijdens RNA replicatie en/of transcriptie van het prototype arterivi-
rus, equine arteritis virus (EAV). Na een korte inleiding over de nidovirus replicatiecyclus 
en onze kennis van de moleculaire details van hun ongewone transcriptie- en mRNA 
modificatiemechanisme (hoofdstuk 1), wordt in hoofdstuk 2 de kristalstructuur van het 
enzymatisch actieve EAV helicase nsp10 gepresenteerd, die verkregen en geanalyseerd 
is in nauwe samenwerking met Chinese collega’s. Interessant genoeg, werd een sterke 
gelijkenis duidelijk tussen dit virale eiwit en het geconserveerde cellulaire helicase Upf1, 
vooral wat betreft het N-terminale zink-bindende domein. Aangezien dit cellulaire heli-
case verondersteld wordt betrokken te zijn in een aantal eukaryote mechanismen voor 
posttranscriptionele kwaliteitscontrole, wordt voor nsp10 (en homologen in andere 
nidovirussen) een rol in genoomexpansie voorgesteld. Deze en andere mogelijke func-
ties van nidovirus helicases in RNA replicatie, transcriptie en translatie, evenals virion 
biogenese, worden verder besproken in hoofdstuk 3, dat een overzicht presenteert van 
onze huidige kennis over nidovirus helicases. Bijzondere aandacht wordt daarbij ge-
geven aan de resterende lacunes in onze kennis, feiten die minder eenvoudig overeen 
lijken te stemmen met ons huidige begrip van de nidovirus replicatiemechanismen en 









































Hoofdstukken 4 en 5 richten zich op één van de centrale arterivirus replicatie-eiwitten, 
nsp9, dat een RNA-afhankelijke RNA polymerase (RdRp) domein herbergt. Hoofdstuk 4 
beschrijft een zorgvuldig uitgevoerde studie naar de verschillende polymerase-activi-
teiten die nsp9 zou kunnen hebben, inclusief een eerder beschreven primer-onafhan-
kelijke RdRp-activiteit. Ondanks aanzienlijke inspanningen, waaronder experimenten 
met verschillende preparaten van nsp9 en proeven uitgevoerd in aanwezigheid van 
mogelijke polymerase-cofactoren, werd geen in vitro activiteit gevonden die duidelijk 
toegewezen zou kunnen worden aan dit eiwit. Er werd ook indirect bewijs verkregen 
dat suggereert dat de eerder beschreven activiteit wellicht te danken was aan een 
contaminatie van het recombinant nsp9 met het T7 RNA polymerase dat was gebruikt 
om het eiwit in E. coli tot expressie te brengen. In arterivirussen, is het RdRp domein 
gelokaliseerd in het C-terminale twee-derde van nsp9. In hoofdstuk 5 wordt voor het 
eerst beschreven dat het RdRp-domein N-terminaal geflankeerd wordt door een ander 
domein dat is geconserveerd in alle nidovirussen. In tegenstelling tot het RdRp-domein, 
zijn van dit domein geen homologen gevonden in andere RNA virussen. Daarom wordt 
voorgesteld dat dit domein een tweede universeel kenmerk voor de Nidovirales orde is, 
naast het N-terminale zink-bindende domein van de helicase subunit. Aminozuren die 
onderdeel zijn van drie geconserveerde sequentiemotieven werden zonder uitzonde-
ring geassocieerd met een nieuw ontdekte nucleotidyleringsactiviteit van recombinant 
nsp9. Deze activiteit speelt mogelijk een rol in de modificatie van het 5’ einde van virale 
RNAs middels ofwel RNA ligatie, eiwit priming van RNA synthese of guanylyl overdracht 
tijdens RNA capping. Nader onderzoek is vereist om nsp9 definitief met één van deze 
mogelijkheden in verband te brengen. Niettemin was alanine-substitutie van ieder van 
deze geconserveerde residuen ofwel letaal voor EAV en het severe acute respiratory syn-
drome coronavirus (SARS-CoV) of het beperkte deze virussen ernstig in hun replicatie, 
wat uiteindelijk resulteerde in reversie van de mutatie. Deze resultaten demonstreren 
dus de essentiële aard van dit domein voor virusreplicatie, ongeacht wat de exacte 
functie zal blijken te zijn.
Twee methyltransferase-activiteiten, vereist voor mRNA capping, werden eerder ge-
identificeerd in twee ORF1b-gecodeerde coronaviruseiwitten, nsp14 en nsp16. Terwijl 
de eerste geen tegenhanger heeft onder de niet-structurele eiwitten van arterivirussen, 
bezetten de laatstgenoemde en het C-terminale subunit van arterivirussen, nsp12, 
vergelijkbare posities in het ORF1b-gecodeerde gedeelte van de replicase, hoewel 
de twee eiwitten geen detecteerbare sequentiegelijkenis delen. Het is een langdurig 
openstaande vraag hoe arterivirussen de modificatie van het 5’ einde van hun mRNAs 
katalyseren, en in dat kader hebben we een eerste karakterisering van het nog ongeka-
rakteriseerde nsp12 van EAV uitgevoerd (hoofdstuk 6). Gebaseerd op de genomische 

















































secundaire structuur werd verondersteld dat nsp12 mogelijk een unieke arterivirus 
methyltransferase zou zijn, dat zich afgesplitst heeft van nidovirus homologen waar-
door noemenswaardige gelijkenis ontbreekt. Om deze hypothese te toetsen werd 
recombinant nsp12 tot expressie gebracht in en gezuiverd uit E. coli, en zowel alleen 
als in combinatie met potentiële cofactoren getest op N7- en 2’-O-methyltransferase 
activiteit. Hoewel de positieve controles, de beide SARS-CoV methyltransferases (nsp14 
en het nsp10:nsp16 complex), de functionaliteit van het experiment demonstreerden, 
werd geen activiteit voor EAV nsp12 gedetecteerd. Op basis van de sequentievergelij-
king werd een uitgebreide set van EAV mutanten gegenereerd en gekarakteriseerd op 
plaquefenotypen en de geproduceerde virus titer, evenals op eiwitexpressie. Deze re-
verse genetics experimenten onthulden een aantal fenotypen, variërend van nagenoeg 
wild-type via niet-verspreidend tot replicatie-incompetent, wat aangeeft dat nsp12 
essentieel is voor virale replicatie.
De bovenstaande hoofdstukken die de biochemische eigenschappen van bepaalde 
eiwitten beschrijven kunnen uiteindelijk een bijdrage leveren tot de identificatie van 
drug targets voor de bestrijding van nidovirus infecties. In hoofdstuk 7 worden de rand-
voorwaarden geanalyseerd die bepalen of de marketing van een dergelijke antivirale 
drug economisch levensvatbaar zou kunnen zijn. Dit project werd gerealiseerd onder 
de begeleiding van verscheidene specialisten van Janssen Infectious Diseases, één van 
de industriële partners van het EUVIRNA consortium, de Marie Curie Initial Training 
Network waartoe dit onderzoeksproject behoorde. Deze studie wees uit dat, op dit 
moment, geen van de circulerende nidovirussen een voldoende grote markt vormt om 
de aanzienlijke investeringen die nodig zijn voor drugontwikkeling te rechtvaardigen. 
De situatie kan anders zijn als een nieuw, hoog-pathogeen nidovirus zou opduiken, 
zoals geïllustreerd in 2002 door SARS-CoV en in 2012 door MERS-CoV. Met het oog op 
zulke bedreigingen, zou het pre-pandemisch aanleggen van drugvoorraden overwogen 
kunnen worden. Echter, ook onder die omstandigheden lijkt het waarschijnlijk dat de 
inherente financiële risico’s een onafhankelijk privaat initiatief uitsluiten, hoewel markt-
parameters en goedkeuringsprocedures gunstig lijken te zijn.
Tenslotte wordt in hoofdstuk 8 de samenhang beschreven tussen eerder beschreven 
data en enkele van de voornaamste bevindingen in dit proefschrift. Vooral de poten-
tiële verschillen tussen kleine en grote nidovirussen op het niveau van de moleculaire 
mechanismen van de initiatie van RNA synthese en mRNA capping worden besproken. 
Voor dit doel worden ook alternatieve mechanismen in beschouwing genomen die con-
sistent zouden zijn met de arterivirus data gepresenteerd in dit proefschrift en elders. 
Bovendien worden de potentiële rollen van cellulaire helicases in nidovirusreplicatie en 
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